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ABSTRACT 
PURPOSE 
 The purpose of this thesis was to evaluate the potential of contact lenses as ciprofloxacin 
drug delivery devices. 
METHODS 
 Investigations into ciprofloxacin uptake and release characteristics, and the possibility of 
their eventual clinical applications were elucidated through three broad experiments: 
 In the first experiment (Chapter 3), the uptake and release characteristics of 
commercially available contact lenses, both hydrogels and silicone hydrogels, were 
examined in vitro. 
 In the second experiment (Chapter 4), novel contact lens materials were manufactured 
using a molecular imprinting strategy to modify in vitro ciprofloxacin release 
characteristics. 
 In the final experiment (Chapter 5), utilizing the results gleaned from the first two 
experiments, contact lenses were manufactured using the molecular imprinting strategy. 
The material properties of the novel lenses were evaluated. The antibacterial activity of 
these lenses were evaluated both in vitro and in an in vivo rabbit model of microbial 
keratitis. 
RESULTS 
 Examination of commercial contact lens materials for their ciprofloxacin delivery 
potential demonstrated a measurable difference between the different lens types, with the 
hydrogel lenses taking up more ciprofloxacin and releasing more over time. Silicone hydrogels 
 v 
as a group did not release as much antibiotic as the hydrogels, but neither group of lenses were 
able to release the antibiotic for any extended periods of time.  
 Novel materials created using a molecular imprinting strategy demonstrated substantial 
improvements to release times measured in vitro. Some of the materials were able to demonstrate 
sustained release within the vials for up to two weeks. The molecular imprinting strategy was 
subsequently applied to contact lenses manufactured in-house, which were shown to have similar 
contact lens properties to lenses already on the market. Testing of the lenses in vitro and in vivo 
demonstrated a superior profile in eradicating pathogenic bacteria in models of microbial 
keratitis. 
CONCLUSIONS 
 The results from this thesis detail the potential for novel, custom-made contact lenses 
with extended ciprofloxacin releasing characteristics. These novel lenses may influence or be a 
part of future treatment paradigms for ocular infections. 
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CHAPTER 1 - INTRODUCTION 
1.1 BIOMATERIALS 
 Mankind has been using materials to aid in improving the human condition since ancient 
times. Early examples of the use of gold in dental fillings, and of using wood for prosthetics for 
severed limbs are evident from anthropological history. 1, 2 However, it took until the turn of the 
20th century for advancements in materials and chemical engineering, as well as our 
understanding of relationships between materials and their effect on the body and vice versa  to 
develop sufficiently to allow for the field of "biomaterials" to truly develop. Biomaterials are 
commonly defined as any nonviable material used in a medical device, but recent examples of 
non-medical applications of biomaterials such as DNA microarrays and cell culture platforms 
suggest that the common definition may be a bit too narrow. 1, 3 Regardless, success of 
biomaterials used in humans span diverse applications from scaffolding for the growth of new 
bones, stents to keep narrow blood vessels open and dental implants to replace lost teeth. 
Reaching modern day levels of success did not come overnight. Unfavorable host-material 
interactions initially prevented successful use of materials in medical applications. 3 Use of 
organic material such as wood as medical devices inevitably led to undesirable immunologic 
responses by the body and device failure. 1 The success of modern biomaterials has seen insights 
into the design, synthesis and application of materials to have favorable host-material 
interactions.  
1.1.1 CHARACTERISTICS OF SUCCESSFUL BIOMATERIALS 
 The use of intraocular lenses (IOLs) after cataract extraction surgery, where an artificial 
lens is implanted into an eye in place of the removed, cloudy, natural lens, provides a useful 
example of the properties needed for successful biomaterials. Success of a biomaterial depends 
 2 
on two distinct, broad properties. First, it must be somehow accepted by the body. The material 
cannot cause an immunologic reaction that results in persistent inflammation or a host immune 
response or the material will eventually be rejected. The material also cannot be toxic to the area 
of the body where it is to be used. Second, the biomaterial must in some way fulfill a function. 3 
In the majority of cases, the function of the biomaterial will be defined by the disease that is 
being treated. 4 These two defining features of biomaterials are described in the broadest terms 
available to illustrate the fact that what is needed will necessarily be disease and location 
specific. In the design of IOLs, for example, the choice of material such as acylates, hydrogels 
and silicone were chosen not only because they had favorable host-material interactions with the 
eye, but also because they could be manufactured with the desired optical properties to correct 
vision. 5 Properties that facilitate success within blood vessels, where desirable properties may 
include prevention of blood clot formation, and stability in enlarging the blood vessels, may not 
be applicable for biomaterials used in the mouth for example, where the toughness of the 
material against wear and corrosion are more important. 1 Consideration must also be made for 
the timeframe of use of the biomaterial, as materials that are intended to be used indefinitely 
within the body may have required properties different than those that will be removed at a later 
date. Materials used indefinitely within the body have to be carefully studied for any long term 
adverse effects, and maintenance of desired function. For example, while one may think hip 
replacement surgery to be an indefinite operation, the lifespan of the materials in this very 
mobile joint is only 10-15 years. 6 
 Initially, the aim of biomaterials was biological inertness in conjunction with their 
intended function. Materials were chosen that would not interact biologically with the host 
organism and behave effectively invisible to the immunological process. The majority of these 
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early materials served a more mechanical support type of role. Titanium and titanium alloys for 
orthopedic applications are a prime example of an early biomaterial whose main biological aim 
was inertness. 4 Titanium alloys benefitted from having strength and structural rigidity to aid in 
the healing of broken bones, with the added benefit of being corrosion resistant and invisible to 
the immune system for years after implantation. 4 In contrast, as the field of biomaterials has 
continued to evolve, newer materials are being engineered to positively interact and affect the 
course and management of diseases in addition to mechanical support. An example of these 
newer materials have been introduction to the market of heart stents which release compounds to 
prevent vessel re-stenosis, and thus improve recovery time after a cardiac ischemic event. 1 The 
materials still have a mechanical function in keeping the blood vessel open, but now they also 
can release factors to encourage the body to behave in a therapeutically beneficial way.  
1.2 CONTACT LENSES 
 Arguably, contact lenses (CLs) are the most commercially successful biomaterial ever 
released, with estimates of between 125-140 million wearers as of 2010. 7 CLs are small 
biomaterials specifically engineered to correct for refractive error while being worn on the ocular 
surface. 8 CLs have become so common in modern society that it is often easy to overlook the 
challenges in their development before they reached commercial success. As CLs are 
biomaterials, the challenge to the successful commercialization of CLs was the same as the 
challenges to all biomaterials - the material needed to be designed to perform an intended 
function, while also being positively received by the body. The function of CLs is the correction 
of refractive error. They needed to be formed of a material that had the appropriate optical 
characteristics in terms of light transmission and ability to refract light rays. Second, the lens 
needed to be compatible with the ocular surface with which it would interact. 9 The need for CL 
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biocompatibility is what prevented successful use of CLs until midway into the 20th century. 
Mankind already had a long history of using glass for optical applications such as glasses, 
telescopes and microscopes before the invention of CLs, and was thus the material used for the 
very first CLs. 9 Glass ultimately failed as a possible material for CLs because it has poor 
biocompatibility. Early examples of large CLs made from glass, even when lathed with as much 
precision as possible so that they fit into the contours of the cornea and the rest of the ocular 
surface, were so uncomfortable that wearers could not wear them for long periods of time even 
with the aid of anesthetics. 9 Glass also does not transmit any oxygen to the cornea, hampering 
normal corneal physiology. 
1.2.1 HISTORY AND DEVELOPMENT OF CONTACT LENSES 
 Poly(methyl methacrylate) (PMMA) was used as early as the 1930s as the first successful 
CL material. The material, an acrylate polymer, was used because it was found to have the 
desired optical properties while also being relatively well tolerated by the ocular surface during 
wear and for many years was the basis for successful rigid CL wear. 10 Indeed, the 
biocompatibility of PMMA in the eye was further elucidated by events in World War II. A 
British ophthalmologist, Harold Ridley, made the observation that shards of PMMA embedded 
into the eyes of fighter pilots from canopies blown out by machine gun fire did not induce large 
inflammatory reactions as they healed, and thus did not need to be removed. 3 Ridley eventually 
used the material in his design of an IOL. It would  take until the 1960s for Otto Wichterle, a 
Czech chemist, to fashion an efficient and simple means to form poly(hydroxylethyl 
methacrylate) (pHEMA) lenses through spin casting, which would serve as the basis of future 
soft CLs. 9 pHEMA was biocompatible with the ocular surface, and importantly, because of the 
ability of the material to absorb and retain water, it had significantly better comfort when worn 
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on the ocular surface compared to rigid lenses made from PMMA. 11 Further developments in 
spin casting allowed for the reproducible large scale industrial production of lenses to be a reality 
and allow for successful commercialization of this means of refractive error correction. pHEMA 
and variants of pHEMA dominated the CL market for many years since their commercial 
introduction, but they did suffer from some drawbacks, chief among them being reduced oxygen 
flow to the ocular surface. 11 The primary sources of oxygen to the ocular surface are through the 
tears which are in contact with the outside air, and the circle of blood vessels which encircle the 
cornea in the area known as the limbus. By introducing another barrier between the ocular 
surface and the eye, the cornea was relatively oxygen starved whenever CLs were worn. 10 
Prolonged wear of CLs based on pHEMA material eventually led to symptoms associated with 
hypoxia, as metabolic functions of the cornea are hampered by the scarcity of oxygen. In the 
short term, the ability of the endothelium, a layer of cells in the cornea whose primary function is 
to regulate the hydration of the cornea, is affected and led to clinical manifestations of edema 
within the cornea, affecting vision and comfort. 12 Long term, chronic starvation of oxygen by 
the cornea induced the growth of new blood vessels into the normally avascular cornea, leading 
inevitably to an inflammatory response and decreased CL tolerance. 12 There was also some 
speculation by practitioners within the CL field that the relative hypoxia experienced by the 
cornea during CL wear led to decrease ability of the eye to ward off pathogens and thus 
explained the increased risk of developing sight threatening microbial keratitis when wearing 
CLs. 13 
1.2.2 DEVELOPMENT OF SILICONE HYDROGELS 
 The solution from the CL industry to the problems associated with pHEMA-based 
materials was to search for novel ways to increase the amount of oxygen that was able to flow 
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through the lens and be delivered to the cornea. Within pHEMA lenses, oxygen transport is 
dictated by the water content and thickness of the lens. 10 The water content in pHEMA based 
lenses thus put a limitation on the amount of oxygen that could theoretically be delivered. High 
water content CLs also suffered from protein deposition and poor lens reproducibility. For many 
years, it had been known that silicone had excellent oxygen transport capabilities. Indeed, to 
combat the effects of CL induced hypoxia in children who required CLs after pediatric cataract 
surgery, they would be fitted with CLs made solely of silicone rubber. 14-18 The large downside 
to these silicone lenses was their extreme hydrophobicity, preventing appropriate lens wetting in 
contact with the tear film, and leading to increased deposition of the hydrophobic components of 
the tear film such as lipids, eventually fouling the lenses. 17 For commercial applications for the 
simple correction of refractive error, the issues of discomfort would be enough to prevent 
silicone rubber lenses becoming commercially viable, and the use of silicone elastomers today is 
restricted to pediatric cases. 10 
 The introduction of silicone hydrogels the late 1990s revolutionized the CL market by 
providing the high oxygen properties of silicone, while retaining the desirable handling and 
comfort characteristics of hydrogels by incorporating hydrophilic monomers with silicone 
containing materials. 19 The silicone within these new materials would provide the desired 
oxygen transmission, and the hydrophilic monomers would provide the water and ion 
permeability that are critical for lens comfort. 20 The hydrophobicity of the silicone within the 
lenses was combated by modifying the surface. Bausch & Lomb's lens, the Purevision 
(balafilcon A) went through a plasma oxidation process by putting the material in a plasma 
chamber, which partially transformed the surface silicone into wettable silicate. 19 As the entire 
surface was not converted into silicate, the surface was described as being composed of silicate 
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"islands", which when worn gave the effect of a continuous wettable surface. CIBA Vision's 
Focus NIGHT AND DAY (lotrafilcon A) material used a plasma coating process to put down an 
ultrathin wettable coating onto the lens surface. 19 The initial aim of these materials were 
overnight, continuous 30 day and night’s wear. 11 The thinking was that with improved oxygen 
transport, complications with chronic hypoxia would be eliminated, and by eliminating the need 
and use of solutions, complication from preservatives would also be eliminated. Practitioner 
prescribing habits ultimately derailed attempts at eliminating solutions, as overnight, extended 
wear was not widely prescribed due to the increased risk of developing sight threatening 
infections with this type of wear modality. Other generations of silicone hydrogels followed. The 
Acuvue silicone hydrogel product range from VISTAKON, Acuvue OASYS (senofilcon A) and 
Acuvue Advance (galyfilcon A) utilized incorporation of an internal wetting agent, 
polyvinylpyrollidone, to improve the wettability of the surface, without modifying the surface in 
any way. 20 CooperVision's Biofinity line (comfilcon A) represents the third generation of 
silicone hydrogel technology. The comfilcon A material does not utilize any wetting agent or 
surface modification - rather the design of the silicone polymers incorporates a highly wettable 
moiety to improve comfort. 11 The aim of all of these developments were to improve patient 
comfort and acceptance. It was disappointing to clinicians that with the introduction of silicone 
hydrogels, and the significant improvement in the amount and severity of hypoxic complications, 
that the rate of CL drop-out did not significantly change. 21 Clearly, hypoxia was but one piece of 
the puzzle to CL discomfort. Contemporary materials will likely continue to utilize silicone for 
the superior oxygen transmission profiles, the challenge to the manufacturers will continue to be 
to improve the notion of CL "comfort" to prevent patient drop out.  
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1.2.3 DEMOGRAPHICS OF CONTACT LENS WEAR 
 International surveys paint an interesting picture of CL wear and CL prescribing within 
the contemporary eye care market, with the results from the most recent worldwide surveys 
being detailed in publications headed by Morgan and Efron as part of the International Contact 
Lens Prescribing Consortium. The results of surveys being sent to practitioners worldwide for 
many consecutive years yield data in terms of wear modality, refractive errors being corrected 
and lens replacement frequency, and the general results are summarized in Table 1-1. It was 
found that there is a continual decrease in the prescribing of rigid CLs over soft lenses, with rigid 
gas permeable lenses accounting for only about 10% of all lens fits. 22 When prescribed, rigid 
lens patients tended to be older, male, and more likely to be fit with multifocal or bifocal lens 
designs. The worldwide distribution of rigid CL prescribing also varies greatly, from a high of 
37% of all fits in Malaysia to only 0.2% of all fits in Lithuania. 22 Regardless of the worldwide 
distribution, the authors noted that the prevalence of rigid CLs has decreased over time, but there 
still exists a population of practitioners and patients who prefer this type of lens material. 
 The refractive condition corrected by CLs has also expanded greatly. Initial designs for 
CLs were merely for the correction of spherical refractive error, hyperopia and myopia, but 
designs to correct astigmatism and presbyopia are now also available and commonly prescribed. 
23 The demographics for presbyopic CL wearers skews to significantly more females. The 
majority of presbyopic patients were not corrected with some form of presbyopic correction, as 
multifocals or monovision was only prescribed 37% of the time in presbyopic patients. 23 When 
presbyopic corrections were prescribed, three times more patients were fit with multifocal CLs 
versus monovision, highlighting the greater acceptance by practitioners and patients of 
multifocal contact lens designs. There was again spread of presbyopic prescribing seen 
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throughout the world, with a high of 79% of presbyopes fit with presbyopic CLs in Portugal, to a 
complete lack of any presbyopic CL prescriptions for patients  in Singapore. 23 Correction of 
patients with astigmatism, in contrast to patients with presbyopia, has seen a gradual increase in 
the number of toric astigmatic CLs being prescribed. On the whole, patients being fit with toric 
lenses tended to be older and of male gender. 24 There was significantly less patients fit in daily 
disposable wear modalities for patients being fit with toric lenses. Overall, 25% of patients were 
fit with toric lenses. This figure still falls short of the presumed 45% of the population who are 
estimated to have more than 0.75D of astigmatism, but has been rising over the years that the 
survey has been performed. 24 Again, regional differences were found, with a high of 48% of 
patients in Portugal being fit with toric lenses, and a low of only 6% being fit in Russia. 24 
 The wear modality and replacement frequency demographics that have been gleaned 
from these surveys also illustrate the efforts of the industry to shape the CL wearing experience. 
Extended wear, once thought to be the wear modality of the future, was only prescribed 7.8% of 
the time. 25 The trend for extended wear appears to be downward, with decreasing prevalence 
throughout the years measured by the survey after reaching a peak in 2006. 25 Patients who were 
prescribed extended wear tended to be male, older and were fit with silicone hydrogels. 25 The 
authors of this study suggest that it is likely that, given the established risk that extended wear 
has on the development of sight threatening microbial keratitis, patient and practitioners do not 
see the benefits outweighing the potential complications of extended wear. 25 Malaysia had the 
lowest rate of extended wear being prescribed, with only 0.6% of all fits using this modality, 
compared to the high of 27% extended wear seen in Norway. 25 Daily disposable CL wear, where 
a lens is worn once straight out of the packaging before being replaced the next day with a new 
lens, is another example of the ways in which the CL industry has attempted to regulate the wear 
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modality of the CL population. Daily disposable lens prescribing has been increasing over time, 
accounting for 24% of all fits by the end of the survey. 26 Daily disposable CL wearers tended to 
be older and of the male gender. Interestingly, there is a positive correlation between the 
proportion of CL fits being daily disposable and the country's gross domestic product, suggesting 
that the initial lens cost may be a factor in the ability of the lenses to be dispensed. 26 Nepal saw 
the lowest prescriptions for daily disposable lenses (0.6%), while 66% of patients in Qatar were 
fit with daily disposable lenses. 26 
 Finally, even though silicone hydrogels are not being used extensively for extended wear 
applications, they have seen a continued increase in popularity for fits on a daily wear basis. The 
proportion of fits with silicone hydrogels have increased from 3-4% of all fits the year after they 
were released on to the market to approximately 36% today. 27 Silicone hydrogel prescribing is 
not significantly different between the two genders, or between the different age groups. 
Highlighting the perceived utility of silicone hydrogels in combating complications, a large 
proportion of silicone hydrogels were refits rather than initial fittings. Regionally, Australia had 
the highest penetration of silicone hydrogels at 65%, while delayed introduction into the 
Japanese market let to a relative low market penetration in that country (20%). 27  
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Studied Factor 
% Proportion 
of All Fits 
Demographics of 
contact lens 
population 
Most often 
prescribed country 
(%) 
Least often prescribed 
country (%) 
Trend over time 
Rigid Lenses 10 % - Older - Male Malaysia (37%) Lithuania (0.2%) Decreasing 
Presbyopic 
Correction 
(multifocal or 
monovision) 
37 % (of all 
presbyopic 
patients) 
- Female Portugal (79%) Singapore (0%) Increasing 
Toric Lenses 25 % - Older - Male Portugal (48%) Russia (6%) Not reported 
Extended Wear 7.8 % - Older - Male Norway (27%) Malaysia (0.6%) 
Decreasing after 
peaking in 2006 
Daily Disposable 24 % 
- Older 
- Male 
- Affluent Country 
Qatar (66%) Nepal (0.6%) Increasing 
Silicone Hydrogel 36% - Refits Australia (65%) Japan (20%) Increasing 
Table 1-1   Demographics and Trends in Contact Lens Prescribing 
 There has been considerable change in availability and options to prescribers of CL in terms of material (eg soft, rigid, 
silicone hydrogel), wear modality (eg non-replacement, monthly wear, daily wear, daily disposal, extended wear), and 
refractive conditions correctable by CLs (astigmatism, presbyopia) in the past 15 years. The interplay between the 
industry, eye care practitioners and patients will continue to dictate what types of lenses will have success and market 
share. 22-27
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1.2.4 CONTACT LENS MANUFACTURING 
 The materials used for CLs throughout history have centered around two man-made 
materials which have excellent light transmittance characteristics: Glass and polymers. Glass, 
which had a much longer history than polymers, was initially used in attempts to make CLs but 
proved to be very uncomfortable. 28 The work of Dallos in making eye impressions improved the 
comfort somewhat by providing a “negative” mould to which the lens could be formed, and 
continues to be useful for creating larger custom designed scleral lenses. 28 The first true 
revolution in CLs was in the introduction of polymers in the 1930s and 40s, and the techniques 
used in attempts to mould the material to the patient’s eye shape. 
 Initial techniques in the forming of polymer CLs involved lathing, where a cylindrical or 
round piece of preformed material was mounted on an apparatus to grind and cut away the front 
and back surface to give a desired shape/refractive power. 29 In this application of lathe cutting, 
the manufacturers at the time were using knowledge gained from the manufacture of glass lenses 
for spectacle applications. The downside of this technique were that it was time consuming, and 
that, at least at the beginning, was dependent on the skill of the technician operating the lathe. 
Understandably, reproducibility of the lenses were an issue. 28 It also took some time to develop 
the proper skill to be able to lathe both the front and back surface. Lathe cut CLs still exist today, 
with the major change being the use of computer controlled lathes to greatly improve the 
precision, reproducibility and time needed to produce the lenses. These lenses are mainly used in 
specialty applications. 28 
 The introduction of soft CL materials expanded the possibilities of manufacture. Spin 
casting was the initial method proposed by Wichterle in producing CLs from liquid solutions. 30 
In spin casting, the liquid mixture to be polymerized is placed into a mould which forms the front 
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surface of the lens. The lens is forced to assume the contours of the mould by centripetal force as 
the mould is spun, and the speed of rotation is controlled to produce the desired posterior surface 
shape. 31 Cast CL materials are also possible with liquid polymerization mixtures. In cast 
moulding, the polymerization mixture is injected between two moulds which provide the anterior 
and posterior shape of the lens as the lens is polymerized. 28 
 Regardless of spin or cast moulding, the manufacture of soft CLs is classified as a 
polymerization reaction. In polymerization reactions, long, repeating molecular chains are 
produced. When exposed to certain wavelengths of light, or raised to certain temperatures, 
special molecules within the polymerization mixture known as "initiators" will produce energetic 
unpaired electrons called free radicals. 32 These free radicals provide energy to facilitate the 
joining of molecules, and the process repeats and continues until the reaction mixture is 
exhausted of raw materials or free radical generation stops. During this time, the individual 
molecules are attached to the ever growing and elongating molecule, much like adding links on a 
chain. The end result of a polymerization reaction is the conversion of a reaction mixture of 
simple monomers into a long polymer chain. 32 In CLs, the main monomer used in the 
polymerization reaction is hydroxyl ethyl methacrylate (HEMA) (Figure 1-1a), which when 
elongated is termed poly(HEMA) or pHEMA (Figure 1-1b). To successfully form pHEMA, the 
elongated chains also require a crosslinker, a molecule to join these long repeating chains 
together so that a meshwork can be formed that has the ability to absorb water. The molecule 
most often used is EGDMA (ethylene glycol dimethacrylate) (Figure 1-1c). As can be seen by its 
structure, EGDMA contains two double bonds on either side, each of which can participate in the 
polymerization reaction and thus can serve to attach chains together. Modern silicone hydrogel 
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materials also incorporate into the mixture silicone containing monomers such as 
tris(trimethylsiloxy)silane.  
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Figure 1-1 Chemical Structure of Contact Lens Components 
  Chemical structure of components commonly used in CLs. a) Hydroxyl ethyl 
methacrylate (HEMA), the common base material b) Structure of polymerized 
HEMA, pHEMA c) Ethylene Glycol Dimethacrylate (EGDMA), variants of 
which are commonly used as crosslinkers to join extending pHEMA chains 
together to form the meshwork of the CL. 
 
 Today, initiation of the free radical reaction is through UV light initiated 
photopolymerization. The initiators of reaction are photoinitiators which absorb particular 
wavelengths of light to produce the free radicals needed for the polymerization reaction. 32 The 
advantage of photoinitiated polymerization reactions are that large volumes of individual lenses 
can be polymerized at once, the reaction tends to occur very quickly, and the process can be 
started and stopped quickly by modifying how long the light is on. In comparison, heat initiated 
polymerization suffers from lower degrees of polymerization control, and longer rates of 
reaction, with the advantage of lower temperatures being reached in the reaction and longer 
polymer chains eventually being produced. 31 
  
1.3 PHARMACOLOGY 
 Pharmacology is the study of the interactions between drugs and the body. 33 Drugs can 
be man-made, endogenous or naturally occurring, but can be broadly defined as substances 
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which have some physiological effect on the body and are used to treat or diagnose a disease. 34 
Much of the advances in modern medicine rely on the advances in our understanding of 
molecules and their effects on the body, which are elucidated by those in the pharmacological 
field. 34 The study of pharmacology is necessarily an interdisciplinary study, as elements of 
biology, medicine, molecular biology, organic chemistry, physics, physiology and biochemistry 
are all necessary to understand the role that drugs have on the body and disease. 
1.3.1 PHARMACOKINETICS AND PHARMACODYNAMICS 
 Key to our understanding of pharmaceuticals and their effects when administered is the 
study of two fundamental concepts - pharmacokinetics and pharmacodynamics. 34 
Pharmacokinetics studies how an administered agent is handled by the body, while 
pharmacodynamics is the study of the effect of the drug on the body. 35 Pharmacokinetics are 
generally studied in four main stages, which are commonly expressed through the acronym 
ADME - which represent the pharmacokinetic stages of Absorption, Distribution, Metabolism 
and Excretion/Elimination. 36 The study of pharmacokinetics is fundamentally the study of the 
passage of a drug through the body, and for the majority of drugs it is concerned with the 
concentration of a drug in the plasma or circulatory system. 34 Study of Absorption is intractably 
linked to the route of administration, or the method to which the drug is given to the body. There 
are many different ways in which a drug can be administered to the body, but most commonly, 
they include oral administration and intravenous injection. Other methods include sublingual 
administration, by inhalation, intramuscular and subcutaneous injections, rectal suppositories and 
topical applications. 37 Regardless of the route of administration, the goal is to deliver the drug to 
the body through the most efficient way possible to treat the specific disease. In general, a drug 
is expected to be absorbed faster if administered to areas with greater blood flow and with 
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greater surface areas. 35 The second step in the study of pharmacokinetics is the study of 
Distribution. An administered drug has potential to be distributed throughout the entire body 
through either the blood or lymphatic system. Even seemingly locally administered drugs, such 
as direct intramuscular injection or transdermal patches, are transported through the body. 37 
Depending on the solubility characteristics of the drug, a drug may distribute preferentially to 
certain sites in the body, such as within the fatty tissue, or within the blood system. Metabolism 
occurs when the drug begins to be changed or modified by the body. The key player in the 
metabolism of drugs is the liver and the various cytochrome oxidase enzymes (also known as the 
cytochrome P450 series of enzymes) produced by the liver. 36 The goal of metabolism from the 
body's standpoint is to modify a foreign substance to allow for easier excretion from the body. 
The liver cytochrome enzymes primarily work in oxidative reactions to increase the polarity of 
molecules to allow easier excretion by the kidneys in the urine. Other reactions by the liver 
conjugate the drug with other molecules to create more stable, insoluble complexes, which can 
eventually be mixed with bile acids and excreted in the stool. 37 
 The primary activity of the liver in metabolizing drugs coupled with the preferential 
passage of the blood from the gastrointestinal tract to the liver through the hepatic portal vein can 
pose a significant problem for drug administered orally. 35 As blood from the small intestine is 
passed through the liver before being circulated through the rest of the body, an orally 
administered drug that is metabolized by the liver may see a significant proportion inactivated 
before it can reach the systemic circulation and its site of action. This phenomenon is known as 
the hepatic first pass effect. 35 This limitation to oral bioavailability, or the amount of drug 
administered orally that reaches its target site of action unchanged, leads to investigations into 
alternative routes of administration for certain diseases. For example, in the treatment of angina 
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pectoris, a painful sensation in the chest and heart area due to cardiac ischemia, treatment 
involves dilation of the coronary blood vessels using nitroglycerin, which becomes nitric oxide, a 
potent vasodilator. Nitroglycerin is given underneath the tongue (sublingually) in part because 
the hepatic first pass effect would inactivate the majority of nitroglycerin administered orally. 33, 
36 The final stage in the study of pharmacokinetics is Elimination/Excretion.  Through the actions 
of metabolism, the administered drug is made to be excretable through the urine or the stool and 
is removed from the body. Though less common, drugs can also be excreted through other body 
secretions such as sweat or saliva, or through the lungs by exhalation. 33 Ultimately, 
phamacokinetics is the study of the effect that the body has on an administered drug. The impact 
of this knowledge guides the selection of a particular drug for a particular disease situation, and 
critically, the dosage and the dosing frequency needed to efficiently combat the disease of 
interest. 37 
 In contrast to pharmacokinetics, the study of pharmacodynamics concerns the effect that 
a drug has on the body. The purpose of an administered drug is to have some sort of change in 
biological function, to affect some component of a disease process. 34 Central to our modern 
understanding of the molecular mechanism of drugs and their effects is the study of cell 
receptors and cells signaling. 34 The ability of a drug to lower blood pressure, to kill cancerous 
tumour cells or aid in sexual dysfunction ultimately come down to the ability of the drug or the 
by-products of the drug's metabolism to interact with cell receptors, whether they be on the 
surface of the cell or within, and initiate a cascade of cell signaling to affect a desired clinical 
outcome. Thus, for a drug to be effective, cells at the site of action require receptors that can 
interact with that drug, and interaction of that drug with those receptors must then initiate the 
desired outcome. 36 In the absence of those specific receptors in that part of the body, the drug 
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will have no effect. Consideration also has to be given to the distribution of these receptors in 
other places within the body, and the effect that the drug may have on those cells and those 
signaling processes, as these can lead to undesirable side effects. 35 For example, in the chemical 
treatment of cancer, chemotherapy drugs affect cancerous cells by selectively killing rapidly 
growing and dividing cells. Unfortunately, there are many cells within the body that are also 
rapidly growing and dividing through normal actions which are affected by chemotherapy 
treatment. This leads to the typical side effects of hair loss and nausea during cancer treatment, 
as the rapidly dividing hair follicle cells and epithelial cells of the intestine are destroyed as 
“collateral damage” to the destruction of cancerous cells. 36 It is also important to acknowledge 
the set of tools that administered drugs must work with. The ability of drugs to affect change 
within the body is limited by the abilities of the cells themselves – a drug cannot signal for cells 
to perform actions that they do not have the capacity to already perform. The search for new 
drugs in the treatment of disease thus becomes intertwined with our ability to understand the 
body's systems and cell processes.  
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1.3.2 OCULAR PHARMACOLOGY 
1.3.2.1 OCULAR ANATOMY AND PHARMACOLOGY 
 
Figure 1-2 Anatomical Structures of the Eye 
 Figure courtesy of the National Eye Institute, National Institute of Health, Ref 
#NEA09 
  
 The key structures in the anatomy of the eye is detailed in Figure 1-2. The anatomy of the 
eye, from a pharmacological perspective, can be divided into the anterior and posterior segment, 
which is roughly defined as the areas anterior and posterior to the physiological lens. 38 The 
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reason for this segmentation is that it corresponds to the tissues that can reasonably be reached 
through topical application on the ocular surface (anterior segment), and what tissues require 
more invasive local treatment or systemic treatment (posterior segment). 39 The anterior segment 
of the eye is surrounded by the ocular orbit and ocular adnexa, consisting of the eyelids and 
eyelashes which cover the ocular surface when the eyes are closed. The most anterior structure of 
the eye proper is the clear cornea. The cornea consists mainly of an organized, avascular, 
hydrated collagen network bordered on either side by epithelium termed the stroma, which 
consists of 90% of the corneal thickness. 39, 40 On the anterior surface, the corneal epithelium is 
several layers thick and are held together with tight junctions which seal the surface as much as 
possible from the influx and efflux of water and other aqueous soluble substances. 39-41 On the 
posterior side, the cornea is covered with a single layer of specialized epithelium called the 
endothelium, whose primary function is to control the corneal hydration and thus transparency. 
42, 43 The three section structure of the cornea has implications for topical drug delivery, as the 
two epithelial layers primarily serve as a barrier to hydrophilic molecules while allowing 
lipophilic molecules through, while the very hydrated stroma behaves exactly the opposite. 39, 44 
The design of a drug to be delivered through the cornea thus requires both hydrophilic and 
hydrophobic characteristics, or have some sort of vehicle or strategy to penetrate these barriers. 
45 Surrounding the cornea is the highly vascularised area known as the limbus, which is the site 
of the corneal epithelial stem cells, and the membranous, vascularised conjunctiva, which serves 
to aid in the lubrication of the eye through secretion of mucous. 46 Due to a higher surface area 
and blood supply, uptake of instilled molecules can be an order of magnitude larger for the 
conjunctiva when compared to the cornea. 40, 45 Uptake into the conjunctiva is not considered 
useful to the eye as absorbed molecules are quickly moved to the systemic circulations by the 
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blood vessels and lymphatics. 39 The sclera is a continuation of the cornea beyond the anterior 
portion of the eye. 46 In comparison to the clear cornea, because the collagen is not precisely 
organized, the sclera is completely white and opaque rather than being clear, but is extremely 
tough. 46 The entire anterior surface of the eye, cornea, conjunctiva and sclera are lubricated 
through the production of tears secreted by the lacrimal glands. The tears serve a host of diverse 
functions - lubrication, transport of nutrients, removal of waste, refraction of light and defense 
against pathogens. 47, 48 
 Posterior to the cornea lies an area known as the anterior chamber. The anterior chamber 
is usually filled with a liquid termed the aqueous humour, a low protein fluid produced by the 
ciliary body. The aqueous humour serves several functions, including a mechanical function 
supporting the shape of the eye through its effect on intraocular pressure, providing nutrition and 
removal of waste for several energy intensive structures such as the endothelium and trabecular 
meshwork, and finally, as an optical component to aid in the proper focus of light rays as they 
traverse through the eye. 44, 48 The production of aqueous from the blood is highly controlled, 
involving active secretion of select components by the ciliary epithelium. This energy dependent, 
specific generation of aqueous from the blood differentiates aqueous from a mere blood filtrate. 
The separation from the aqueous and the blood is termed the "blood-aqueous" barrier (BAB). 38, 
39 The highly vascular iris separates the anterior chamber from the posterior chamber. The iris 
primarily serves to control the amount of light that enters the eye by controlling the size of the 
pupil. 49 Posterior to the iris is the posterior chamber, which is also filled with aqueous humour 
and also contains the lens. The lens is one of the main refractive elements of the eye, and in 
conjunction with the ciliary body, is responsible for the ability of the eye to change its focal 
length and allow for the eye to focus from optical infinity and closer. 48, 50 The lens serves as the 
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de facto separation between the anterior and posterior segment of the eye pharmacologically 
because it is realistically the most posterior structure that treatments applied to the ocular surface 
(eye drops, ointments, etc) can possibly reach and have an effect. 39 All of the structures 
mentioned anterior to the lens can be targeted to some degree with topical therapy, with 
structures beyond the lens minimally affected by agents applied on the surface. 41, 46 
 The space between the  lens and retina is filled with the vitreous. The composition of the 
vitreous is similar to the cornea in that it is avascular, and composed mainly of water with a 
small amount of dissolved collagen. It also contains very few cells. 44 The vitreous has recently 
become an important target for the treatment of posterior segment disorders because agents can 
be safely injected into the vitreous to eventually spread to other posterior structures such as the 
retina which cannot be targeted directly without a high degree of risk. 51 The retina is nervous 
tissue adapted to the capture and processing of light. It consists of specialized cells to capture 
light (the rods and the cones) and networks of neural tissue (the bipolar, ganglion and amacrine 
cells) to provide rudimentary processing of light information before being sent from the eye to 
the central nervous system through the optic nerve. 44 The retina is a highly metabolic area of the 
body, and is fed by a highly vascularised area posterior to the retina known as the choroid, which 
is in the same anatomical layer in the eye as the ciliary body and iris, which all together form the 
uveal tract. 42, 46  
  Like the central nervous system, the retina also has preferential and privileged blood 
flow. 52 Control of blood components transported to the retina is tightly controlled to protect 
these vital and sensitive tissues, and this preferential transport of blood components is termed the 
"blood retinal barrier" (BRB). 38, 39, 46 The BRB often prevents successful systemic treatment 
from affecting the retina, necessitating surgical intervention and its associated risks. 52 
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1.3.2.2 CONSIDERATIONS FOR OCULAR DRUG DELIVERY 
 Considering the anatomy of the eye, all of its barriers and mechanisms to remove 
unwanted molecules, the design and engineering of successful ophthalmic pharmaceuticals can 
be quite complex. As always, the ideal characteristics of a drug will be defined by the disease 
being treated, the location in which it is occurring, how the drug will be administered and the 
health status of the patient. All things being considered, the ideal drug would be able eradicate 
the disease in question quickly in a minimum number of doses and a minimum amount of side 
effects. For the vast number of treatments these ideals are not reached, and so a cost benefit 
analysis must be undertaken - weighing the cost of treatment in terms of economics and side 
effects against the potential benefit of eradicating the disease, or decreasing recovery time. 53 The 
eye is readily accessible to treatment, and thus the preference is local therapy to the eye only, to 
prevent the side effects associated with systemic therapy. 38, 52 The eye also has a very specific 
function in conveying visual information. Treatments should preserve this function as much as 
possible if they are to be successfully adopted by practitioners and patients alike. 43, 53 The 
frequency of dosing needs to also be considered. It is well known that patient compliance with 
treatment decreases as the number of drugs and the frequency that those drugs need to be taken 
increases, and thus a formulation which maximizes the therapeutic effect of treatment with a 
minimum number of instillations and drugs is preferred. 40, 45 
 For the eye, the majority of the drug that has an effect is absorbed through the cornea. If a 
topical treatment is to penetrate past the ocular barriers, the molecule would be best served if it 
could traverse both hydrophobic and hydrophilic environments, as this would allow easy passage 
through the relatively hydrophobic corneal epithelial layers, while also passing through the 
hydrophilic stroma and final passage into the aqueous humour. 44, 52 Varied factors, from the size 
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of the molecule, the charge, shape and degree of ionization all have a potential effect on the 
ability of the molecule to pass through the cornea. 40, 43 Many molecules do not possess the ideal 
properties for corneal passage, and thus the drug concentration and dosing frequency are often 
modified to overcome the molecular shortcomings. Tear flow and tear drainage also serve as a 
significant barrier to efficient anterior drug transport. 54 The sudden increase in volume on the 
ocular surface by an instilled drop causes reflex tearing and blinking, which dilute and flush 
away the drug. Estimates of ocular residence time of an eye drop can be as short as only 3-5 
minutes. 45 The immunopriviledged status of the eye through the incorporation of the two blood 
barriers (the BRB and BAB) limit the effectiveness of systemically applied therapy. 43, 52 
Treatments intended for the eye which are given systemically through the oral or intravenous 
route face significant hurdles in trying to pass the BRB and BAB, as unless the molecule 
partitions preferentially into the nervous tissue, a very large dose would be needed to be 
administered systemically for the drug to force its way past these barriers. 55 For this reason, 
systemic treatment for strictly ocular disorders have uneven effectiveness, and are fraught with 
the potential to cause significant side effects due to the large doses often required. 38  
1.3.2.3 ADVANTAGES AND DISADVANTAGES OF EYE DROPS AND OINTMENTS 
 The advantages of using eye drops and ointments for topical treatment of ocular disorders 
over other forms of treatment centre around the location and accessibility of the eye. 45 The 
anterior segment of the eye is readily accessible externally, and thus treatment with eye drops 
and ointments can directly target the eye and surrounding structures. 52 Frequent dosing can 
allow for relatively high concentrations of the drug to be reached within the ocular tissues fairly 
easily, as long as the patient is compliant. 40 By applying the treatment directly to the ocular 
tissues, the hepatic first pass effect can be bypassed compared to orally administered agents. 45  
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The chief challenge to effective eye drop therapy are issues with patient compliance. Often, the 
dosing frequency may be too difficult to manage for patients with acute conditions, and during 
treatment of chronic conditions even once a day dosing can be very difficult to adhere to 100% 
of the time. 56, 57  Eye drops have also been shown to be a relatively inefficient means of 
delivering drugs to the eye. 49 Computer modeling and measurements estimate that only between 
1-7% of the active ingredient within an eye drop is able to overcome all of the ocular barriers and 
exert a therapeutic effect within the eye. 45, 52, 58 This is clearly economically and therapeutically 
disadvantageous, as drugs that do not reach the site of action are wasted and unnecessary. 59 
Current eye drops thus achieve appropriate concentration profiles by utilizing highly 
concentrated solutions instilled frequently. 59 The volume being instilled from a commercial eye 
drop bottle is also significantly larger, at 35-56 μL, than what can be reasonably accommodated 
by the ocular surface which has a theoretical maximum capacity of 30 μL, and routinely only has 
7 μL of tears on it. 39, 45, 59 The excess fluid overflows out of the eye and spreads across the 
patient's cheek. Approximately 75% of the instilled drop which is retained by the ocular surface 
is removed by the nasolacrimal duct, with the remaining 25% being lost to the conjunctival 
vasculature. 46 The surface area of the conjunctiva is approximately 17 times larger than that of 
the cornea, limiting direct diffusion and absorption of the drop by the cornea. 45 The 
pharmacokinetics of eye drops are also not ideal. Eye drop pharmacokinetic profiles are 
characterized by pulsatile delivery, with only a short period of time within the therapeutic 
window, surrounded by periods of either overdose or underdose. 60 Finally, as mentioned 
previously, treatment of the eye through the anterior segment is also unable to affect the posterior 
segment. 38, 39 
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 Ophthalmic ointments partially alleviate some of the disadvantages of eye drops by 
significantly improving ocular residence time. 45 The ointment vehicle is often a petroleum or 
jelly-like substance with low water solubility, and thus when placed on the ocular surface is 
much more difficult to be flushed away through actions of the tears or blinking. 38 The major 
disadvantage of ophthalmic ointments is their unfortunate side effect of impairing vision. 45 The 
thick ointment causes a significant blockage of light transmission, such that they are generally 
only useful for overnight use when the visual function of the patient is not a primary concern. 59 
1.4 OPHTHALMIC DRUG DELIVERY SYSTEMS 
 The use of drug impregnated reservoirs for the treatment of ocular disorders has a long 
and ancient history. It has been recorded that the ancient Romans utilized honey soaked 
bandages as ophthalmic dressings, and there are some recordings of the Egyptians also utilizing 
drug soaked bandages for treatment of ocular infections. 59 In modern times, the interest and 
development of drug releasing devices for the eye continues in attempts to improve patient 
compliance and decrease treatment side effects. 
1.4.1 ANTERIOR SEGMENT DRUG DELIVERY SYSTEMS 
 An overview of commercially available anterior segment drug delivery systems is 
summarized in Table 1-2. To date, the most widely known commercially available anterior 
segment ocular drug delivery system has been the Ocusert® pilocarpine insert, introduced to the 
USA market in 1974 by Alza. 61 The system consisted of a small disc containing two insoluble 
semipermeable membranes made of ethylene vinyl acetate (EVA) encasing the pilocarpine active 
ingredient. The system was designed to control intraocular pressure by precisely releasing 
pilocarpine over the course of 7 days. 40 By modulating the release of pilocarpine from the 
device in an almost linear fashion, rather than pulsatile delivery as is often seen in eye drops, 
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most of the significant side effects of pilocarpine treatment such as induced myopia and pupillary 
miosis were significantly reduced. 61 The system suffered from several significant disadvantages 
unfortunately, chief among them being device awareness leading to a foreign body sensation and 
patient discomfort. 61 The device was also difficult to insert and remove from the eye, and in 
some cases would also spontaneously eject. 46, 62 Even though the system was designed for 7 
days, the recommendation was that these devices should not be worn for more than 12 hours, and 
as such required the patient to remove it themselves rather than an eye care provider as had been 
envisioned. 61 The system is no longer available, likely due to the evolution of glaucoma 
treatment away from pilocapine as a first, second or even third line agent in the treatment of that 
disease, in addition to the noted device shortcomings. 
 Other attempts through the 1990s to develop anterior segment devices had only minimal 
success. Collagen shields, thin dissolvable films formed from porcine sclera, are often used as a 
bandage for a damaged or scratched eye. Suggestions have been made that they could be used to 
concurrently deliver drugs, with the significant advantage that they eventually are completely 
dissolved and cleared from the eye in a relatively short amount of time without any additional 
intervention. 63 Investigations of these shields to release anti-glaucoma agents, antibiotics, anti-
inflammatories and some combination drugs have been performed, but no commercially 
available product has yet to be released. 64-69 Rod shaped devices, designed to be improved 
versions of the discs used for the Ocusert® device have been investigated as they potentially 
have better retention properties within the conjunctival fornix. The Lacrisert® system by Merck 
uses such a rod, which is placed in the fornix to slowly release a moisturizing agent 
(hydroxypropyl cellulose) in the treatment of dry eye over the course of a single day. 41 Use of 
Lacrisert® in trials was shown to be preferred by patients when compared to four times a day 
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dosing with artificial tears. 41 The Minidisc Ophthalmic Therapeutic System by Bausch & Lomb 
was designed to mimic a CL, but to be fitted to the shape of the superior or inferior sclera, and in 
trials was investigated to release the antibiotics gentamicin and sulfisoxazole for over 100 hours, 
and was reported to be easier to insert and had better comfort than the fornix-located Lacrisert® 
device. Unfortunately, the device was never released to the market. 61 The failure of inserts as a 
whole likely stems from the lack of any real commercial traction seen by Ocusert®. 
 Advances to the design of eye drops have focused on the development of gels or 
mucoadhesive drops which increase residence time, or the application of penetration enhancers 
such as preservatives to aid in drug penetration, although these preparations are often limited by 
their blurring effects on vision or poor ocular tolerability. 55, 58 Durasite®, a propriety vehicle 
from InSite vision in California, is a polycarbophil vehicle, designed to specifically hydrogen 
bond with the ocular mucus and ocular epithelium. This greatly improves the residence time of 
the instilled drop. AzaSite, from Inspire Pharmaceuticals in North Carolina, was the first eye 
drop formulated with Durasite® to be released into the market. 46 With this formulation, the 
dosing schedule for the antibiotic is significantly reduced for cases of bacterial conjunctivitis, 
from the usual four times a day for most antibiotics, to only twice a day on the first two days, 
then only a single drop for a further five days. 70 The vehicle also appears to be well tolerated in 
patients. 46 
 Given that such a large proportion of an instilled drop is drained through the nasolacrimal 
duct, thoughts on utilizing a punctal plug as a drug delivery system has been explored. Some 
evidence exists that in the treatment of glaucoma with eye drops, if the puncta is occluded it may 
lead to further decreases in the observed IOP. 71, 72 The next step has been to design the punctal 
plug to be the reservoir of the drug, which is slowly eroded by the tears, releasing the drug into 
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the tear film and onto the ocular surface. Phase II trials have shown that such devices releasing 
glaucoma drugs such as latanoprost and brimatoprost have good retention within the puncta, but 
their effectiveness at lowering IOP were not ideal. 46A punctal plug to release antihistamines in 
the treatment of allergic conjunctivitis is also being examined, as well as one to release the 
antibiotic moxifloxacin. 46, 73 Punctal plugs have to be used with caution, as they may cause 
epiphora (excess tearing) if used in patients with normal tear production and blocked drainage, 
and may be difficult to remove if the patient is experiencing adverse effects from the drug. 
 A sustained drug delivery system for the anti-inflammatory dexamethasone has recently 
been investigated for use in the anterior chamber. Termed Surodex™ from Allergan in 
California, the implant is used after cataract surgery to control postoperative inflammation. The 
device is bioerodable, formed from poly lacto-co-glycolide (PLGA) and is designed to release 
dexamethasone for 7-10 days. Current clinical trials however have demonstrated that the device 
may have no better clinical outcome compared to topical anti-inflammatory therapy, so its 
usefulness has come into question. 42  
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Device 
Name 
Manufacturer Composition Active Agent(s) Time Frame Indications Design 
Ocusert® Alza Corp Ethylene vinyl acetate Pilocarpine 
Up to 7 days, 
but 
recommendation 
is only 12 hours 
Primary Open 
Angle 
Glaucoma 
Small disc placed 
in inferior cul-de- 
sac 
Lacrisert® Merck Hydroxypropyl cellulose 
Hydroxylpropyl 
cellulose 1 day Dry Eye 
Rod place in 
upper or lower 
fornix, 
biodegradable 
Minidisc 
Ocular 
Therapeutic 
System 
Bausch & Lomb 
Polyhydroxymethyl 
methacrylate, 
proprietary 
monomers, 
hydroxypropyl 
cellulose 
gentamicin and 
sulfisoxazole 100-300 hours 
Prophylaxis 
against bacterial 
infections 
Miniature contact 
lens - designed to 
fit on sclera 
AzaSite® Inspire Pharmaceuticals 
Durasite®, a 
proprietary 
polycarbophil 
vehicle 
Azithromycin 1 day Bacterial Conjunctivitis 
Mucoadhesive 
Eye Drop 
Surodex™ Allergan Poly-lacto-co-glycolide (PLGA) Dexamethasone 7-10 Days 
Postoperative 
Inflammation 
Anterior Chamber 
Injection, 
biodegradable 
Table 1-2 Summary of Commercially Developed Anterior Segment Drug Delivery Devices 
 Anterior segment commercially developed drug delivery systems. Ocusert® is no longer commercially available, and 
the Minidisc Ocular Therapeutic System never reached the market. 40-42, 46, 61, 70  
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1.4.2 POSTERIOR SEGMENT DRUG DELIVERY SYSTEMS 
 Commercially developed posterior segment sustained drug delivery devices are 
summarized in Table 1-3. In contrast to the anterior segment, the posterior segment of the eye 
has seen a greater interest in the development of sustained drug delivery devices. This interest 
likely stems from the inaccessibility of the posterior segment of the eye without some sort of 
surgical intervention, and the associated risks with repeated surgeries and injections. 53 In the 
modern treatment of posterior segment diseases, the trend has been toward multiple 
treatments/injection of agents into the back of the eye to treat diseases of an aging population 
such as age related macular degeneration, diabetic macular edema and chronic inflammation. 
Development of a sustained released device would have clear advantages, particularly with 
regards to decreased surgical complications and increased patient compliance by reducing the 
number of necessary visits, and several devices have been developed sufficiently to reach 
commercialization.74  
 The first commercially released posterior segment sustained drug release device was the 
Vitrasert® device designed for the sustained released of ganciclovir, an antiviral agent, in 1992.  
53 Cytomegalovirus (CMV) infection of the retina is visually devastating and common in those 
who are immunocompromised, mainly due to the human immunodeficiency virus (HIV). A large 
and consistent dose of an antiviral is necessary to prevent infectious sight loss. The Vitrasert® 
device is a non-degrading implant that will release ganciclovir for more than 80 days, and in the 
Food and Drug Administration (FDA) approval studies demonstrated good control of CMV 
retinitis. 53 The device is relatively large and requires a sclerotomy to be implanted and the 
device sutured into place. 43 Since it is not degradable, a second surgery is needed to remove the 
device after it has been drained and to implant a second device if necessary. 75 The device 
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consists of the drug, and coats of EVA, which is a relatively impermeable barrier to aqueous 
fluids, and polyvinyl alcohol (PVA), which allows ganciclovir flow. 76 The device suffered from 
a relatively high (12%) complication rate from the implantation procedure, commonly causing 
undesirable outcomes such as cataracts, endophthalmitis or retinal detachment, which impacted 
visual acuity and visual function. 77 It is expected that earlier detection and treatment of CMV 
retinitis in at-risk HIV patients will decrease the prevalence of the disease and thus the need for 
the Vitrasert® device. 
 The Retisert® ophthalmic device is based on the Vitrasert® device and was developed by 
Bausch & Lomb in Rochester, New York. The device is designed to release the corticosteroid 
fluocinolone acetonide for approximately 1000 days. 78 It is composed of a silicone elastomer 
cup containing an orifice to allow drug diffusion. The orifice is covered by PVA to serve as an 
additional barrier, and the entire device is anchored through a suture tab to the sutured hole made 
during implantation. 79 Clinical trials for the device were initiated for the treatment of recurrent 
posterior uveitis and recurrent diabetic edema, and although benefit from the device was seen for 
both of these conditions, the rate of complications from the device were severe enough to limit 
application to recurrent uveitis only. 78 In a 34 week trial, the device reduced uveitis recurrence 
from 51% in the treated eyes to 6%, while the fellow, untreated eyes had recurrence jump from 
20% to 42%. At this time, 50% of the patients required anti-ocular hypertensive medications, 
with 6% requiring more serious glaucoma filtering surgery. At 34 weeks, 10% of the patients 
required cataract surgery. 78 These trends continued as more time passed. 1 year post 
implantation saw a uveitis recurrence rate in treated eyes of only 5.4%, compared to 46% in the 
control eye. 38 3 years post treatment there was a near universal need for cataract surgery. 80 
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 The Iluvien® (formerly Medidur®) device from Alimera Sciences, Atlanta, Georgia, 
attempts to alleviate some of the glaucoma complication rates seen with the Retisert® device. 
While also a fluocinolone releasing device, the size of the device is significantly smaller and rod 
shaped, allowing for significantly simpler implantation through injection with a proprietary 25 
gauge needle, allowing for self-sealing of the wound without the need for stitches. 76 Unlike the 
previous devices, the device is freely floating within the vitreous after implantation. 81 The 
device implant location and steroid release profile is suspected to be contributory to the 
decreased rate of ocular hypertension and glaucoma seen with this device, as the need for IOP 
lowering intervention is seen with only 38% and 47% of patients with the low and high doses of 
the implant, compared to over 70% for the Retisert® device. 81 Accelerated cataract formation 
was still observed, with peaks at 6 to 18 months. The company is attempting to gain approval for 
the device application for treatment of recurrent diabetic macular edema, as well as other trials 
evaluating its efficacy in treating wet age-related macular degeneration, geographic atrophy and 
macular edema secondary to retinal vein occlusion. 82 
 Ozurdex® is a degradable intravitreal implant designed for the release of dexamethasone. 
Composed of PLGA, the device is targeted for the treatment of persistent macular edema. 76 The 
device is administered through a specially designed injector directly into the vitreous cavity. 83 In 
a six month trial, two different dosing formulations of the device were able to improve patient's 
vision faster, to a greater degree and with less likelihood of significant vision loss. 84 18% of 
treated patients achieved a greater than 15 letter improvement, deemed to be a significant visual 
improvement, versus only 6% of the sham treated controls. 84 The device did cause a significant 
IOP spike, but returned to normal and was no different to the sham treatment by the 180th day 
 34 
post implantation. 84  The device is also approved for use in non-infectious uveitis, and is being 
investigated for its use in diabetic macular edema. 
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Device Name Manufacturer Composition Active Agent(s) Time Frame Indications Design 
Vitrasert® Bausch & Lomb 
Ethylene Vinyl 
Acetate Ganciclovir 80 Days 
Cytomegalovirus 
Retinitis 
Large tab, surgically 
implanted and sutured into 
place 
Retisert® Bausch & Lomb 
Silicone 
Elastomer Fluocinolone 1000 Days 
Recurrent Posterior 
Uveitis 
Disc shaped implant 
surgically implanted and 
sutured into place 
Iluvien® 
(formerly 
Medidur®) 
Alimera 
Sciences 
Polyvinyl 
Alcohol, 
Silicone 
Fluocinolone 18-30 Months 
Recurrent Macular 
Edema  
Small rod injected with 
proprietary needle 
Ozurdex® 
(formerly 
Posurdex®) 
Allergan Poly lacto-co-glycolide Dexamethasone 180 Days 
Macular edema 
secondary to retinal 
vein occlusion, 
recurrent uveitis 
Small biodegradable rod 
injected with proprietary 
needle 
Table 1-3 Summary of Commercially Developed Posterior Segment Drug Delivery Devices 
Posterior segment commercially developed posterior segment drug delivery devices. The Iluvien® system is currently 
in trials for treatment of various forms of age related macular degeneration, while Ozurdex® is currently seeking 
approval for treatment of diabetic macular edema. 38, 41, 54, 76, 78, 81, 84
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1.4.3 CONTACT LENS DRUG DELIVERY SYSTEMS 
1.4.3.1 ADVANTAGES OF CONTACT LENS DRUG DELIVERY SYSTEMS 
 Use of CLs to serve as a drug reservoir for drug delivery to the anterior segment of the 
eye is not a new idea. Sedlacek first proposed the idea in 1965, and this was followed by further 
postulations in the 1970s by Gasset, Kaufman and Waltman. 85-88 The theory was that the CL 
could serve as a depot for the therapeutic agent, decreasing the number and frequency of 
administrations, and potentially increasing the drug's effectiveness by improving drug 
penetration or improved drug residence time. 89, 90 There are also several commercially available 
CLs (balafilcon A, lotrafilcon A, etafilcon A) which have a special designation by the FDA for 
"therapeutic use", that is, they can be employed in situations primarily to aid in the management 
of diseases or disease process within an individual, rather than for the correction of ametropia. 
The FDA categorizes "therapeutic use" of CLs into applications for pain relief, the promotion of 
wound healing (such as after a corneal abrasion), providing mechanical support (such as post 
traumatic injury), maintenance of corneal hydration (in severe dry eye cases) and drug delivery. 
90 The use of lenses as a drug delivery device is underutilized, while the first four applications 
are routinely seen and used in clinical practice when indicated.  
 The main goals in investigating CLs as a drug delivery platform are to improve ocular 
bioavailability, improve patient compliance, decrease drug wastage and prevent undesirable side 
effects. 60 In this application, the CL can be loaded with the drug by soaking within a drug 
solution before lens insertion, or combined with eye drop instillation over the top of an already 
worn lens. There exist some evidence that simply by wearing a CL on the ocular surface during 
drop instillation increases drug penetration, with one study suggesting that diffusion into the 
cornea may be up to five times higher. 90 Indeed, mathematical modeling suggests that up to 50% 
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bioavailability from a drug releasing CL, versus the 1-7% seen with eye drops alone. 91, 92 CLs 
would thus provide an ideal platform for treatments which require a large amount of drug to 
enter into the anterior segment. Investigations into the concurrent use of CLs and antibacterials, 
anti-inflammatories, an anti-allergy eye drops found that they offered increase corneal and 
aqueous humour concentrations when compared to the use of CLs alone. 93-96 The increase in 
drug penetration and bioavailability would have a direct effect on the efficiency and rates of 
adverse reactions systemically, as more of the active agents reach the intended tissues. 91 The 
concentration of the solution used to load the lenses could also be decreased due to better 
bioavailability. 29 The effect on patient compliance is unknown, but is speculated to have a 
positive effect due to the dual nature of CLs in drug delivery applications. By coupling the 
delivery of needed medication to the eye, which can be easily ignored for many diseases which 
have little or no symptoms until the latter stages of the disease (such as glaucoma), to the 
correction of refractive error, which provides a real, immediate and tangible benefit to the 
patient, it is expected that patient compliance can readily be improved. 91 Simplification of drug 
treatment regimens have also been shown to improve patient compliance, which is particularly 
important if one wishes to prevent the development of bacterial resistance in the use of 
antibiotics. 60 CL manufacturing is also well established on a large, industrial scale, which would 
drive the unit cost of each one of these lenses down. 91 Finally, the biocompatibility and 
complications of CL wear are well known, and there is comfort in both prescribing eye care 
practitioners and patients alike in the use of CL technology. 89 Insertion and removal of CLs is 
relatively easy, ensuring that they will both be used appropriately, and can be withdrawn quickly 
if they are causing any complications. When surveyed, eye care practitioners have indicated that 
they would use a CL drug delivery device, should one be available. 97 
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1.4.3.2 CHALLENGES TO CONTACT LENS DRUG DELIVERY SYSTEMS 
 Ultimately, the overarching challenge of a CL drug delivery system will be 
demonstration that the system is able to improve patient outcomes, whether through improved 
drug delivery and bioavailability, improved recovery time, improved patient compliance, 
decreased adverse events or decreased economic burden. 91 Success will depend on correct 
identification of a disease or disease process which could conceivably be treated with a CL. As 
discussed previously, there is minimal impact within the posterior segment of the eye through 
topical treatment, and thus treatments of posterior segment diseases will unlikely to be targeted 
with such a device. The course of treatment needed for the disease must also be considered. For 
prolonged treatments, the drug delivery system must be sufficient to deliver an appropriate 
amount of the drug and for the appropriate duration of time, all in the absence of causing 
significant adverse reactions. 98 For example, if the system is designed for the chronic, indefinite 
treatment of glaucoma through the release of IOP lowering drugs, then consideration has to be 
made to the wear modality of the lens (daily wear or extended, overnight wear), the drug release 
kinetics needed to maintain target intraocular pressures, the total amount of drug needed to be 
released over the course of treatment, and whether the chosen lens material can be worn safely 
for the treatment period 98 Each of these factors is a significant engineering and development 
challenge that needs to be addressed through the course of development of the devices .  
  The focus of the majority of the research into CL drug delivery devices has 
understandably been on the drug release kinetics, as this poses the largest engineering challenge. 
However, addition of drug delivery properties, and all of the modifications that they entail, 
cannot adversely affect the significant and useful ocular properties that are necessary for 
successful CL wear. 60 The optical transmission, water content, ion transmission, oxygen 
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transport, lipid and protein deposition profile need to all be tightly maintained and regulated 
within a small range of acceptable values if the lenses are to be successfully worn by patients. 91 
Establishment of the device's CL material properties are arguably as important as establishment 
of its drug delivery properties, as it is such a crucial element in the overall success of such a 
combination device that if any elements are missing it cannot go forward. Consideration has also 
to be made to the eventual manufacturing methods that the device will go through. If the process 
needed to manufacture these CL-drug delivery devices involve a significant change in method, 
raw materials or equipment then the economic feasibility of the device will be put into question 
by the CL manufacturers. 91 The active agent being investigated must also be compatible with 
CL manufacturing. Much of the polymerization of CLs begin with irradiation using light in the 
ultraviolet range. If the pharmaceutical being delivered is required to be part of the 
polymerization process then exposure to the UV light source, or any other procedure in the lens 
manufacturing, sterilization and storage, should not affect its pharmaceutical activity. 99 
 Finally, the most critical component for these devices if they are to reach the market is 
consideration of patient and prescribing practitioner acceptance. The superiority, or at the very 
least, non-inferiority, of the CL drug delivery device can be demonstrated in the laboratory, in 
animal subjects and in clinical trials, but if the proposal is too radical or too far from 
contemporary clinical practice then the system will likely be met with resistance.  
1.4.3.3 DRUG DELIVERY FROM UNMODIFIED COMMERCIAL CONTACT LENS MATERIALS 
 Initial studies on CL drug delivery focused on the use of unmodified commercial CL 
materials. The strategy with commercial materials would be to soak the lenses within a drug 
loading solution, allowing for drug uptake. Once worn, the lens would be able to serve as a depot 
of the drug as either a primary means of treatment or as an augment or supplement to eye drops. 
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This methodology would appeal to those in clinical practice, as the materials, namely CL 
samples, and the eye drop pharmaceuticals are often available in office separately, and thus could 
be quickly combined on an as-needed basis. There are significant advantages to using lenses 
which are already commercially available. They can be obtained easily on a large scale with 
consistent quality control checks built in by multinational corporations that need to comply with 
federal regulators, ensuring quality and consistency. The biocompatibility of the materials and 
the treatment drops would presumably also be a non-issue, as each individual component has 
already been tested for use in the eye, and thus testing for biocompatibility can focus on the 
safety of the combination rather than each component itself.  
 The first studies into drug soaked CLs mainly focused on the treatment of glaucoma or 
the release of prophylactic amounts of antibiotics from CLs in the 1970s. 100-105 In some of the 
early papers by Hillman, it was demonstrated that by soaking a CL in only 1% pilocarpine before 
application to the eye that IOP control was equivalent to that of "intensive" control using 4% 
pilocarpine drops for the treatment of glaucoma. 100 Experiments with volunteers wearing CLs 
soaked in the antibiotic gentamicin were shown to maintain antibacterial concentrations three 
days after lens insertion, with no toxic or adverse effects. 102 
 More recently, the work on commercial lenses has moved from the clinic using human 
participants to the laboratory and in vitro models of drug release kinetics from the lenses. Lenses 
soaked in the pharmaceutical of interest would have their uptake and release elucidated through 
various laboratory based assays. Antibiotics (ciprofloxacin hydrochloride), anti-inflammatories 
(dexamethasone phosphate, ketorolac tromethamine), anti-allergy agents (ketotifen fumarate, 
cromolyn sodium) and surface rewetting agents (polyvinyl alcohol) have all been investigated 
from unmodified, off the shelf CLs. 106-110 From these studies, a few common conclusions can be 
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reached about release from commercial materials. First, the absolute amount of drug released 
from different commercial materials can vary substantially. On the whole, silicone hydrogels 
tend to release a lower amount of drug than hydrogel materials. 109 The water content of the 
lenses appears to have an effect, with the higher the water content the more drug possibly being 
released. 107 The total amount of drug loaded is however limited, as is the drug release times. 98 
The vast majority of lenses tested in vitro do not demonstrate any sustained release 
characteristics, as the monitored drug concentrations very quickly reach their maximum and 
plateau for the rest of the experimental time. 107-109 The majority of lenses reach release plateaus 
within one to two hours. For the development of CL drug delivery devices, these unfavorable 
release kinetics is a major impediment for the applicability of commercial lenses as therapeutic, 
sustained drug releasing devices, and so alternative strategies were sought to improve the drug 
kinetics 
1.4.3.4 DRUG DELIVERY FROM VITAMIN E COATED CONTACT LENSES 
 Considering the poor release characteristics of commercially available lenses, but their 
advantages regarding availability and biocompatibility, researchers have looked into 
methodologies to modify commercial materials post-manufacture. The use of Vitamin E, an 
antioxidant, has been the most extensively studied for its ability to retard drug diffusivity and 
thus extend drug release times. By coating commercially available silicone hydrogels in Vitamin 
E, a transport barrier is formed that forces loaded drug molecules to travel a long and tortuous 
path to be released into solutions or the ocular surface. 111 The authors of this group have used 
this technique to demonstrate extended release in vitro of lenses loaded with antifungals 
(fluconazole), anti-glaucoma agents (timolol), anti-inflammatories (dexamethasone), anaesthetics 
(lidocaine) and immunomodulators (cyclosporine A). This approach has exhibited various levels 
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of success, with some of the modified lens and drug combinations showing in vitro release times 
of over 400 times higher than from unmodified lenses. 111-116 Addition of Vitamin E to the lenses 
decreased UVA and UVB light transmittance, and slightly decreased the oxygen permeability, 
but not to the extent that the authors were concerned with the possibility of the development of 
hypoxic complications. 111 
 In vivo testing has been performed with lenses that have been modified using these 
protocols for the delivery of the IOP lowering drug timolol maleate. 116 In a head to head trial, 
the ability of timolol releasing CLs to control IOP was compared to the IOP using topical timolol 
drops. The experiment was performed in a species of beagle dogs who spontaneously develop 
glaucoma due to their consistently high IOPs. 116 Treatment with the extended release lenses 
were equal in their ability to reduce IOPs when compared to eye drops. The concentration of 
drug needed to be loaded into the lenses could also be reduced with little effect on the response, 
suggesting a greater bioavailability of the drug when given as a CL. 116 
1.4.3.5 DRUG DELIVERY FROM PLGA DRUG IMPREGNATED FILMS WITHIN CONTACT LENSES 
 One of the drawbacks to regular CLs as drug delivery is the limited loading capacity of 
the lenses. The total amount of drug loaded into a lens is of less importance if the disease treated 
requires only a minimum amount of drug to be effective, or if the lens can be replaced with a 
high frequency. These two factors do not appear to be applicable when one considers the use of a 
lens to treat an active infection. In that case, not only would a drug delivery device require a 
large amount of drug to be released to combat fast replicating microorganisms, but also that this 
dose be sustained over long periods such as overnight to combat the infection as the patient 
sleeps. To solve these two problems simultaneously, researchers have devised a radical change in 
CL design. Rather than utilizing the CL material as a drug reservoir, a drug reservoir was formed 
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using PLGA, a polymer formed between lactic and glycolic acid, and previously discussed for its 
use in the posterior segment drug delivery devices such as Ozurdex®. 117 This PLGA film was 
loaded with a large amount of the antibiotic ciprofloxacin, and the polymerization of the 
pHEMA CL material is done in two steps. 117 The first step creates the bottom portion of the lens 
before the drug impregnated PLGA film is placed on to the surface, before more of the liquid 
mixture is placed overtop, and the polymerization mixture initiated again to seal the film in 
between the two pHEMA halves. Release studies in vitro were able to demonstrate continual 
release for 25 days, and the ciprofloxacin released retained antibacterial properties even after 
going through the lens polymerization process. 117 The authors have also demonstrated similar 
release kinetics and antimicrobial activity with a lens designed for the release of the antifungal 
agent econazole. 118 The limitation to the design of these lenses lie in the CL properties. The 
PLGA films do not transmit light in the visible spectrum, being opaque, white substances when 
loaded with the pharmaceuticals. Thus, if the film covers the entire area of the CL then vision 
would be impossible. The authors combat this problem by cutting a small, 3 mm pupil into the 
centre of the lens that would be used for viewing, but whether this would be sufficient to allow 
for both patient and prescribing practitioner acceptance is doubtful. The modifications also 
increase the size and thickness of the lens (450 μm thickness compared to regular CLs of 80-100 
μm thickness), 111 which would decrease the oxygen transmission, adversely affecting the 
biocompatibility of the lens, and thus limit the device's commercial viability. 
1.4.3.6 DRUG DELIVERY FROM MOLECULAR IMPRINTED CONTACT LENSES 
 Molecular imprinting is a polymerization based strategy to increase the affinity of a 
molecule of interest to a polymer to slow down diffusion. 119 Originally, molecular imprinting 
was used in the field of chromatography to aid in the selective removal of particular molecules 
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from solutions. 119 This was accomplished by modifying the polymerization mixture. Prior to the 
initiation of polymerization, a template molecule of interest is also dissolved within the reaction 
mixture, as well as other small molecules which have been termed "functional monomers". The 
purpose of the functional monomers is to form non-covalent interactions with the template 
molecule within the polymerization solution so that after polymerization, shape specific and 
functional group specific areas are created within the material for the template. The interactions 
can be in the form of hydrogen bonding, ion pairing and dipole-dipole interactions. 119 These 
areas of recognition for the template have alternatively been termed as "biomimetic", "cavities" 
or "molecular memory". 120 Regardless, the effect of the molecular imprinting modification to the 
standard polymerization reaction is to increase the affinity of the template molecule to the 
material, and thus slow down the diffusion of the template from the material. 121 This would 
clearly be advantageous in terms of drug delivery applications, as this could prove to be useful in 
modifying or extending release times from polymerized molecules or membranes such as CLs.  
 Molecular imprinting is the most widely utilized strategy by different groups 
investigating CL drug delivery systems in attempts to modify release times.121 Investigators have 
produced materials capable of releasing antibiotics (norfloxacin), anti-inflammatory 
(dexamethasone, prednisolone, diclofenac), anti-allergy (ketotifen fumarate), and anti-glaucoma 
(timolol, dorzolamide) treatments. 122-131 Through this body of work, several general conclusions 
about effective molecular imprinting CLs have emerged. 
 The first conclusion is that the nature of the polymers and functional monomer selection 
were crucial to sustained drug release characteristics. 132 Certain combinations of template (drug) 
molecules, CL monomers such as pHEMA or N,N-dimethylacrylamide (DMAA) and functional 
monomers such as methacrylic acid (MAA) are better at loading larger amounts of drug, or 
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releasing for longer periods of time. In one study, a threefold difference in measured release time 
was seen between the two extremes of the releasing lenses formed using different monomer 
compositions. 132  
The second critical insight was in the concentration of the crosslinker. The greater the 
amount of the crosslinker added to the hydrogel mixture, the greater the stiffness of the material 
and thus selectivity and specificity of the formed "molecular memory". 123 There exists, however, 
an upper limit to the amount of crosslinker that can be present if the material is to be formed into 
a comfortable CL, as well as a lower limit if the imprinting process is to be formed efficiently 
and effectively. 123 Through this work, there was an established minimal crosslinker 
concentration of 80 mM within the polymerization mixture to allow for efficient imprinting to 
occur. Above this, there was no significant change in the release coefficients of the hydrogels 
produced. 123 
 The third key finding was the relationship between the amount of the functional 
monomer to the amount of the template within the polymerization mixture, 124 termed the 
Monomer to Template ratio (M:T). For most monomer-template combinations used for 
molecular imprinting, there exists an ideal M:T ratio that allows for the slowest diffusion times, 
and ratios above or below this ratio are less effective. The theory behind this phenomenon is that 
when there is a low M:T ratio, there exists very little monomer relative to the template to form 
complexes and the cavities needed. At M:T ratios that are too high, the fraction of monomers 
which are randomly distributed are high compared to those that are interacting with the template 
and thus molecular imprinting efficiency decreases. In the ideal ratio, the functional monomer 
surround the template molecules efficiently and this creates the molecular memory within the 
final polymerized product. Through a series of experiments with the antibiotic norfloxacin, 
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Alvarez-Lorenzo and colleagues were able to demonstrate that the ideal ratio of acrylic acid 
functional monomer to norfloxacin template was approximately 4:1. 124 Utilizing the ideal M:T 
ratio increased the loading capacity of the hydrogels and extended release times to 5 days, which 
was significantly improved over the less optimally imprinted materials, which differed little from 
non-imprinted controls. Differences between the lenses was also most readily seen when the 
lenses were loaded through soaking in the least concentrated solution, so that the bulk of the 
release characteristics could be dominated by the molecular imprinted cavities versus simply the 
bulk polymer or water content of the lens. 124 It should be noted however that the ideal M:T ratio 
will vary with both the choice of the monomer and the choice of the template. 
 In recent years, as other research groups have continued to investigate and expand our 
understanding of the process of molecular imprinting, other factors have been shown to have 
some effect on the ability to control drug release rates. Some groups have demonstrated that 
more than one functional monomer can be used simultaneously, and a combination of functional 
monomers can have a greater effect on extending the release than one functional monomer alone. 
125 Sophisticated release experiments have also begun to evolve in vitro. To better mimic the tear 
production, flow and drainage that is actually seen on the eye, a sophisticated "microfluidic" 
device was engineered by the authors of one study. 126 With such a device, a loaded CL can be 
placed under "physiological" flow rates of saline or artificial tear fluid, and the amount of drug 
being released over time can be monitored in a closer approximation of what occurs on the eye. 
Use of such a device with molecular imprinted lenses showed that the modification allows for 
almost zero order/concentration independent release from the lenses for periods of several days, 
which offer significant improvements over the monitored controls. 126 
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 Several studies have also investigated the use of molecular imprinted lenses in vivo. A 
molecular imprinted lens for the delivery of ketotifen fumarate, a mast cell stabilizer and anti-
histamine, was compared head to head with the instillation of topical drops. 133 The use of the CL 
led to a sustained therapeutic concentration on the ocular surface for more than 24 hours, while 
the eye drop concentration dropped off within a single hour, and a non-imprinted lens maintained 
drug residence on the ocular surface for only 3 hours. 133 Other studies have investigated 
imprinted CLs for the delivery of timolol, a beta blocker which is used in the treatment of 
glaucoma. Again, these lenses were applied to rabbits, and the concentration within the tear fluid 
of the drug was monitored over time. 134 Use of imprinted lenses improved the length of time that 
measurable concentrations could be found within the tear film 2 and 3 fold times more than non-
imprinted lenses and drops respectively. 134 
 The advantage of using a molecular imprinting technique to sustain drug delivery from a 
CL is that the factors that contribute to drug release are well known. Modification of the polymer 
compositions, functional monomer selection and concentration, concentration of the crosslinker 
and template can all be optimized to design the desired release characteristics. 123, 132, 134, 135  The 
downside to using molecular imprinting is that a new material is being created, and thus all of the 
relevant testing of appropriateness of the material to serve as a CL are also required. There are 
also limitations to the amount of drug that can be loaded onto the lens through this process, and 
as mentioned previously, the effect of the imprinting is seen more strongly when the materials 
are loaded with low concentrations of the drug. The drug molecules used as a template within the 
polymerization process may also have to be removed. If the drug is light or heat sensitive and 
does not survive the polymerization process intact, then it needs to be removed before being 
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reloaded. 136 It may also be desirable to remove the template so that a precise amount of drug can 
be loaded into the material to prevent overdose or toxicity.  
1.5 BACTERIOLOGY 
1.5.1 BACTERIAL ORGANISMS 
 Phylogenetically, a significant division in the diversity of organisms occurs according to 
cell structure and organization. Eukaryotic organisms, which include humans, animals, fungi, 
algae and protozoans, all consist of cells which contain membrane bound organelles as well as a 
nucleus which houses the organism's genetic code. 137 By enclosing organelles within 
membranes, specialized areas within the cell can perform specific functions such as energy 
production, DNA replication and transcription, or protein synthesis without interfering or 
affecting activities elsewhere within the cell. In contrast, prokaryotic organisms lack membrane 
bound organelles and more importantly, do not have a membrane bound nucleus. The genetic 
material of the cell is localized within a specialized area of the cell known as the nucleoid, but is 
not separated or protected from the activities occurring within the cell. 138 Prokaryotes consist of 
bacteria and archaea. They are generally smaller than eukaryotic cells, are invisible to the naked 
eye, and of less complexity due to their lack of organelles. However, although each individual 
bacterial cell may be small, they have the ability to replicate extremely quickly and are found in 
every possible environment on Earth. 139 Indeed, the combined biomass of all prokaryotes is 
estimated to significantly outweigh that of all plants and animals. 137 Bacteria have significant 
effect on the life cycle of living organisms on Earth. They can serve as a food source for other 
organisms and have an effect on agriculture and human food production. Symbiosis with some 
plant foods, such as legumes with bacteria, allow for nitrogen fixation, reducing the need for 
fertilizer. They are a significant part of the decomposition of matter, converting carbon, nitrogen, 
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phosphorous and other raw materials from deceased organisms into useful forms that can be 
absorbed by living organisms, and thus part of the life cycle and nutrient cycle of ecosystems, 
biomes and the planet as a whole. 137 
 The study of bacteria is known as bacteriology. The key development in the study of 
bacterial organisms was the invention of the light microscope, which allowed for the first time 
small microscopic organisms to be seen by early pioneers such as Robert Hooke and Antoni van 
Leeuwenhoek. 140 The later seminal work of Louis Pasteur and Robert Koch served to reinforce 
the ubiquity of bacteria in our environment and establishment of the "Germ Theory" of disease 
based on Koch's postulates - namely that a pathogen can be isolated in pure culture from a 
diseased organism, that when introduced into a second, healthy, susceptible organism, the pure 
culture will again induce the disease, and that the organism can be re-isolated from the second 
organism again in pure culture. 141 Later, identification of a key feature in the classification of the 
bacteria, the presence or absence of a second phospholipid bilayer outside of the bacterial cell 
wall, led to classification of Gram positive or Gram negative based on the results of the 
procedure to produce the Gram stain. Gram positive organisms lack a second external 
phospholipid envelope and have a rather thick cell wall. Gram negative organisms have a 
significantly smaller cell wall and a second membrane surrounding the cell wall externally. 138 
 Modern understanding of bacteriology has had a significant impact on medicine and the 
treatment of diseased individuals. Improvements in culturing has allowed for rapid isolation and 
identification of disease causing organisms, and thus an associated increase in the speed of 
identifying useful treatments. Knowledge of the ubiquity of microorganisms has changed 
surgical techniques to prevent post-operative infections. DNA sequencing and generation of 
bacterial phylogeny has identified the evolutionary history of organisms and thus given insight 
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into their host and pathogen relationship, and the evolutionary pressures that each organism has 
exerted on each other. 138 
1.5.2  ANTIBIOTICS AND ANTIBIOTIC THEORY 
 It could be argued that the most prevalent diseases of modern society - cancer, diabetes, 
cardiovascular disease - are all a by-product of the effect of the introduction of antibiotics. Prior 
to the discovery of antibiotics to combat infections, the majority of deaths by human beings were 
due to infectious disease. 142 With the significant decrease in infectious disease in the population, 
life expectancy has increased and allowed for the diseases of old age to begin to present within 
the population. Antibiotics are produced from one microorganism to prevent growth of another 
microorganism. 137 Key for the use of antibiotics in humans and other animals is their relative 
lack of significant side effects or impact on the diseased host. This lack of significant side effects 
is one of the main differentiations between antibiotics and other agents used to kill 
microorganisms, such as antiseptics or disinfectants, which often have detrimental effects on the 
host cells, in addition to bacterial cells. 137 The selectivity of antibiotics stems from the subtle or 
significant differences between bacterial and host cells. 141 Antibiotics target bacteria-specific 
areas such as the bacterial cell wall, the bacterial cell membrane, the bacterial protein synthesis 
pathway and the bacterial nutrient synthesis pathway.138 The effectiveness of antibiotics also 
may depend on the form of the bacteria, planktonic, or free floating, and bacteria found as part of 
a bacterial community adhered to a surface in an extracellular matrix known as a biofilm.143 The 
planktonic form of the bacteria are typically much more susceptible to antibiotics than bacteria 
found within biofilms. 143 
 The majority of modern antibiotic agents are semi-synthetic derivatives of molecules 
found in nature, formed by a microorganism to combat the growth of another microorganism. 
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For example, Penicillin, which was first widely isolated and used in World War II to treat 
wounds and prevent sepsis, was discovered by Alexander Fleming in 1929, when one of his Petri 
dishes containing growing Staphylococci was contaminated by a spore of the fungi Penicillium, 
which create a zone of inhibition surrounding it. 144 This molecule was eventually isolated, 
purified and mass produced as penicillin, and derivates of the molecule continue to play a role 
today in the management of infections. 
 The discovery of new classes of antibiotics went through a significant period of growth 
following the discovery of penicillin, but in recent decades the rate of discovery has slowed 
considerably. This is concerning, as bacteria have begun to develop resistance to common 
antibacterial agents. Due to their very short generation time and vast numbers, mutations and 
recombinations within the genome of bacteria can easily be introduced, and these changes can be 
selected for by natural selection if they confer a survival advantage against such things as 
antibiotics. 145 Use of an antibiotic confers a significant selection pressure for these mutants, 
spurring selection for survival of a population of resistant mutants, if antibiotics are not given 
appropriately. 145 This fact, coupled with the unnecessary overprescribing of antibiotics to the 
population at large, has led to a decrease in effectiveness of common antibiotics, and worryingly, 
selection of strains of common bacteria resistant to multiple antibiotics at once. The problem is 
not only limited to the administration of antibiotics to humans, as the vast majority of antibiotics 
are now being administered to agricultural animals, which eventually work their way up the food 
chain. 146 Bacteria are also able to share genetic information through horizontal gene transfer, 
likely spreading the resistance throughout the bacterial community. 145 Older, less effective or 
agents with more side effects are increasingly being used to control these resistant infections, and 
with the lack of any clear cut new antibiotics being discovered leads to worrisome trends in 
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future medicine if infection control cannot be achieved. There were already penicillin resistant 
strains of bacteria identified before the commercial release of the antibiotic. 146 More than 1000 
different genetic mutations have been discovered in bacteria which confer penicillin resistance, 
exemplifying the numerous avenues that bacteria can become resistant to antibiotics. 146 The 
worry is that medicine may be entering into the "post-antibiotic" era, where a clear lack of 
effective antibiotic agents to prevent and treat infections may have a massive impact on the way 
modern medicine is practiced. 146 
 Antibiotic agents can be classified based on their effects on bacterial cells. Bacteriostatic 
agents do not kill the bacteria outright. Rather, they prevent adequate or efficient cell replication, 
allowing for the host immune system to clean up the infection. Bacteriocidal agents directly kill 
the cell by interfering with some type of critical cellular process. Finally, bacteriolytic agents are 
also bacteriocidal, and kill bacteria by inducing cell lysis. 137 
1.5.3  OCULAR ANTIBIOTICS AND MECHANISM OF ACTION 
 A summary of commonly used ocular antibiotics is listed in Table 1-4.  
1.5.3.1 BETA LACTAMS AND CEPHALOSPORINS 
 The beta lactams were the first antibiotic agents to gain widespread use, and are named 
based on the presence of a characteristics chemical structure containing a "beta lactam" ring. 
Beta lactams include the penicillins and the cephalosporins. Their mechanism of action is to 
serve as an ineffective building block of bacterial cell wall synthesis and repair. 147 The bacterial 
cell wall is used to provide structural rigidity against osmotic stress. The cell wall is constantly 
undergoing remodeling and repair. The structure of the beta lactams is such that it can be 
incorporated into a growing bacterial cell wall, but lacks the correct moieties to allow for 
crosslinking of cell wall chains, destabilizing the structure of the cell wall and eventually leading 
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to cellular lysis. 147 Common examples include penicillin G, amoxicillin, cefazolin, and 
cefalexin. Their spectrum of activity depends on the generation being used. Early generations 
were generally effective against Gram positive organisms, while later iterations had extended 
activity against a greater number of Gram negative organisms, leading to the classification of 
"extended" spectrum of activity. 144 Clinically, what has been shown for the beta lactams is that 
the shape of the concentration-time curve has the most effect on the ability of the drug to kill 
bacteria. For the beta lactams, what is most important in their ability to kill microorganisms is 
the amount of time that the drug is maintained at concentrations above the minimum inhibitory 
concentration (MIC). Increasing the concentration to levels beyond the MIC has only marginal 
effects. 148 The main methods of resistance to the beta lactams is through the production of beta 
lactamases, enzymes which cleave the beta lactam ring and prevent incorporation of the 
molecules into the growing bacterial cell wall. 
 The ocular use of the beta lactams is mainly during severe infections. Fortified 
cephazolin, a cephalosporin antibiotic, is often used in the mix for the topical treatment of 
microbial keratitis. Oral amoxicillin can be used for the treatment of eyelid infections such as 
internal hordeolums, and injections of penicillin can be used for cases of endopthalmitis. 149 
1.5.3.2 AMINOGLYCOSIDES 
 The aminoglycosides are one of the most frequently used ophthalmic antibiotics and were 
considered to be the drug class of choice for ocular infections before the introduction of the 
fluoroquinolones. They are generally not used systemically because they have a high rate of both 
nephrotoxicity and ototoxicity. 144 They are bacteriocidal, and their mechanism of action is 
blockage of bacterial protein synthesis through binding of the bacterial 30S ribosome subunit. 147 
The rate of bacterial killing is concentration dependent. 148 They are derived from the 
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Streptomyces species of bacteria. They are generally useful against Gram negative organisms, 
but are considered to be broad spectrum because of their moderate effectiveness against Gram 
positive organisms. 144, 150 Examples of aminoglycosides include streptomycin, gentamicin, 
neomycin and tobramycin. Mechanisms of resistance to the aminoglycosides include mutations 
in the 30S ribosomal subunit, and production of enzymes which destroy the drugs. 144 
 The ocular indications of aminoglycosides vary from mild conjunctivitis to sight 
threatening microbial keratitis. 151 Often, in the treatment of microbial keratitis, fortified and 
compounded tobramycin will be administered alongside the beta lactam cefazolin, to ensure the 
broadest Gram negative and Gram positive coverage. 152, 153 Some ocular preparations of 
aminoglycosides suffer from poor patient tolerance. Neomycin has a particularly high rate of 
hypersensitivity reaction (15-30%) when given for long periods, limiting their usefulness. 153 
Tobramycin is commonly used as a combination drop with the steroid dexamethasone.  
1.5.3.3 MACROLIDES 
 The macrolides are a series of antibiotics which were also discovered from various 
members of the Streptomyces family. Their mechanism of bacterial inhibition is through 
inhibition of protein synthesis through binding of the 50S ribosomal subunit. 144 When used 
clinically, it is considered to have a bacteriostatic effect. 150 They generally are effective against 
Gram positive organisms. Examples of macrolides include erythromycin, clarithromycin and  
azithromycin. Resistance to macrolides is through methylation of the ribosomal subunit, which 
prevents macrolide binding, and unfortunately, resistance to one macrolide confers resistance 
against the entire class. 144 
 Ophthalmically, erythromycin ointments are commonly used in neonatal conjunctivitis 
because of its favorable pediatric safety profile. More recently, new formulations of 
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azithromycin in proprietary vehicles has been shown to be an effective treatment for bacterial 
conjunctivitis, with a significantly simplified dosing schedule due to improved ocular retention 
and bioavailability conferred by the mucoadhsive vehicle. 154 The clinical effect of the 
macrolides is not necessarily concentration dependent. They exhibit a property known as a "post 
antibiotic effect", in that exposed bacteria to the antibiotic which haven't been killed are much 
slower to grow after the antibiotic has been completely removed than non-treated bacteria. This 
likely stems to the injury that the antibiotic has incurred on the bacteria. 148 
1.5.3.4 SULPHONAMIDES 
 The sulphonamides are a group of molecules which are competitive inhibitors of the 
molecule p-aminobenzoic acid (PABA). PABA is used in the folic acid synthesis pathway that is 
critical in the creation of nucleic acids for DNA replication and synthesis in bacterial cells. 144 
The sulphonamides compete with PABA to bind with the bacterial enzymes and thus prevent 
bacterial growth. A related molecule, trimethoprim, inhibits a second enzyme further 
downstream in the folic acid synthesis pathway to the sulphonamides, leading to synergistic 
activity when both agents are administered simultaneously.144 The sulphonamides and 
trimethoprim are considered to have a bacteriostatic effect individually on bacteria, but when 
combined they have a bacteriocidal effect. 150 The sulphonamides were the first antibiotics 
discovered by chemists working on investigating dyes that could inhibit bacterial growth. 144 
They are limited in their use through the development of allergy in patients. Resistance to the 
sulpha drugs is due to overproduction of PABA, changes to the binding affinity for the enzymes 
in folic acid synthesis and changes in drug transport. 144 
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 In the eye, trimethoprim is often combined with the basic polypeptide detergent 
Polymyxin B. The combination of the two is termed "Polytrim" and is effective against Gram 
positive (trimethoprim) and Gram negative (Polymyxin B) organisms. 150  
1.5.3.5 TETRACYCLINES 
 The tetracyclines are bacteriostatic agents derived from the soil bacterium Streptomyces 
aureofaciens.155 They specifically work by inhibiting protein synthesis through binding of the 
30S segment of the bacterial ribosome. 156 They were one of the first antibiotics to be labeled as 
truly "broad spectrum" as they were able to affect the growth of a both gram positive and gram 
negative organisms. Examples include tetracycline, doxycycline and minocycline. Resistance is 
conferred through changes in the drug transport into the bacterial cell. 144 There is some concerns 
about their use in pediatrics, as the drug will deposit in growing bones and teeth, leading to 
discoloration. 147 
 Ophthalmic use of tetracyclines has previously centered on the treatment of the ocular 
manifestations of Chlamydia in both neonates and adults, but recently the discovery of the large 
host of anti-inflammatory activity of these molecules has led to renewed interest in using them 
for such diseases as blepharitis, meibomian gland dysfunction and acne rosacea. 155 
1.5.3.6 FLUOROQUINOLONES  
 The fluoroquinolones (FQ) are bacteriocidal and are the newest generation of antibiotics, 
and were released only in the 1980s. They are unique in that they are completely synthetic and 
not derived from a microorganism source, as they were discovered as a by-product of industrial 
chloroquine synthesis. 157 Their mechanism of action is inhibition of bacterial DNA replication, 
specifically through inhibition of the enzyme DNA Gyrase, as well as, in later iterations, 
Topoisomerase IV, enzymes which are involved in cutting and unwinding of bacterial DNA 
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strands to allow for efficient replication. 158 Common examples include ciprofloxacin, ofloxacin, 
levofloxacin, moxifloxacin, gatifloxacin and besifloxacin. The newest generation of agents show 
broad spectrum activity, but earlier examples were mainly effective against Gram negative 
organisms. 157 Their rate of bacterial killing is concentration dependent. The more times 
concentrations are reached above the minimum inhibitory concentration, the faster the bacteria 
will be eradicated. 148 The main method of bacterial resistance against the FQs is mutation of 
either of DNA Gyrase or Topoisomerase IV enzymes, as well as the generation of active efflux 
pumps which remove the molecules from within the cells into the external environment. 157 
 The FQs are some of the most frequently used antibiotics in ophthalmology, because of 
their broad spectrum of use and their availability as ophthalmic preparations. Some FQs (such as 
gatifloxacin) are only available for ophthalmic use due to systemic side effects. 157 They are 
indicated for use most commonly to treat bacterial conjunctivitis, while a few (such as 
ciprofloxacin and ofloxacin) are also approved for the treatment of bacterial keratitis. 159 While 
they do not have the indication to treat bacterial keratitis, many of the newer agents are used to 
treat microbial keratitis off-label. 160 The newer generation of FQs such as moxifloxacin and 
gatifloxacin have an enhanced spectrum of activity compared to older products such as 
ciprofloxacin, and are thought to suffer less likelihood of resistance development due to their 
dual targeting activities. Mutations to both enzymes are required simultaneously to prevent 
effectiveness of the agents. 159, 161 
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Antibiotic Class Mechanism of Action Isolated from 
Effect on 
Bacteria 
Spectrum of 
Activity 
Common 
Uses 
Ophthalmic Example 
Beta Lactams and 
Cephalosporins 
Inhibition of cell wall 
synthesis 
Fungi - 
Pennicilium and 
Acremonium 
Bacteriolytic 
Gram positive 
or Extended 
Spectrum 
Septicemia Oral amoxicillin for internal hordeolums 
Aminoglycosides Protein Synthesis (30S Ribosome Binding) 
Bacteria - 
Stremtomyces Bacteriocidal 
Mainly Gram 
Negative Endocarditis 
Fortified gentamicin for 
treatment of corneal 
ulcers 
Macrolides Protein Synthesis (50S Ribosome binding) 
Bacteria - 
Streptomyces Bacteriostatic Gram Positive 
Respiratory 
Tract Infection 
Oral azithromycin for 
Chlamydia conjunctivitis 
Sulphonamides/ 
Trimethoprim 
Inhibition of Folic 
Acid Metabolism Synthetic Dyes 
Bacteriostatic 
(individually) 
Bacteriocidal 
(combination) 
Mainly Gram 
Positive 
Seborrheic 
Dermatitis 
Polymyxin B/ 
Trimethroprim solution 
for pediatric 
conjunctivitis 
Tetracyclines Protein Synthesis (50S Ribosome Binding) 
Bacteria - 
Streptomyces Bacteriostatic Broad Spectrum 
Treatment of 
Lyme disease 
Acne Roasacea 
Blepharitis 
Fluoroquinolones 
Inhibition of DNA 
replication (DNA 
Gyrase and 
Topoisomerase 
binding) 
Synthetic - by-
product of 
chloroquine 
production 
Bacteriocidal 
Early examples 
Gram positive, 
Later examples 
Broad Spectrum 
Urinary tract 
infections 
Moxifloxacin drops for 
surgical prophylaxis 
 
Table 1-4 Characteristics of Ophthalmic Antibiotics 
 The antibiotics listed all have some use in the treatment of ocular infections. 144, 150, 155-157, 159, 162, 163
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1.5.4 MINIMUM INHIBITORY CONCENTRATIONS (MIC) 
 The translation between the laboratory testing of antibiotic agents to the bedside when the 
antibiotics are used clinically is difficult. 164 In a controlled setting such as within a laboratory, 
where pure cultures of bacteria can be grown under ideal conditions with plentiful food and 
nutrients, the overall effect of an antibiotic on the growth of the bacteria can be clearly 
demonstrated. Unfortunately, the conditions within the laboratory do not mimic the conditions 
seen when an infection is raging within a living organism, and thus results from testing within 
the laboratory have to be scrutinized carefully. 165 Still, results from the laboratory testing of 
antibiotics can be useful in the setting of antibiotic concentration goals within the body during 
treatment. 165, 166 
 A central tenet in testing of antibiotics within the laboratory is the concept of the 
Minimum Inhibitory Concentration (MIC). The MIC is the lowest concentration of the antibiotic 
within solution that will prevent the growth of bacteria, and is used to determine the potential 
effectiveness of an antibiotic in treating the infection caused by the organism. 165, 167, 168 A related 
concept is that of the Minimum Bacteriocidal Concentration (MBC), which is the minimum 
concentration of a bacteriocidal antibiotic to completely kill the bacteria. In general, the MBC 
will be at a higher concentration than the MIC, but the MIC is the measure that is generally 
discussed clinically. MIC testing can be performed in a variety of ways, but the two most 
common laboratory tests are the agar gradient diffusion and microbroth dilution methods. 167 In 
the agar disk diffusion method, also known as the E-test method, a strip which contains a 
continuous gradient of an antibiotic is placed on an agar plate which has been seeded with a lawn 
of bacteria and incubated at an appropriate temperature. Over time, the bacteria grow over the 
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entire surface of the plate except in areas surrounding the test strip that have high enough 
antibiotic concentrations to inhibit their growth. 165 The pattern created is an ellipse of no 
bacterial growth surrounded by complete bacterial growth, and the MIC is determined at the 
intersection of the bacteria growth and the test strip. 168 The broth microdilution method utilizes a 
96 well microplate. Each well contains Mueller Hinton Broth growth medium and 5x104 colony 
forming units (CFU) of bacteria. The antibiotic is added to each well in two fold dilution steps, 
and chosen to cover the range of antibiotic concentrations typically found within the plasma or 
serum when given to a patient using a typical dosage. 167After incubation for 18-24 hours, the 
wells are checked for turbidity and the MIC determined to be the lowest concentration of 
antibiotic that prevents bacterial replication. 167 The antibiotic dilutions and broth preparation can 
be done manually in house, or there are a number of commercially available kits which contain 
dried antibiotic and growth media, and simply require addition of the bacterial solution. 168 
 Ultimately, the goal of MIC testing in a clinical setting is to determine the causative 
organism's susceptibility to a panel of antibiotics, and recommendation of which is the best 
antibiotic to be used in treatment. Translation of the MIC results obtained from the laboratory to 
clinical recommendations is not clear cut or as simple as it may appear on first glance. Initial 
attempts in the 1970s tried to set interpretive "breakpoints" found within MIC testing. The hope 
was to differentiate between "susceptible" and "resistant" isolates of the bacteria to the antibiotic, 
through the basis of what was the numerical value of the MIC. 166 The usefulness of these 
categories was debatable, as they did not take into account patient and bacterial variables that are 
inherent in all treatments. There is a variation in the susceptibility of the bacteria within the wild 
type population to antibiotics. There is variation in the blood serum concentration of the 
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antibiotic when given to a healthy volunteer versus to an infected individual based on differences 
in the pharmacokinetics and pharmacodynamics within the population and within the health 
status of the patient. 164 There is also variation in the effectiveness of different antibiotics on the 
growth of bacterium based on certain parameters. For example, the effectiveness of penicillins 
within the body at eradicating bacteria is a function of the size of the area underneath the curve 
(AUC) of a time versus plasma penicillin concentration plot. 148, 164 Thus, it is not necessarily the 
concentration of penicillin that is achieved within the bloodstream that is important, but also the 
length of time that the penicillin is administered and found within the bloodstream. Other 
antibiotic effectiveness is measured in how the peak concentration within the plasma compare to 
the MIC, and others, how much time are MIC concentration levels reached and maintained. 164 
Clearly, there is a significant amount of variation to be found in 1) the concentrations of the 
antibiotic that can kill a bacterium within the laboratory, 2) the peak concentration of the 
antibiotic found within the blood stream and 3) the time that the antibiotic is found within the 
bloodstream, and recommendations of treatment for infections clinically need to take all of these 
variations into account. 164 
 There are two major panels which provide these recommendations, the Clinical and 
Laboratory Standards Institute (CLSI) in the USA, and the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 169 EUCAST has a publically available website 
where breakpoints, both laboratory and clinical, are presented and available for consideration 
when interpreting MIC results from routine laboratory testing. 164, 169 
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1.6 MICROBIAL KERATITIS 
1.6.1 OVERVIEW - CLINICAL DIAGNOSIS, SIGNS AND SYMPTOMS 
 A microbial keratitis (MK) is an infection of the cornea by replicating microorganisms. 
The cornea can be infected by a variety of different organisms, such as fungi or protozoans, but 
for the vast majority the infections are caused by bacterial organisms and so they will be the 
focus of the discussion with respect to MK. A patient is diagnosed with presumed MK if they 
present with a break in the corneal epithelium/ulceration overlying a corneal infiltrate. 170 As MK 
is an ocular emergency, diagnosis of presumed MK is sufficient to begin initiating treatment 
before culture and susceptibility (C&S) testing is completed, as any delay in the administration 
of antibiotic agents will have a negative impact on the overall outcome. 171, 172 Other clinical 
signs are discharge, hyperemia and an anterior chamber reaction. A patient with MK will present 
with complaints of severe pain and discomfort, light sensitivity, discharge and variable decrease 
in vision (from 20/20 to no light perception). 172, 173 Without culturing, the ability of eye care 
practitioners to correctly distinguish between the different types of causative organisms in MK 
based on clinical presentation alone is limited. 174  
1.6.2 DEMOGRAPHICS AND RISK FACTORS 
 The risk factors for MK can vary by geography and by climate. 173, 175 Contemporary 
epidemiological studies of the risk factors of MK have identified CL wear as a significant risk 
factor. In certain studies, the proportion of patients who present to tertiary referral centres for 
MK associated with some form of CL wear approaches 50%, with other risk factors such as 
ocular trauma or history of keratoplasty significantly less frequent. 173 Several CL behaviors have 
been identified as increasing the risk of MK, including overnight wear of CLs, reusing CL 
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solutions, poor hygiene associated with CL wear, swimming with CLs, internet supply of CLs 
and poor compliance with lens replacement schedules. 171, 176, 177 The annualized incidence of 
MK in daily CL wear is between 2.7 and 6.4/10 000, based on several independent studies in 
Australia, Scotland, the USA, Holland and Hong Kong, with the risk of those in extended wear 
increasing their risk broadly 10 times, with an annualized incidence rate of 21/10 000. 178, 179 
Given the prominence of CL wear as a modifiable risk factor for MK, several studies have been 
developed to identify the wear modalities with the greatest risk. Overnight wear of soft CLs, 
regardless of the type of lens being worn, continues to be a significant risk factor, increasing the 
relative risk over planned replacement lenses to 5.4 times higher. 180 Unfortunately, "modern" 
CL wear modalities, namely high oxygen transmitting soft silicone hydrogel materials and daily 
disposable wear modalities did not significantly decrease the risk of developing MK in certain 
studies. 180 In other studies, daily disposable CL wear was associated with the lowest incidence 
of MK in soft CL wearers, while silicone hydrogel wear was associated with higher incidences of 
MK when compared to other daily wear CL wear modalities. 179 
 Non CL related risk factors include male gender, younger age, smoking status, ocular 
surface disease, history of ocular trauma or ocular inflammation and depressed immune system. 
171, 177, 181-187 The epidemiology of MK is extremely different in the developing world. The rates 
of MK in the developing world are estimated to be 30-70 times more frequent than in the 
developed world. 172 In the developing world, the major risk factor is ocular trauma. The poor 
socioeconomic status of much of the developing world also puts a large proportion of patients 
there at risk. 172 There has also been an identification of a bimodal age distribution in cases of 
MK, with a cluster in the younger age groups who tend to wear CLs (who are also at a greater 
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risk for ocular trauma), and a cluster in the older age group, who have the significant risk factor 
of ocular surface disease. 173 
1.6.3 CAUSATIVE ORGANISMS IN MICROBIAL KERATITIS 
 Identification of causative organisms during the course of MK often depends on the 
timing through which a corneal scrape or sample was taken, and the susceptibility of the 
causative organism to the initial empirical therapy. If the organism is susceptible to initial 
therapy, then delayed corneal scraping may yield no organisms. 174 The strategy when bacterial 
MK is suspected is to use three to four different media (chocolate agar, blood agar, thioglycolate 
broth and brain heart infusion broth) to allow identification of the organism. In general, it is 
expected that the rate of capturing a positive culture is approximately only 50%. 170 
 Discerning between Gram positive and Gram negative organisms for cases of MK have 
shown some mixed data. In tertiary referral centres, where the MK can be due to any number of 
risk factors including trauma and CL wear, the data shows that the vast majority of the infections 
are caused by Gram positive organisms, of which they are mainly identified as coagulase 
negative Staphylococcus. 173, 175 When only the CL wearing population with MK is examined, 
the causative organisms tend to be Gram negative, and mainly identified as being Pseudomonas 
aeruginosa. 171, 173 
1.6.4 TREATMENT, MANAGEMENT AND PROGNOSIS 
 It is recommended that all cases of MK be sent for C&S testing, should initial empirical 
therapy fail. This requires a corneal scrape to be sent to the laboratory for analysis. The 
recommended treatment for cases of presumed MK before results of C&S testing are returned, is 
frequent dosing with a topical antibiotic. 188 The choice of which topical antibiotic often depends 
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on the risk factors of the patient, but for most practitioners preference is shown towards fortified 
antibiotics compounded by a hospital pharmacy, including tobramycin, gentamicin, vancomycin 
and cephazolin in some combination to provide broad spectrum gram positive and gram negative 
coverage. 173 Commercially, only the fluoroquinolones ciprofloxacin, ofloxacin and levofloxacin 
have been approved by the United States Food and Drug Administration for treatment of MK as 
commercially available monotherapy. 189 Newer and more advanced antibiotics have been 
approved for bacterial conjunctivitis only, and usage of those for treatment of MK is off-label. 
The treatment of MK with fluoroquinolone monotherapy is controversial. 190, 191 The 
fluoroquinolones have been shown in trials to have a broad spectrum of activity effective at 
eradicating microorganisms implicated in MK, and lack the majority of the corneal toxicity seen 
with prolonged fortified antibiotic therapy. However, concerns about developing resistance to the 
fluoroquinolones give pause to practitioners considering monotherapy. Trials have demonstrated 
the equivalence between fluoroquinolone monotherapy and fortified antibiotic therapy. 192, 193 
 Recommended dosage of the antibiotic is quite frequent. Upon diagnosis, dosages given 
every 15-30 minutes are common in attempts to quickly saturate the cornea to high levels of the 
antibiotic, and this frequency of administration may be continued for 36 hours or more in severe 
cases. 172, 175 Continued monitoring of the patient is necessary to chart improvement and 
progress, with acknowledgement that the eye may not appear to be improving due to the large 
number of drops being instilled, as well as manipulations related to taking corneal scrapings. 
Modification of the dosing or type of agent used occurs when there is an improvement in the 
clinical signs and symptoms, or results from the C&S testing return with indicated 
susceptibilities. Improvement of the MK is seen as a decrease in the size of the infiltrate, healing 
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and reepithelialisation of the corneal surface, reduction in the anterior chamber reaction and 
symptomatic improvement in the level of pain experienced. Hospitalization to manage these 
conditions occur frequently, with one study reporting an average stay in hospital of 9 days. 173, 188 
Hospitalization is frequently necessary because of the frequency of the dosing schedule and the 
likely need to take the antibiotics around the clock, which can prove to be difficult, if not 
impossible, on an outpatient basis. Hospitalization is strongly recommended in all MK cases 
involving pediatric, monocular or non-compliant patients.173, 188 
 The long term outcome of the disease depends on the underlying pathogen and the 
condition of the cornea. In one study, while the majority of the cases were cured by treatment, 
only a slight majority (60%) of the patients had improvements to their visual acuity compared to 
their admittance baseline acuity. One patient in twenty also had an extremely poor visual 
outcome. Several patients in that study had severe complications, including endophthalmitis, 
posterior synechiae, and ocular hypertony. As a result, some patients required penetrating 
keratoplasty and for some enucleation was necessary. 173 
1.6.5 PATHOGENESIS AND CONTACT LENSES AND MICROBIAL KERATITIS 
 Issues at hand for the CL industry and the fear of developing a MK are compliance, wear 
modality, hypoxia and bacterial organism. Exposure to microorganisms is not sufficient to cause 
an infection, as the ocular surface without CL wear is constantly being exposed to bacteria and 
yet it rarely becomes infected. 194 Compliance is not a magic bullet, as even the best care system 
used for CLs does not completely disinfect the lenses themselves. The efforts to improve 
compliance may also be in vain. 194 Further understanding is needed of the link between 
extended wear and MK. The understanding of the pathogenesis of MK in overnight wear centres 
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on a change in virulence of the causative organisms, purportedly due to development of biofilms 
on the posterior surface of the CL, in combination with a cornea under stress and less able to up 
regulate defence mechanisms. 195 Hypoxia is an interesting topic because of the introduction of 
silicone hydrogels. As previously mentioned, while the rates of hypoxic related complications 
decreased with the introduction of these lenses, the rates of MK stayed the same. Some data 
suggest that the severity of the disease in these patients with MK is decreased compared to other 
wear modalities, but the rate of disease being similar highlights our continued lack of a complete 
understanding of the link between hypoxia and MK, if any. 196 Finally, questions abound as to 
why Pseudomonas aeruginosa, a common commensal bacteria found on the skin and in water, is 
the most commonly identified organism in MK cases involving CL wear. 197 Current thinking is 
that P. aeruginosa is able to exploit the CL wearing patient due to a large genome encoding 
virulence and survival factors. Coupled with the decrease in frequency of the blink response in 
patients wearing CLs provides for longer residence and contact time between the microorganism 
and the surface it wishes to invade. 194 The organism has also been shown to have significantly 
better lens adherence properties than other bacteria. 198 
1.6.6 ANIMAL MODELS OF MICROBIAL KERATITIS 
 The main animals that have been studied as models for MK are rabbits, mice and guinea 
pigs. The use of rabbits as a model for MK has had a long history because of desirable ocular 
characteristics, chiefly the similarity in size to the human eye (13 mm rabbit corneal diameter 
versus 11 mm corneal diameter in humans). 199 They are also much easier to handle with 
ophthalmic devices designed for human eyes when compared to a mouse or a guinea pig, and can 
be fitted with commercially available CLs. 200 Commonly, New Zealand White rabbits, a non-
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pigmented rabbit strain is used, but pigmented strains of rabbit such as Dutch Belted rabbits have 
also been used. 199 Pseudomonas aeruginosa and Staphylococcus aureus are commonly the two 
organisms used to infect the corneas. Reproducible models of S. aureus MK typically involve 
intrastromal injections of the bacterial solution. 201, 202 P. aeruginosa MK models are, in contrast, 
much more amenable to alternative methods of infection. Classically, infection of the cornea was 
induced through passing of a silk thread that had been soaking in a P. aeruginosa solution into 
the corneal stroma. 199 Intrastromal injection models are still very viable, but infections have also 
been shown to be possible through topical application of bacteria after a corneal scratch or 
epithelial debridement, or application of a bacterial contaminated CL. 203-208 Rabbit models of 
MK are used to investigate the efficacy of new or developing treatments and therapeutic agents, 
as well as to elucidate different mechanisms of disease. Rabbits can be used as models for CL 
induced MK, but this often requires the aforementioned extreme experimental measures to 
ensure infection. The rate of development of MK with animal models under various established 
CL risk factors, such as overnight, extended wear, or poorly maintained CLs, remain surprisingly 
understudied. The drawbacks to using rabbits as in vivo models of MK are their relatively higher 
cost when compared to mice, and the corresponding increased operator time due to their larger 
size. 200 
 Mice, in comparison to rabbits, have significantly smaller eyes and are more difficult to 
assess using clinical tools designed for human sized eyes. Their advantage lies in the wealth of 
resources behind mice-based animal research. Mutated or inbred strains containing certain genes, 
or knockout mice with certain genes removed are readily available and thus can be used to study 
contributory factors to MK pathogenesis. 199 In general, the mouse model of infection typically 
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involves a corneal scratch before introducing the bacteria onto the ocular surface. 200 Mice are 
also typically used to investigate the mechanisms of MK pathogenesis, by investigating both host 
and microorganism related factors in diseased versus non-diseased eyes. 199 
 Guinea pigs have been used as a model of MK since 1975, with the guinea pigs being 
inoculated through intrastromal injection for use in antibiotic quantification studies. 209 There 
have also been some studies that have used specially designed CLs to fit the guinea pig eye in 
modeling CL related MK or inflammation. 210 Guinea pigs were seen as an advantageous 
alternative to using rabbits because they are smaller, easier to handle, eat less and tend to not bite 
or scratch. 209 The model of MK in guinea pigs has also been deemed to be highly reproducible. 
199 
 There are several disadvantages to the use of animal models for studies of MK, and 
mainly these stem from differences in anatomy, behaviour and genetic diversity. The majority of 
laboratory animals are inbred, and so results from those studies may have limitations in their 
applicability on the human population as a whole. 199 As previously mentioned, the size of the 
eye in a rabbit is quite close to that of a human, but it is still slightly larger, and the cornea of the 
mouse and guinea pig are significantly smaller. 199 Rabbits also have the presence of a "third" 
eyelid, the nictitating membrane which moves horizontally across the eye, that is absent in 
humans. 199 Finally, the tear film composition is markedly different between the three animals, 
with different levels and amounts of antibacterial proteins such as lysozyme. 211 The blink 
interval also varies widely, from a short 2-6 seconds in humans to over 30 seconds for rabbits. 199 
For CL MK research, the rates of MK development with extended wear of CLs are not well 
established. Regardless, even with all of these limitations, the advancements gleaned from the 
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results of experiments of animals in the study of MK have been substantial in advancing our 
understanding of the disease, and in improving prevention, diagnosis, treatment and prognosis. 
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CHAPTER 2 - OBJECTIVES AND RATIONALE 
 There has been a significant growth in the ocular pharmaceutical market over the past 10 
years. As the population demographics of North America shift towards the older ages, age-
related diseases of the eye are expected to increase in prevalence. 1 While there are many 
different avenues and modalities of treatment for ocular disease, there exists substantial room for 
improving drug delivery for both acute and chronic diseases. 2 The mainstay treatments for the 
anterior segment of the eye (eye drops and ointments), have several limitations that make them 
inefficient and ineffective vehicles of pharmaceuticals to the eye for treatment. 3 The majority of 
the active agents within an eye drop are drained away quickly from the eye, leading to wastage 
and potential systemic side effects. 4 To be effective, eye drops thus require both an increase in 
concentration and dosing frequency, which are hampered by cost and patient compliance. Even 
with optimal dosing, the reality is that the pharmacological effect of using eye drops provides 
only narrow windows of time wherein the drug is at therapeutic concentrations, interspaced 
between times of over and under dosing. 2 Investigations into alternative means to deliver drugs 
to the eye are thus warranted in attempts to combat these economical, efficiency and therapeutic 
challenges. 
 The eye is ideally suited to investigate the potential of long term drug delivery devices, 
because its relative accessibility and immune privileged status allow for relatively isolated, 
targeted therapy. 5 To date, there have been several commercially available sustained drug 
delivery systems for the eye, but their clinical impact has been minimal as they have not been 
widely used. 6 Given the success of contact lenses, both in terms of commercialization as well as 
biocompatibility, the potential for utilizing them as a platform for sustained drug delivery to the 
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anterior segment of the eye holds great promise. There have been some experiments which have 
demonstrated that simply soaking an off-the-shelf lens within a drug solution before application 
to the eye can have some benefit in ocular residence time, but systematic investigations of 
contact lenses as drug delivery devices are lacking. 7-10 
 Microbial Keratitis (MK) represents a true ocular emergency, representing an infection of 
the cornea by replicating microorganisms, and requires frequent dosing of an antibiotic to the 
surface of the eye if remaining normal sight is to be protected. 11, 12 The frequency of drops 
during episodes of MK can be so frequent as to require hospitalization to ensure adherence to 
therapy. 13 Patients often require treatment at all times, even while sleeping. Thus, if a suitable 
sustained release system for an antibiotic could be found, potentially patient compliance and 
clinical outcomes could be vastly improved in the management of MK. The improvement in 
patient compliance is particularly significant in this age of developing antibiotic resistance, as 
any improvements to patient compliance can stem the growth of resistant microorganisms. 
 The purpose of this thesis was to investigate the potential for contact lenses as a means of 
delivery of the antibiotic ciprofloxacin. With this goal in mind, Chapter 3 begins with 
investigations into the potential of several commercially available contact lens materials for their 
ability to uptake and release the antibiotic ciprofloxacin in vitro. Nine different contact lenses 
were surveyed, and the concentration of ciprofloxacin within the solutions investigated through 
fluorescence spectrophotometry. 
 Chapter 4 details the first attempts to manufacture model contact lens materials for the 
express purpose of sustained release of ciprofloxacin. The model materials were generated using 
a molecular imprinting strategy, in the hopes of modifying their release characteristics. The 
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effect of different functional monomers, concentrations of functional monomers, and ratios of the 
functional monomer to the template ciprofloxacin were investigated for their ability to affect 
ciprofloxacin release and release times in vitro. Material properties such as the dry weight, water 
content and centre thickness of these materials were also evaluated. 
 The final project (Chapter 5) utilized the results from projects detailed in Chapters 3 and 
4 to design actual contact lenses which can sustain the release of ciprofloxacin. The methods 
needed to be used to create sustained ciprofloxacin releasing contact lenses, as well as their 
material properties such as water content, surface wettability and light transmission were 
elucidated. Given the success at extending the release times of these materials, they were tested 
for their ability to control bacterial growth in vitro, as well as within an in vivo rabbit model of 
MK.   
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In the next chapter, the ability of commercially available CLs to uptake and release the antibiotic 
ciprofloxacin will be measured over time using fluorescence spectrophotometry, and 
comparisons between the different lens types will be made.  
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3.1 OVERVIEW 
3.1.1 OBJECTIVES  
 To investigate the uptake and release characteristics of the antibiotic Ciprofloxacin-HCl 
in conventional and silicone hydrogel lenses, and evaluate their potential as therapeutic drug 
delivery devices.  
3.1.2 METHODS  
 Nine differing soft contact lens materials were soaked in a 0.3% Ciprofloxacin-HCl 
solution at 34º. The uptake of the drug into the lenses was measured by the change in 
concentration over 24 hours using fluorescence spectrophotometry. The lenses were then placed 
in a buffered saline solution, and the release of the drug from the lenses was also measured using 
spectrophotometry.  
3.1.3 RESULTS   
 The release of drug varied from 0.016 ± 0.004 mg/lens for lotrafilcon A lenses to 0.42 ± 
0.03 mg/lens for etafilcon A lenses, with an average of 0.133 mg/lens. The three conventional 
lenses used in the study released a statistically significantly different amount of drug when 
compared to the silicone hydrogels. The release of drug was very rapid, with drug release 
reaching a plateau after no more than ten minutes for the majority of the lenses. The majority of 
the lenses were able to release enough drug to achieve MIC90 for most resistant ocular pathogens. 
Ciprofloxacin was found to heavily precipitate on the etafilcon A lenses during the release phase 
at physiological pH.  
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3.1.4 CONCLUSIONS 
 Whilst balafilcon A released the most drug from the SH materials, all materials released 
the drug too quickly to be effective as drug delivery devices.    
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3.2 INTRODUCTION 
 Patients who develop a severe ocular infection of the outer surface of the eye require 
frequent dosing of an antibiotic to resolve this potentially sight-threatening complication. The 
dosing regimens for the antibiotics can be very frequent. As an example, for a microbial ulcer, a 
dosing regimen of a drop of antibiotic every fifteen minutes is common, at least in the early 
stages, and thus many patients may require hospitalization to comply with the dosing regimen. 1 
Therefore, development of a slow-release ocular drug delivery device could potentially ease the 
amount of labor required during treatment of ocular infections and may provide benefits for both 
the patient and the clinician in charge of the medical management. The use of contact lenses as 
drug delivery devices was proposed as early as 1965, 2 but complications with long-term, 
overnight wear of older, conventional contact lenses reduces the desirability of these lenses as 
drug delivery devices for a number of reasons. Most contact lenses based on polyHEMA do not 
transmit sufficient oxygen to the cornea to allow for normal metabolic activity during sleep, 3 
resulting in edema and inflammatory reactions of the cornea, 4 decreasing both the healing 
process and patient comfort. The introduction of highly oxygen permeable soft contact lenses 
(also known as “silicone hydrogels”, “siloxane hydrogels” or “high Dk soft lenses) 5, 6 has 
revolutionized the way in which clinicians can use contact lenses as drug delivery devices, as 
these lenses transmit substantially more oxygen that conventional, older materials. 7-9  
 These new silicone hydrogel lenses would thus be ideal candidates for use as extended 
wear, drug delivery devices. However, the kinetics of delivery of drugs using contact lenses is 
still only poorly understood and few publications have addressed this issue with modern lens 
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materials. 10, 11 While some information is available on the uptake and release of certain agents, 
10-12 newer, second-generation silicone hydrogel lens materials have yet to be evaluated.  
 Ciprofloxacin is a second generation fluoroquinolone antibiotic with a wide range of 
activity against gram negative and gram positive bacteria, 13, 14 and is very commonly applied 
topically as an eye drop after corneal abrasions or in the treatment of microbial keratitis, 
conjunctivitis or endophthalmitis. 15, 16 It preferentially inhibits bacterial DNA Gyrase 17 and has 
low solubility at physiological pH due to the presence of aromatic ring structures, and has 
increased solubility in acidic or basic mediums due to the presence of ionizable functional 
groups. 18 A notable side effect of treatment with ciprofloxacin treatment is the formation of 
white corneal precipitates after prolonged use, which may delay epithelial healing. 19 
 The current study examined the time course for the uptake and release of Ciprofloxacin-
HCl in six commercially available silicone hydrogel contact lenses - balafilcon A (PureVision, 
Bausch & Lomb, Rochester, NY), comfilcon A (Biofinity, CooperVision, Scottsville, NY), 
galyfilcon A (Acuvue Advance, Johnson & Johnson, Jacksonville, FL), lotrafilcon A (Night and 
Day, CIBA Vision, Duluth, GA), lotrafilcon B (O2Optix, CIBA Vision, Duluth, GA), and 
senofilcon A (Acuvue OASYS, Johnson & Johnson, Jacksonville, FL) and three “old 
generation”, conventional soft contact lenses - alphafilcon A (SofLens 66, Bausch & Lomb, 
Rochester, NY), etafilcon A (Acuvue2, Johnson & Johnson, Jacksonville, FL) and polymacon 
(SofLens 38, Bausch & Lomb, Rochester, NY), to evaluate their usefulness as drug delivery 
devices.  
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3.3 MATERIALS AND METHODS 
3.3.1 PREPARATION OF DRUG SOLUTIONS 
 Ophthalmic ciprofloxacin solutions typically have a concentration of 0.3% (w/v). A 0.3% 
(w/v) Ciprofloxacin-HCl (LKT Laboratories Inc, St.Paul, Minnesota) solution was prepared in 
Unisol®4 saline solution (Alcon, Fort-Worth, Texas) and the pH was adjusted with HCl to pH 
4.0. A pH 4.0 solution was chosen as it allowed for complete solubility of the drug into solution 
at 0.3% (3 mg/mL). 18 At physiological pH, ciprofloxacin only has a solubility of 0.09 mg/mL. 18 
The drug is light sensitive, and thus experiments and storage were performed in light minimizing 
amber glassware. 
3.3.2 SPECTROGRAPHIC ANALYSIS OF CIPROFLOXACIN-HCL 
 The absorbance and emission spectra of the Ciprofloxacin-HCl solution was determined 
using a Hitachi F-4500 Fluorescence Spectrophotometer (Hitachi Ltd, Tokyo, Japan). 
Ciprofloxacin-HCl was determined to have a maximum excitation wavelength of 274 nm, 
resulting in a maximum emission at 419 nm and thus these were the conditions chosen for study. 
3.3.3 DETERMINATION OF CIPROFLOXACIN-HCL CONCENTRATION – 
PREPARATION OF THE STANDARD CURVE 
 Samples of the 0.3% Ciprofloxacin-HCl solution were diluted to a range of 
concentrations from 0.0001 mg/mL to 0.0014 mg/mL, to create a linear standard curve to be used 
as a reference to correlate absorbance readings to Ciprofloxacin-HCl concentrations in solution. 
The generated curves typically had a correlation coefficient above 99.5%. 
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3.3.4 LENSES USED 
 Six silicone hydrogel lenses (balafilcon A, comfilcon A, galyfilcon A, lotrafilcon A, 
lotrafilcon B, senofilcon A) and three conventional lenses (alphafilcon A, etafilcon A and 
polymacon) were used. All lenses (except for comfilcon A) were -3.00 D prescription, obtained 
from the manufacturer in their original packaging solution. The comfilcon A lenses were of -2.50 
D prescription, due to limited power availability at the time of the study. Table 3-1 and Table 3-2 
contain detailed lens properties.  
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 Night & Day O2OPTIX PureVision Acuvue OASYS Acuvue Advance Biofinity 
United States 
adopted name lotrafilcon A lotrafilcon B balafilcon A senofilcon A galyfilcon A comfilcon A 
Manufacturer CIBA Vision CIBA Vision Bausch & Lomb Johnson & Johnson Johnson & Johnson CooperVision 
Center thickness (@  
–3.00 D) mm 0.08 0.08 0.09 0.07 0.07 0.08 
Water content (%) 24 33 36 38 47 48 
Oxygen permeability 
( 10–11) 140 110 91 103 60 128 
Oxygen 
transmissibility  
( 10–9) 
175 138 101 147 86 160 
Surface treatment 
25 nm plasma 
coating with high 
refractive index 
25 nm plasma 
coating with high 
refractive index 
Plasma oxidation 
process 
No surface treatment. 
Internal wetting agent 
(PVP) throughout the 
matrix that also coats 
the surface 
No surface treatment. 
Internal wetting agent 
(PVP) throughout the 
matrix that also coats 
the surface 
None 
FDA group I I III I I I 
Principal monomers DMA + TRIS + siloxane macromer 
DMA + TRIS + 
siloxane macromer 
NVP + TPVC + 
NVA + PBVC 
mPDMS + DMA + 
HEMA + siloxane 
macromer + TEGDMA 
+ PVP 
mPDMS + DMA + 
EGDMA + HEMA + 
siloxane macromer + 
PVP 
FM0411M + HOB + 
IBM + M3U + NVP + 
TAIC + VMA 
 
Table 3-1 Types and Properties of Silicone Hydrogels Used in Study 34,35  DMA (N,N-dimethylacrylamide); EGDMA (ethyleneglycol dimethacrylate); FM0411M (-Methacryloyloxyethyl 
iminocarboxyethyloxypropyl-poly(dimethylsiloxy)-butyldimethylsilane); HEMA (poly-2-hydroxyethyl methacrylate);  HOB (2-Hydroxybutyl 
methacrylate); IBM (Isobornyl methacrylate); MA (methacrylic acid); mPDMS (monofunctional polydimethylsiloxane); NVP (N-vinyl 
pyrrolidone); TEGDMA (tetraethyleneglycol dimethacrylate); TPVC (tris-(trimethylsiloxysilyl) propylvinyl carbamate); TRIS (trimethylsiloxy 
silane); M3U (-Bis(methacryloyloxyethyl iminocarboxy ethyloxypropyl)-poly(dimethylsiloxane)-poly(trifluoropropylmethylsiloxane)-
poly(methoxy-poly(ethyleneglycol)propyl methylsiloxane)); NVA (N-vinyl amino acid); PBVC (poly[dimethysiloxy] di [silylbutanol] 
bis[vinyl carbamate]); PC (phosphorylcholine); PVP (polyvinyl pyrrolidone); TAIC (1,3,5-Triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione); 
VMA (N-Vinyl-N-methylacetamide).  
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 Proprietary Name 
 SofLens 38 (formerly Optima FW) SofLens 66 Acuvue2 
USAN polymacon alphafilcon A etafilcon A 
Manufacturer Bausch & Lomb Bausch & Lomb Johnson & Johnson 
Water Content (%) 38 66 58 
Dk 10 30 22 
FDA Group I II IV 
Surface Treatment None None None 
Principal monomers pHEMA HEMA + NVP HEMA + MA 
 
Table 3-2 Types and Properties of Conventional Lenses Used in Study 34 
  HEMA (poly[2-hydroxyethyl methacrylate), MA (methacrylic acid), NVP (N-vinyl pyrrolidone)
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3.3.5 UPTAKE AND RELEASE STUDIES - UPTAKE 
 Three lenses of a given type were removed from their packaging and placed into 5 mL of 
Unisol®4 in 15 mL, round bottom polypropylene tubes (VWR International, Mississauga, 
Ontario) and gently shaken for 30 minutes to remove any packaging solution. The lenses were 
removed and partially dried on lens paper, before being transferred into an amber vial (Wheaton, 
Millville, NJ) containing 2 mL of 0.3% Ciprofloxacin-HCl solution. The vial was incubated in a 
shaking water bath at 34 °C, to simulate eye conditions. 20 Uptake evaluations were undertaken 
at various times over a 24 hour period. During the first 30 minutes, readings were taken every 5 
minutes. For the next 1.5 hours readings were taken every 15 minutes. Thereafter, readings were 
taken every hour, out to 24 hours. At each time point under investigation, 5 μL of solution was 
removed, and diluted 4000 fold, to obtain a reading within the linear range of the standard curve.  
3.3.6 UPTAKE AND RELEASE STUDIES - RELEASE 
 After the 24th hour uptake reading was taken, the lenses were removed from the 
Ciprofloxacin-HCl solution and briefly dipped into Unisol®4 to remove any residual drug 
solution not absorbed or adsorbed. The lenses were then partially dried on lens paper, and placed 
into a fresh amber vial containing 2 mL of Unisol®4 (at a measured pH of 7.4). The vial was 
incubated in a shaking water bath at 34 °C to simulate eye conditions. At time points identical to 
that used during the uptake phase of the study, either 5 μL or 10 μL of release solution 
(depending on lens type) was removed and diluted to 1 mL (1:200 or 1:100 dilution) with 
Unisol®4.  
3.3.7 PHOTOGRAPHS 
 Photographs of the lenses were undertaken using a slit lamp mounted lens holder, and 
taken with a Panasonic 3CCD digital camera, using diffuse and direct lighting with 5X, 8X or 
 85 
 
12X magnification, as indicated. This was conducted to visualize the optical impact of the uptake 
of the ciprofloxacin into the various lens materials.  
3.3.8 STATISTICS AND CALCULATIONS 
 Statistical analysis was performed using Statistica Ver7.1 (StatSoft Inc., Tulsa, OK, 
USA). All the data are reported as mean ± standard deviation, unless otherwise indicated. In all 
cases, calculations took into account the volume change due to sampling, through comparison of 
the concentrations actually measured and theoretical concentrations (if no lens was present). A 
repeated measures Analysis of Variance (ANOVA) was performed to determine differences 
across various time points within the same lens type. An ANOVA was performed to determine 
differences between lens types.  Post-hoc Tukey HSD tests were used as needed. Statistical 
significance was considered when p values of less than 0.05 were obtained.  
3.4 RESULTS 
 Typical uptake curves over a 24 hour period for four of the lenses (etafilcon A; 
senofilcon A; lotrafilcon A; galyfilcon A) are illustrated in Figure 3-1, and summarized for all 
lens types in Table 3-3. Inspection of Figure 3-1 shows that up to 60 minutes post exposure to 
the ciprofloxacin solution that all lens materials showed an uptake of the drug (p<0.05), and that 
the differences between lens types was minimal (p=NS).  
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Figure 3-1 Ciprofloxacin Uptake (mg/lens) 
Ciprofloxacin uptake (mg/lens) for etafilcon A (▲),senofilcon A (○), lotrafilcon 
A (▼) and galyfilcon A (●),over time determined by spectrophotometry. Values 
plotted are the mean ± standard deviation. Of the silicone hydrogel lenses, the 
senofilcon A lenses took up the most drug (1.29 ± 0.13 mg/lens; range 0.39 ± 0.36 
to 1.29 ± 0.13 mg/lens), although these differences were not statistically 
significant (p=NS). Senofilcon A was only second in its uptake of ciprofloxacin to 
etafilcon A lenses (1.51 ± 0.14 mg/lens).  
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Lens 
mg of ciprofloxacin taken up / lens 
60 mins 180 mins 360 mins 1440 mins 
Alphafilcon A 0.15 ± 0.12 0.37 ± 0.18 0.18 ± 0.08 0.68 ± 0.18 
Balafilcon A 0.39 ± 0.21 0.18 ± 0.04 0.16 ± 0.15 0.53 ± 0.28 
Comfilcon A 0.80 ± 0.10 0.85 ± 0.05 0.89 ± 0.04 0.93 ± 0.04 
Etafilcon A 1.46 ± 0.14 1.56 ± 0.07 1.46 ± 0.09 1.31 ± 0.11 
Galyfilcon A 0.28 ± 0.09 0.51 ± 0.04 0.51 ± 0.03 0.77 ± 0.13 
Lotrafilcon A 0.57 ± 0.01 0.68 ± 0.12 0.80 ± 0.01 1.12 ± 0.01 
Lotrafilcon B 0.62 ± 0.06 0.64 ± 0.13 0.76 ± 0.10 1.01 ± 0.07 
Polymacon 0.49 ± 0.08 0.59 ± 0.04 0.87 ± 0.05 0.71 ± 0.03 
Senofilcon A 1.12 ± 0.13 1.31 ± 0.10 1.34 ± 0.12 1.11 ± 0.07 
 
Table 3-3 Summary of Uptake of Ciprofloxacin-HCl into Different Lens Types  
  Results are expressed as the mean ± standard deviation of 3 lenses. 
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 Typical release curves over a 24 hour period for five of the lens types (etafilcon A; 
alphafilcon A; polymacon; balafilcon A; comfilcon A) are illustrated in Figure 3-2 and 
summarized for all lens types in Table 3-4. All lenses released a statistically significant amount 
of drug when compared to the initial time point (p<0.001). The majority of the lenses released 
their drug within the first 10-15 minutes, as evidenced by the lack of statistically significant 
difference (p=NS) between sequentially measured values after the initial fifteen minutes. Of all 
the lenses, only etafilcon A and polymacon lenses showed statistically significant (p<0.05) 
changes over time beyond the first few measurements; etafilcon A released drug significantly for 
the first 25 minutes before reaching a plateau (changing from 0.10 ± 0.03 mg/lens to 0.37 ± 0.01 
mg/lens), while polymacon continued to show significant changes for 20 minutes before 
reaching a plateau (changing from 0.01 ± 0.007 mg/lens to 0.19 ± 0.005 mg/lens). With respect 
to lens type, the conventional lens types (etafilcon A, polymacon and alphafilcon A) all had 
statistically significantly higher (p<0.001) release of drug over all time points, when compared to 
all other lens types. Release from etafilcon A lenses were statistically different (p<0.001) from 
alphafilcon A and polymacon lenses after 10 minutes had elapsed; statistical difference between 
the remaining two conventional lenses is seen after 30 minutes had elapsed (p<0.001). 
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Figure 3-2 Ciprofloxacin Release (mg/lens) 
Ciprofloxacin release (mg/lens) from etafilcon A (▲), polymacon (●), alphafilcon 
A (■), balafilcon A (○) and comfilcon A (▼) over time determined by 
spectrophotometry. Values plotted are the mean ± standard deviation. The 
etafilcon A lenses released the most ciprofloxacin, with a maximum release of 
0.42 ±0.03 mg/lens., the polymacon lens released 0.27 ± 0.01 mg/lens, the 
alphafilcon A lens released 0.18 ± 0.01while the silicone hydrogels balafilcon A 
and comfilcon A released only 0.078 ± 0.01 and 0.06 ± 0.004 mg/lens 
respectively. Release from the conventional lenses (alphafilcon A, etafilcon A and 
polymacon) was statistically different from each other, as well as all other lenses 
(p<0.001). All lenses except for lotrafilcon A lenses showed statistically 
significant release when compared to the first time point (p<0.001), but only 
etafilcon A and polymacon showed a statistical significant change over time; 
etafilcon A release was statistically significant for the first 25 minutes (p<0.001) 
while release from polymacon lenses was statistically significant for the first 20 
minutes (p<0.001). There is was no significant difference between balafilcon A 
and comfilcon A lenses over time. 
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Lens 
mg of ciprofloxacin released / lens 
60 mins 180 mins 360 mins 1440 mins 
Alphafilcon A 0.19 ± 0.01 * 0.18  ± 0.01 * 0.17 ± 0.01 * 0.19 ± 0.01 * 
Balafilcon A 0.086 ± 0.01 0.080 ± 0.01 0.08 ± 0.01 0.099 ± 0.02 
Comfilcon A 0.063 ± 0.004 0.062 ± 0.003 0.057 ± 0.001 0.058 ± 0.004 
Etafilcon A 0.42 ± 0.009 * 0.41 ± 0.009 * 0.40 ± 0.011 * 0.48 ± 0.003 * 
Galyfilcon A 0.077 ± 0.004 0.075 ± 0.003 0.071 ± 0.003 0.063 ± 0.002 
Lotrafilcon A 0.016 ± 0.003 0.014 ± 0.001 * 0.013 ± 0.001 * 0.022 ± 0.005 * 
Lotrafilcon B 0.05 ± 0.005 0.046 ± 0.002 0.044 ± 0.003 0.057 ± 0.01 
Polymacon 0.25 ± 0.008 * 0.26 ± 0.009 * 0.26 ± 0.008 * 0.26 ± 0.008 * 
Senofilcon A 0.047 ± 0.002 0.059 ± 0.009 0.060 ± 0.007 0.056 ± 0.002 
 
Table 3-4 Summary of Release of Ciprofloxacin-HCl from Different Lens Types  
Results are expressed as the mean ± standard deviation of 3 lenses. * Represents 
values significantly different (p<0.05) from all other lens types at that time point.  
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 Visually, most of the lenses remained clear throughout both the uptake and release phases 
of the experiment. The only lens with a marked change was etafilcon A, which showed a 
dramatic precipitation of the drug. The drug precipitated on the lens during the uptake phase (at 
pH 4.0), and became completely white and opaque once placed within the release solution at pH 
7.4 (Figure 3-3a and Figure 3-3b). There was also some evidence of precipitation on the 
alphafilcon A (Figure 3-3c) and polymacon lenses during the release phase of the experiment. 
This was in contrast to the lack of any noticeable precipitate on all of the other lenses (Figure 
3-3d).  
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Figure 3-3 Ciprofloxacin Precipitates 
Ciprofloxacin precipitates on etafilcon A during (a) Uptake (12X magnification) 
and (b) Release (5X magnification) and on (c) alphafilcon A (8X magnification) 
during release. Absence of precipitate is seen on (d) galyfilcon A (8X 
magnification) during release. Etafilcon A lenses show the most uptake and 
release of ciprofloxacin but the presence of white precipitates on the lens limit 
their use as a drug delivery device. Alphafilcon A lenses also show a high amount 
of ciprofloxacin release but also presence of precipitates. In contrast, the silicone 
hydrogel lenses (such as the representative galyfilcon A lens pictured) do not 
show any precipitate, but also release much less drug. 
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3.5 DISCUSSION 
 Uptake profiles (Table 3-5) indicate that the highest uptake is with etafilcon A, followed 
by senofilcon A. Release profiles (Table 3-5) indicate that the highest release is with etafilcon A, 
followed by polymacon and alphafilcon A, with lotrafilcon A having the lowest release. Table 
3-5 also shows the percentage of ciprofloxacin that is released, as a proportion of that taken up. 
These values show that the three conventional lens materials (etafilcon A, polymacon and 
alphafilcon A) release the highest percentage of the drug that is taken up, and lotrafilcon A 
releases the least. These values suggest that conventional materials typically are able to release 
the drug more easily than silicone hydrogels, which appear to bind the drug relatively firmly to 
the lens material. This is obviously a disadvantage for a drug delivery device, although could be 
an advantage, if the delivery was sustained at a low level for a long period of time.  
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Lens 
Mass (mg) of ciprofloxacin per lens Percentage of 
Drug Released 
Max ciprofloxacin 
released (mg/lens) x Dk Uptake Release 
Alphafilcon A 0.32 ± 0.24 0.18 ± 0.008 * 56.2 5.4 
Balafilcon A 0.39 ± 0.36 0.078 ± 0.01 20 7.1 
Comfilcon A 0.89 ± 0.06 * 0.06 ± 0.004 6.7 7.7 
Etafilcon A 1.51 ± 0.14 * 0.42 ± 0.03 * 27.8 9.2 
Galyfilcon A 0.57 ± 0.12 0.071 ± 0.005 12.5 4.3 
Lotrafilcon A 0.79 ± 0.19 0.016 ± 0.004 * 2.0 2.2 
Lotrafilcon B 0.75 ± 0.16 0.047 ± 0.006 6.3 5.2 
Polymacon 0.72 ± 0.13 0.27 ± 0.008 * 37.5 2.7 
Senofilcon A 1.29 ± 0.13 0.057 ± 0.002 4.4 5.9 
   Average 5.5 
 
Table 3-5 Average Ciprofloxacin Uptake and Release after Plateau from 120 Minutes 
to 1440 Minutes 
Results are expressed as the mean ± standard deviation of 3 lenses. * Represents 
values significantly different (p<0.05) from all other lens types. 
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 Based on ocular studies, the range of minimum inhibitory concentrations for 90% of 
bacterial isolates (MIC90) range from 0.00025 to 0.032 mg/mL21 for ciprofloxacin against 
common susceptible and resistant ocular pathogens. To achieve this concentration within the 2 
mL volume of the test cuvette, a lens must release a minimum of 0.0005 mg/lens for susceptible 
isolates, or up to 0.064 mg/lens for more resistant isolates. All lenses released enough drug to 
meet the MIC90 concentrations for the more susceptible isolates, but lotrafilcon A, lotrafilcon B, 
senofilcon A and comfilcon A do not release enough drug to meet the concentrations needed for 
more resistant organisms.  As evidenced by Figure 3-1 and Figure 3-2, for the majority of lenses, 
the time course for the uptake and release of the antibiotic occurred very quickly. For uptake, 
typically by 60 minutes the uptake of drug into the lens had essentially plateaued, with minor 
increases thereafter. For release, within the first 20 minutes the majority of lenses had released 
their maximum amount of drug into solution. 
 Compared to a previous study by Karlgard et al., 10 the results from the current study 
appear to indicate a lower amount of drug being taken up by the lenses, as well as that being 
released. The Karlgard study 10 established a maximum uptake for all lenses of approximately 
1.8 mg/lens, compared to the current study, which shows an uptake varying from 0.47 mg/lens to 
1.5 mg/lens (mean 0.96 mg/lens). The amount of drug released also differs considerably, with the 
previously reported release ranging from 0.065 mg/lens to 0.217 mg/lens (mean: 0.140 mg/lens), 
while the current study varies from 0.021 mg/lens to 0.48 mg/lens (mean 0.145 mg/lens). The 
reasons for the discrepancy between these two studies may be attributable to the doping solution 
used. The current study utilized a pH-adjusted solution, which allowed for a fully dissolved, 
uniform, concentrated 0.3% ophthalmic solution to be used, compared to a 0.15% partial 
suspension in unmodified Unisol®4 in the previous study. 10 
 96 
 
 Although etafilcon A lenses took up and released the most ciprofloxacin when compared 
to all the other lens types, its use as a drug delivery device for the delivery of ciprofloxacin 
should be discouraged, as the lens is rendered completely opaque by drug precipitates at 
physiological pH, as seen in Figure 3-3b. While the dosage of the drug delivered is exceptional, 
the decrease in visual performance and comfort provided by the lens would limit its use in a 
practical sense. The precipitates seen on polymacon lenses would also discourage their use, as 
this precipitation would likely decrease visual performance as well as comfort. 
Previous studies have shown that drug - lens interactions are multi-faceted and are influenced by 
several factors, including water content, ionicity, porosity, surface treatment, surface 
morphology of the lens material under test and also the organization of water in and around the 
material. 10, 22-25 The results from this study show that among the silicone hydrogel lens 
materials, balafilcon A had the highest percentage of drug released (Table 3-5). Balafilcon A is a 
low water content lens material with a negative charge due to the presence of N- vinyl amino 
acid (Table 3-1), and is thus classified as a United States Food & Drug Administration group III 
material. The balafilcon A material undergoes a surface modification process which results in a 
mosaic-like surface with glassy discontinuous silicate coatings, at a thickness of approximately 
10-25nm. 26 In addition, balafilcon A is relatively more porous when compared to other SH lens 
materials. 26 Ciprofloxacin has an amino group (pKa of 8) and a carboxylic acid group (pKa of 
6). 18 At the doping pH of 4, Ciprofloxacin will carry a net positive charge as the amino group is 
protonated and the carboxylic acid will be non-ionized, resulting in Ciprofloxacin being 
adsorbed into the negatively charged balafilcon lens material. Whereas, at the release pH of 7.2, 
Ciprofloxacin will be neutral, as the carboxylic acid will carry a negative charge and the amino 
group will carry a positive charge, resulting in the drug being easily released from the lens 
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material. Thus, the combination of a discontinuous surface treatment, open pore-like network 
and the charge on the drug may result in an increased percentage of ciprofloxacin being released 
from the balafilcon A material.   
 The ideal “bandage lens drug delivery device” would be able to deliver a high amount of 
ciprofloxacin over an extended period of time, while also transmitting a high amount of oxygen 
to the cornea, as determined by its quoted oxygen permeability (Dk) or transmissibility (Dk/t). 
An index relating these two important parameters could be determined by multiplying the 
maximum ciprofloxacin release by the material Dk, and this “index” is shown in Table 3-5. 
These values show that etafilcon A has the highest index, due to its high release, but the 
aforementioned precipitates preclude its usefulness. Of the silicone hydrogels, it should be noted 
that balafilcon A and comfilcon A are above average, while lotrafilcon A and galyfilcon A 
perform below average, when compared to the rest of the lenses.  
 In conclusion, nine different soft contact lenses were tested for their uptake and release 
characteristics when soaked in the ocular antibiotic Ciprofloxacin-HCl. The majority of the 
lenses were able to release levels of the antibiotic into solution which would be clinically 
relevant, but released them too quickly under experimental parameters to be clinically useful as 
drug delivery devices. These results suggest that etafilcon A lenses should not be used as a drug 
delivery device or as a bandage lens concurrent with the delivery of ciprofloxacin-HCl eyedrops, 
as drug precipitation renders it ineffective for adequate visual performance. If a practitioner is 
looking for a balance of high oxygen transmissibility with “high” delivery levels of 
ciprofloxacin, then balafilcon A lenses appear to provide an encouraging mixture of these two 
factors. Balafilcon A lenses are FDA approved for use as therapeutic lenses and previous studies 
have shown that they work well in this format. 7 27 28 It is worth noting that the other two silicone 
 98 
 
hydrogel lens materials approved for therapeutic use (lotrafilcon A and senofilcon A) both 
released lower amounts of ciprofloxacin than balafilcon A. To date, no studies have been 
published on the use of senofilcon A as a bandage lens, but studies looking at lotrafilcon A have 
also shown this material to be an excellent therapeutic lens. 8 27 29 30 31 32 33 However, these 
studies did not investigate its performance when used with concurrent drug delivery.    
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In the next chapter, a molecular imprinting strategy is employed in an attempt to modify the 
ciprofloxacin release kinetics in vitro. The effect of different ratios of functional monomer to 
template ratio within the polymerization mix, the concentration of the functional monomer and 
the concentration of the loading solution were all examined for their effects on ciprofloxacin 
release kinetics. The structure of the chapter is dictated by the journal into which it was 
published, Materials by MDPI.  
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4.1 OVERVIEW  
 Contact lenses, as an alternative drug delivery vehicle for the eye compared to eye drops, 
are desirable due to potential advantages in dosing regimen, bioavailability and patient 
tolerance/compliance. The challenge has been to engineer and develop these materials to sustain 
drug delivery to the eye for a long period of time. In this study, model silicone hydrogel 
materials were created using a molecular imprinting strategy to deliver the antibiotic 
ciprofloxacin. Acetic and acrylic acid were used as the functional monomers, to interact with the 
ciprofloxacin template to efficiently create recognition cavities within the final polymerized 
material. Synthesized materials were loaded with 9.06 mM, 0.10 mM and 0.025 mM solutions of 
ciprofloxacin, and the release of ciprofloxacin into an artificial tear solution was monitored over 
time. The materials were shown to release for periods varying from 3 to 14 days, dependent on the 
loading solution, functional monomer concentration and functional monomer:template ratio, with 
materials with greater monomer:template ratio (8:1 and 16:1 imprinted) tending to release for 
longer periods of time. Materials with a lower monomer:template ratio (4:1 imprinted) tended to 
release comparatively greater amounts of ciprofloxacin into solution, but the release was somewhat 
shorter. The total amount of drug released from the imprinted materials was sufficient to reach 
levels relevant to inhibit the growth of common ocular isolates of bacteria. This work is one of the 
first to demonstrate the feasibility of molecular imprinting in model silicone hydrogel-type 
materials. 
Keywords: molecular imprinting; ciprofloxacin; antibiotic; contact lens materials; silicone 
hydrogel; drug delivery; combination devices 
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4.2 INTRODUCTION  
 As the contact lens industry continues to grow and develop, novel uses and applications 
of contact lenses are constantly being contemplated and investigated. Contact lens materials as a 
vehicle for sustained ophthalmic drug delivery to the eye has had a renewal of interest in the past 
decade, mainly due to the advent of silicone hydrogel materials, which provide sufficient oxygen 
delivery to the eye to permit hypoxia-free wear during overnight use [1]. Indeed, in the original 
patents and designs of soft contact lens materials, the concept of using contact lenses as a reservoir 
for drugs delivered to the eye was noted, although little work investigating this application has 
been conducted for over thirty years [2]. Recently, there has been an explosion in the number of 
studies and groups who have demonstrated an interest in the development of contact lens drug 
delivery materials. The rationales for the use of contact lenses as drug delivery devices are 
numerous. First, contact lenses are arguably the most successful biomaterial currently available, 
with estimates of over 140 million wearers worldwide [3], and are thus firmly embraced by 
patients and, more importantly, practitioners. Second, contact lenses have already been 
demonstrated to successfully correct refractive errors in patients. The addition of drug delivery to 
this correction of refractive error can potentially increase the quality of life in patients by 
decreasing dosing frequency, while also potentially increasing compliance rates in acute or 
chronic ophthalmic treatment. Third, there is some evidence that concurrent contact lens and 
topical ophthalmic treatment is more effective than topical treatment alone. Use of contact lenses 
has been demonstrated to increase the residence time and/or increase ocular penetration of 
topically administered agents [4, 5]. Use of contact lenses may thus decrease the amount of drug 
needed to successfully treat ocular disease in patients. Finally, there are many situations or locales 
around the world where access to pharmacological therapy is inconsistent at best, necessitating 
the use of treatments that can be administered at a single time and have a long lasting effect. 
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Development of these devices to combat these medical challenges is thus warranted and 
potentially useful. 
 There are several clinical scenarios in which a contact lens is already used medically to 
aid the healing of a patient, with topically prescribed agents being used concurrently with contact 
lenses. For example, following photorefractive keratectomy (PRK), an ocular laser surgical 
method used for the correction of refractive error, a bandage contact lens is used for several days 
post-surgery, due to the absence of the corneal epithelium, which is removed during the course 
of the procedure [6]. Antibiotic drops are used on top of the lens prophylactically to prevent any 
post-surgical infection. In patients who present with a traumatic corneal abrasion, a bandage 
contact lens is often used to increase the rate of healing, while also providing symptomatic pain 
relief. These patients are often prescribed an antibiotic agent, either prophylactically or to treat 
any current infection sustained during the trauma. It is evident that if the bandage lens was 
concurrently providing the symptomatic relief as well as the release of the prophylactic antibiotic 
agent, then the patient could be permitted to rest and recuperate rather than worrying about drug 
dosing schedules. 
 The extended release of drugs from soft contact lens materials (hydrogels) is 
unfortunately not that simple. Previous studies have demonstrated that commercially available 
lenses soaked in ophthalmic pharmaceuticals are capable of releasing clinically relevant amounts 
of drugs, but the release times from these materials is in the order of only minutes to hours [7-
10]. Furthermore, these materials are not designed for extended wear, so even if long term 
release was achieved, the hypoxia of the cornea that would occur with extended wear would 
necessitate their removal. Thus, strategies to optimize release times to be more on the order of 
days or even weeks are needed, if these devices are to be used and marketed effectively.  
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 Numerous strategies have been investigated to slow and/or control the release of 
pharmaceuticals from contact lenses. Some investigators have found the addition of a diffusion 
barrier could impede the movement of the drug out of the lens, thus slowing the release. In recent 
studies investigating this concept for the delivery of dexamethasone and timolol [11, 12], vitamin 
E was used as a diffusion barrier and the authors were able to demonstrate sustained release from 
these materials for days to weeks, with the time for release being controlled by the amount of 
vitamin E used. This technique may prove particularly beneficial as it can be used with 
commercially available materials, thus shortening the regulatory approval processes. Other 
authors have proposed the use of a drug-impregnated coating on the surface of the lens, using 
cyclodextrins, nanoparticles or liposomes [13-15]. This strategy may be particularly useful for 
drugs with poor solubility in aqueous environments, as the microenvironment of the coating can 
be different from the rest of the lens.  
 One of the more successful strategies in generating extended release times from contact 
lens materials has been molecular imprinting. Molecular imprinting is a polymerization strategy 
in which a molecule of interest is present within the pre-polymerization solution of a polymer. 
The addition of other molecules known as functional monomers, which serve to interact with the 
functional groups of the template molecule, create “cavities” or “molecular memory” within the 
material after polymerization is complete [16]. These “cavities” specifically interact with the 
template molecules, slowing the diffusion of the templates out of the material into solution, and 
thus extending release times [17]. This technique was originally designed for highly crosslinked, 
hard plastics for the specific removal of components out of solutions [18]. The challenge has 
been to adapt this technique for contact lenses, in which a highly crosslinked, rigid type material 
would not be useful. Despite these challenges, several recent papers have shown this technique to 
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be applicable to the creation of contact lens materials to deliver anti-glaucoma, antibiotic, 
antihistamine, non-steroidal anti-inflammatory agents (NSAIDs) and wetting agents [17, 19-22]. 
The gains in delivery time for materials created using this concept have been substantial; 
whereas non-modified materials may release for only a few hours at most, delivery from 
imprinted materials in the order of several days have been achieved [22]. Several key insights 
have been gleaned from previous authors. First, the choice of the template and functional 
monomer is crucial. There has to be an appropriate interaction between the template and 
functional monomer to efficiently create the cavities to be fixed during the polymerization 
process [22]. Second, the amount of functional monomer relative to the template in the 
polymerization mix is also important. A low functional monomer:template will yield an 
insufficient number of cavities being created around the template; a too high functional 
monomer:template ratio will lead to inefficient creation of cavities, as much of the functional 
monomer will not have the opportunity to interact with the template [20]. Much of the work to-
date on imprinted molecules have involved “conventional” higher water content hydrogel 
materials based on poly-hydroxyethyl methacrylate (pHEMA) [21, 23], but more recent work has 
been performed on the more oxygen permeable siloxane-based hydrogels [24].  
 Ciprofloxacin-HCl is a second generation fluoroquinolone antibiotic. It interferes with 
bacterial DNA gyrase, preventing bacterial DNA replication [25]. It is a broad spectrum 
antibiotic, with activity against both gram-negative and gram positive bacteria [26, 27]. It is used 
ophthalmically as either an eye drop or as an ointment. It is commonly used as a treatment for 
bacterial conjunctivitis, and is one of only a few drugs that have United States Food and Drug 
Administration (FDA) indications for the treatment of bacterial ulcers/microbial keratitis [28, 
29]. Ciprofloxacin exhibits poor aqueous solubility at physiological pH due to its overall neutral 
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charge as a zwitterion at this pH, and the presence of its dual aromatic rings [30]. Its solubility in 
aqueous media is greatly enhanced in acidic or basic solutions, leading to commercially available 
ophthalmic preparations having a pH of approximately 4.0, which may cause some stinging or 
irritation upon instillation [29, 30]. When dissolved in high concentrations, ciprofloxacin 
solutions have a yellowish colour. During a severe infection, the dosing of ciprofloxacin can be 
as frequent as two drops every fifteen minutes. This high dose and long term use, coupled with 
poor solubility of the drug at physiological pH, can lead to the development of white, crystalline 
precipitates in the cornea or inferior conjunctival sac, although this does not necessarily indicate 
the need to discontinue treatment [31].  
 In this current study, molecular imprinting techniques were used to create model silicone 
hydrogel materials for the delivery of the antibiotic ciprofloxacin-HCl. Acetic and acrylic acid 
were used as functional monomers, and the effect of functional monomer:template ratio, overall 
functional monomer concentration and drug loading concentration were all investigated and 
explored. This study is one of the few studies investigating the use of silicone hydrogel-type 
materials for the delivery of pharmaceuticals using a molecular imprinting strategy. 
4.3 RESULTS AND DISCUSSION 
4.3.1 PILOT STUDY: CIPROFLOXACIN PHEMA-METHACRYLOXYPROPYLTRIS 
(TRIMETHYLSILOXY) SILANE (TRIS) MATERIALS WITH ACETIC ACID 
FUNCTIONAL MONOMERS 
 The water content and dry weight of the different acetic acid imprinted model materials is 
detailed in Table 4-1. Model lenses created would all be classified as being of low water content, 
and would require some increase in water content if they were to be used as actual contact lenses 
on the eye. There was no statistically significant difference between the pHEMA-TRIS-Acetic 
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Acid controls and the pHEMA-TRIS-Acetic Acid Ciprofloxacin imprinted materials, based on a 
one way analysis of variance (ANOVA) (p > 0.05).  
Table 4-1 Dry Weight and Water Content of Acetic Acid Imprinted pHEMA-TRIS 
Materials. 
Model Lens Type 
Dry Weight (g)  
(Average ± 
Standard 
Deviation) 
Water Content (%) 
(Average ± Standard 
Deviation) 
Centre Thickness 
(mm) (Average ± 
Standard 
Deviation) 
Volume (mm3) 
(Average ± 
Standard 
Deviation) 
pHEMA + TRIS + 1% by 
weight Acetic Acid Control 0.0457 ± 0.0089 15.5 ± 2.7 0.87 ± 0.12 68.1 ± 9.3 
pHEMA + TRIS + 1% by 
weight 4:1 Acetic 
Acid:Ciprofloxacin 
0.0428 ± 0.0078 14.8 ± 2.5 0.93 ± 0.16 73.2 ± 12.9 
pHEMA + TRIS + 1% by 
weight 8:1 Acetic 
Acid:Ciprofloxacin 
0.0396 ± 0.0059 16.7 ± 2.1 0.99 ± 0.14 77.3 ± 10.8 
 The release curves from these materials loaded with 9.06 mM, 0.10 mM and 0.025 mM 
ciprofloxacin over the first 24 hours are seen in Figure 4-1(a–c). There was no statistically 
significant difference seen between the imprinted and control model lenses loaded with 9.06 
mM, over the course of the 24 h (p > 0.05). The initial release from the 0.10 mM and 0.025 mM 
model lenses are of interest. For 0.10 mM loaded model lenses, the control exhibited a very fast 
release and almost immediate plateau, at a level higher than the two imprinted materials. For the 
0.025 mM loaded model lens, the control model lens again almost immediately reached its final 
plateau level, but in this situation it was at a level that was below that of the two imprinted 
materials. Whether this was caused by some residual loading solution on the 0.10 mM loaded 
discs is unknown. For the imprinted materials, for both the 0.10 mM and 0.025 mM loaded 
model lenses, there was a slow release of ciprofloxacin into solution over the course of the 24 
hours, but there was no statistical significance between the 4:1 and 8:1 imprinted materials.
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Figure 4-1 (a–c) Release Curves from Acetic Acid Imprinted Materials over 24 hours 
Release curves from acetic acid imprinted materials loaded with (a) 9.06 mM 
ciprofloxacin; (b) 0.10 mM ciprofloxacin and (c) 0.025 mM ciprofloxacin 
over 24 h. Values plotted are means ± standard deviations. 
 
(a) 
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(b) 
 
(c) 
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 The release curves of the acetic acid imprinted materials and controls after 14 days of 
release is seen in Figure 4-2 (a–c). For model lenses loaded with 9.06 mM of ciprofloxacin, there 
was an overall statistically significantly greater amount of drug released by the imprinted 
materials compared to the control (p < 0.05), but there was no significant difference between the 
two imprinted materials (p > 0.05). The time to reach the plateau was also different; 
interestingly, the imprinted materials appeared to reach their plateaus within 4 or 5 days, while 
the statistics suggest that the control was releasing for up to 8 days. Unfortunately, there is a 
greater amount of variation in the determination of the concentration of ciprofloxacin within the 
solution when loading with such a high concentration, as dilutions are necessary to reach 
concentrations relevant to the linear portion of the standard curve, potentially confounding 
results. The effect of imprinting in comparison with the non-imprinted controls is most evident 
again when the materials are loaded with the lower concentration solutions (0.10 mM and 0.025 
mM), as seen in Figure 4-2b and Figure 4-2c. Here, the imprinting demonstrates two key 
advantages over the non-imprinted control, with a longer release time and a greater amount of 
ciprofloxacin being released. For the 0.10 mM loaded materials, analysis suggests that a plateau 
level is reached in as little as 45 minutes for controls. In contrast, the 4:1 imprinted and 8:1 
imprinted materials demonstrate continued significant release compared to earlier time points out 
to 10 days. Similar results are seen in model lenses loaded with 0.025 mM solutions. The control 
released so little that there was statistically no difference over the course of the 14 days 
compared to the initial time point, whereas the imprinted materials were releasing for up to 8 
days. As can be clearly seen from the release curves, there was no statistically significant 
difference between the two ratios of acetic acid to ciprofloxacin in terms of the plateau amount 
of ciprofloxacin released, or the time to reach a plateau.  
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Figure 4-2 (a-c) Release Curves from Acetic Acid Imprinted Materials over 14 Days 
Release curves from acetic acid imprinted materials loaded with (a) 9.06 mM 
ciprofloxacin; (b) 0.10 mM ciprofloxacin and (c) 0.025 mM ciprofloxacin 
over 14 days. Values plotted are means ± standard deviations. 
 
(a) 
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(c) 
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 The results from these initial attempts to create imprinted silicone hydrogel materials 
were very encouraging in that they achieved two separate goals. First, the effect of the imprinting 
was demonstrated when the model lenses were loaded with lower concentrations of the drug, as 
there was a clear difference between the imprinted and non-imprinted materials in their ability to 
deliver drugs for an extended period of time, as evidenced by drug release occurring for a period 
of 8 to 10 days (depending on the loading concentration). Second, we were able to confirm the 
delivery of relevant amounts of the antibiotic. When loaded with the clinical concentration of 
ciprofloxacin (9.06 mM), concentrations were achieved in the 2 mL reaction vial that were 
clinically relevant in achieving the minimum inhibitory concentration (MIC90) of common ocular 
isolates [32]. Not surprisingly, when the loading concentration was decreased by approximately 
100 times, the amount of drug released was less, and the MIC90 only reached concentrations 
relevant to more susceptible bacteria. Finally, the pilot study failed to demonstrate any 
differences between the ratio of acetic acid to ciprofloxacin used to create the imprinting that has 
been demonstrated previously [2, 17, 18, 20, 22]. This was possibly due to the lack of precision 
in choosing to add the imprinting mixture on the basis of percentage weight rather than by molar 
concentration of the functional monomer, in relation to the number of moles of the other 
components of the polymerization as a whole. 
4.3.2 CIPROFLOXACIN PHEMA-TRIS MATERIALS WITH ACRYLIC ACID 
FUNCTIONAL MONOMERS 
 To further explore the effect of imprinting on the model silicone hydrogel materials, a 
second, larger study was conducted with a few key modifications to the imprinting process. The 
overall functional monomer concentration within the polymerization mix was varied between 
two concentrations (100 mM and 200 mM), and the functional monomer was changed to a 
related molecule, acrylic acid, which has had some success in the literature in terms of efficiently 
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creating imprinted cavities [20]. The same three loading concentrations were used, and three 
separate imprinted ratios of acrylic acid to ciprofloxacin were used: 4:1, 8:1 and 16:1. The dry 
weight (g) and the water content (%) of the created materials are listed in Table 4-2. Similar to 
the model materials, the majority of the model materials were of low water content, and some 
degree of modification would be necessary to increase the water content if these materials were 
to be used on the human eye. A one way ANOVA revealed a significant difference between the 
dry weights and water contents of the materials (p < 0.05). Post Hoc Tukey tests revealed that 
this difference was mainly confined to two model—the pHEMA+TRIS+ 200 mM Acrylic Acid, 
8:1 ratio to ciprofloxacin and the pHEMA + TRIS + 200 mM Acrylic Acid, 4:1 ratio to 
ciprofloxacin were found to be statistically different than the other model lens materials (p < 
0.05).  
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Table 4-2  Dry Weight and Water Content of Acrylic Acid Imprinted pHEMA+TRIS 
Materials. 
Model Lens Type 
Dry Weight (g) 
(Average ± 
Standard 
Deviation) 
Water Content (%)  
(Average ± Standard 
Deviation) 
Centre 
Thickness (mm) 
(Average ± 
Standard 
Deviation) 
Volume (mm3) 
(Average ± 
Standard 
Deviation) 
pHEMA + TRIS + 100 
mM Acrylic Acid Control 0.0417 ± 0.0058 16.8 ± 4.1 0.96 ± 0.07 75.5 ± 6.0 
pHEMA + TRIS + 200 
mM Acrylic Acid Control 0.0454 ± 0.0064 15.1 ± 1.8 1.05 ± 0.16 82.2 ± 12.6 
pHEMA + TRIS + 100 
mM Acrylic Acid, 4:1 
ratio to ciprofloxacin 
0.035 ± 0.0076 16.2 ± 3.6 0.78 ± 0.16 60.87 ± 12.3 
pHEMA + TRIS + 200 
mM Acrylic Acid, 4:1 
ratio to ciprofloxacin 
0.0576 ± 0.011 12.6 ± 2.2  1.13 ± 0.3 88.3 ± 23.6 
pHEMA + TRIS + 100 
mM Acrylic Acid, 8:1 
ratio to ciprofloxacin 
0.0428 ± 0.0054 14.5 ± 2.1 1.01 ± 0.12 79.6 ± 9.3 
pHEMA + TRIS + 200 
mM Acrylic Acid, 8:1 
ratio to ciprofloxacin 
0.0397 ± 0.010 17.7 ± 3.6 0.97 ± 0.22 75.8 ± 17.4 
pHEMA + TRIS + 100 
mM Acrylic Acid, 16:1 
ratio to ciprofloxacin 
0.0497 ± 0.0053 14.3± 2.2 1.13 ± 0.13 88.6 ± 9.9 
pHEMA + TRIS + 200 
mM Acrylic Acid, 16:1 
ratio to ciprofloxacin 
0.0523 ± 0.0062 13.6 ± 1.4 1.20 ± 0.14 94.6 ± 10.9 
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 Ciprofloxacin release curves from 100 mM acrylic acid materials loaded with 9.06, 0.10 
and 0.025 mM of ciprofloxacin within the first 24 h are detailed in Figure 4-3 (a–c). A similar 
trend to that seen with the acetic acid imprinted materials is seen, as there are little differences in 
the amount or the rate at which ciprofloxacin was released from the 9.06 mM loaded model 
lenses, but when the materials were loaded with progressively lower amounts of ciprofloxacin 
the difference between the imprinted and the non-imprinted control became more apparent, with 
the imprinted materials releasing relatively more and at a greater rate. The release curves from 
these materials over the course of two weeks are detailed in Figure 4-4(a–c). Analysis of the 
model lenses loaded with 9.06 mM ciprofloxacin (Figure 4-4a) showed that the control model 
lens was only releasing for a maximum of 3 days before reaching a plateau, while the imprinted 
materials were releasing for periods up to 7 days. At plateau, the materials with 4:1 imprinting 
were found to be statistically significantly higher than the other model lens types (p < 0.05). The 
other model lens types (including the control) tended to cluster together. Analysis of the 0.10 
mM loaded materials showed no significant release compared to the initial time point for the 
control, and significant release from the imprinted materials for up to 14 days in the case of the 
8:1 imprinted material. The 16:1 imprinted material was found to be different from the other two 
imprinted materials (p < 0.05), while releasing for 11 days. The 4:1 imprinted materials released 
the most drug, but for the shortest period of time, at only 5 days. For materials loaded with 0.025 
mM ciprofloxacin, the results were similar but with more extended release times. The 4:1 and 
8:1 model lenses tended to cluster together and release the most amount of drug, while the 16:1 
was statistically significantly lower, but still higher than the control (p < 0.05). All of the 
imprinted materials in this case took 10 days to reach a plateau level.  
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Figure 4-3 (a-c) Release Curves from 100 mM Acrylic Acid Imprinted Materials over 
24 Hours 
Release curves from 100 mM acrylic acid imprinted materials loaded with 
(a) 9.06 mM ciprofloxacin; (b) 0.10 mM ciprofloxacin and (c) 0.025 mM 
ciprofloxacin over 24 hours. Values plotted are means ± standard 
deviations. 
 
(a) 
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(b) 
 
(c) 
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Figure 4-4 (a-c) Release Curves from 100 mM Acrylic Acid Imprinted Materials over 
14 Days  
Release curves from 100 mM acrylic acid imprinted materials loaded with 
(a) 9.06 mM ciprofloxacin; (b) 0.10 mM ciprofloxacin and (c) 0.025 mM 
ciprofloxacin over 14 days. Values plotted are means ± standard 
deviations. 
 
(a) 
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(b) 
 
(c) 
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 Ciprofloxacin release curves from 200 mM acrylic acid imprinted materials loaded with 
9.06 mM, 0.10 mM and 0.025 mM ciprofloxacin solutions for the first 24 h is presented in 
Figure 4-5(a–c). The loading of the high concentration (9.06 mM) led to all materials releasing a 
significant amount of drug, but there was no difference between the imprinted materials and the 
control (p > 0.05) over the first 24 h. For the model lenses loaded with 0.10 mM and 0.025 mM, 
the imprinted materials released a larger amount and at a faster rate compared to the control (p < 
0.05), but there was no difference between the imprinted materials, although it appeared that the 
4:1 loaded materials released more than the 8:1, and the 16:1 imprinted material released the 
lowest amount.  
  
 122 
 
Figure 4-5 (a-c) Release Curves from 200 mM Acrylic Acid Imprinted Materials over 
24 Hours 
Release curves from 200 mM acrylic acid imprinted materials loaded with 
(a) 9.06 mM ciprofloxacin; (b) 0.10 mM ciprofloxacin and (c) 0.025 mM 
ciprofloxacin over 24 hours. Values plotted are means ± standard 
deviations. 
 
(a) 
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(b) 
 
(c) 
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 Ciprofloxacin release curves from 200 mM acrylic acid imprinted materials loaded with 
9.06 mM, 0.10 mM and 0.025 mM ciprofloxacin solutions over the course of 14 days is presented 
in Figure 4-6 (a–c). The 9.06 mM loaded materials again showed a large amount of variation, and 
there was not statistically significant difference between the various imprinted materials versus 
the controls. The materials did release more than the required amount of antibiotic to be 
clinically relevant against common ocular pathogens. In the course of measurement over the two 
weeks, there was one anomalous group of readings. The 0.10 mm loaded, 4:1 imprinted materials 
began to show a declining concentration of ciprofloxacin within solution over time. Whether this 
was due to contamination, or drug degradation is unknown, regardless, the data is not presented 
here. Examination of the other 0.10 mM loaded materials shows that the imprinted materials 
released for up to 4 days, significantly different than the control (p < 0.05). The 0.025 mM 
loaded model lenses demonstrated significant differences between the 4:1 loaded and the other 
imprinted materials and the control, although the release time was relatively short at only 2 days. 
The 8:1 and 16:1 imprinted materials released comparatively less ciprofloxacin, but released it 
for longer periods of 13 and 14 days respectively. The control material loaded with 0.025 mM in 
comparison released relatively little ciprofloxacin over the course of 4 days, before no further 
changes were measured. 
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Figure 4-6 (a–c) Release Curves from 200 mM Acrylic Acid Imprinted Materials over 
14 Days 
Release curves from 200 mM acrylic acid imprinted materials loaded with 
(a) 9.06 mM ciprofloxacin; (b) 0.10 mM ciprofloxacin and (c) 0.025 mM 
ciprofloxacin over 14 Days. Values plotted are means ± standard 
deviations. 
 
(a) 
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(b) 
 
(c) 
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 Thorough examination of the acrylic acid imprinted materials leads to several 
conclusions. The loading concentration of ciprofloxacin has a large role on the ability to detect 
the effect of the molecular imprinting. When the model lenses are loaded with a large 
concentration (9.06 mM), which is equivalent to the concentration of ciprofloxacin in 
commercially available 0.3% eye drops, there is little to no difference in the various imprinted 
materials and the controls. In this situation, it is likely that the majority of the ciprofloxacin was 
loaded into the material through non-specific concentration gradients, and the release from all the 
materials reflected that. One cannot discern the effect of the need for dilution to generate 
readings in the range of the linear standard curve as this could potentially affect the sensitivity to 
detect subtle changes in concentration within the solution, and may have contributed to the 
variability. However, this effect would be minimal.  
 When loaded with lower concentrations of ciprofloxacin, a different picture emerges 
from the data, in that the effect of imprinting these materials with template and the functional 
monomer become apparent. The imprinted materials release a larger amount compared to 
similarly loaded control materials, and for a significantly longer time. Release times for up to 14 
days were seen in some cases, such as the 0.025 mM loaded, 200 mM acrylic acid 8:1 imprinted 
material, while control materials were confined to minimal release amounts for periods of only a 
few days. Interestingly, there was little to no difference between materials created with the two 
different concentrations of acrylic acid in terms of the amount or rate of ciprofloxacin being 
released. There has been some evidence in the literature that not only is the functional 
monomer:template ratio important, but so is the functional monomer:cross linker ratio [33]. In 
this experiment, there was no variation in the amount of crosslinker chosen, which was ethylene 
glycol dimethacrylate (EGDMA), so it would be interesting to see if the drug release rate 
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dependence on functional monomer to crosslinker ratio would prove to be important in this 
model silicone hydrogel-type system. 
 In comparison with the pilot study, the functional monomer was changed to acrylic acid, 
and the precision to which the imprinting process was performed was more carefully controlled. 
In doing so, greater differences in the imprinted materials were demonstrated, with materials 
imprinted with the 4:1 ratio in general releasing the greatest amount of drug, with decreasing 
release from 8:1 and 16:1 imprinted materials respectively. This is similar to the results that were 
seen in a previous paper imprinting norfloxacin, another fluoroquinolone antibiotic [20].  
 The majority of the model lenses released enough antibiotic to reach concentrations that 
were clinically relevant for common bacterial isolates, especially with model lenses loaded with 
the clinical concentration of ciprofloxacin [32]. The difficulty is that sustained release over time 
was really only observed when loading with much lower concentrations, which can pose a 
problem with antibiotic therapy in preventing the development of bacterial resistance. To combat 
this, future studies should use newer and more potent antibiotics, whose minimum inhibitory 
concentrations are much lower than ciprofloxacin, such as the fourth generation fluoroquinolones 
moxifloxacin and gatifloxacin [34]. The challenge for these contact lens combination devices, 
especially antibiotic ones, beyond the demonstrated ability to sustain drug release, is acceptance 
into clinical practice. Considering the perception of the role of contact lenses in the etiology of 
severe ocular infections, use of a contact lens in such a situation faces an uphill climb in 
acceptance, and it will be the challenge to researchers and companies marketing such products to 
demonstrate advantages of such a device over traditional therapy. 
 The results from this study were generated using what is commonly known as the 
“infinite sink” technique, in which the release of drug is into the same static solution over time. 
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This clearly does not necessarily mimic the ocular surface, in which tear production, evaporation 
and drainage can play a significant part in drug residence time and ultimately bioavailability to 
the cornea. The use of a static solution can also have a significant effect on release times for a 
drug such as ciprofloxacin, which is poorly soluble at physiological pH, potentially limiting 
release times due to the drug reaching a maximum soluble concentration within the solution. 
Several authors have proposed different solutions to this infinite sink problem. The simplest is to 
transfer the lenses to fresh solutions free of any drug at various time points, and sum up the 
release from all these release solutions [35]. A more sophisticated solution involves creation of 
an ocular tear flow device, in which the flow into, and drainage out of a tear solution as it 
interacts with the drug delivery device is controlled to mimic ocular tear flow. When such a 
system is used, authors have found that release rates are much slower than in infinite sink 
conditions, which is probably due to significantly smaller volumes of solution available to the 
device at any one given time. The release was also shown to follow zero order kinetics [23], and 
it would be interesting to test the materials created in this study under such conditions to observe 
any changes in release kinetics. 
4.4 EXPERIMENTAL SECTION 
4.4.1 MATERIALS 
 2-Hydroxyethyl methacrylate (HEMA), ethylene glycol dimethacrylate (EGDMA), 
acrylic acid, acetic acid, and ciprofloxacin-HCl were purchased from Sigma-Aldrich (Oakville, 
ON, Canada). Methacryloxy propyl tris (trimethylsiloxy) silane (TRIS) was purchased from 
Gelest (Morrisville, PA, USA). IRGACURE was purchased from CIBA (Mississauga, ON, 
Canada). The HEMA and TRIS monomers were purified of the polymerizer inhibitor 4-
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methoxyphenol (MEHQ) by passing through an Aldrich inhibitor removers (Sigma-Aldrich). All 
other materials were not modified and used as obtained. 
4.4.2 MODEL SILICONE HYDROGELS 
 Model silicone hydrogel materials were created using a UV induced polymerization 
process. 3.6 g of HEMA was mixed with 0.4 g of TRIS. 0.2 g of EGDMA was subsequently 
added, allowed to mix, and finally 0.02 g of the photoinitiator IRGACURE was added. The 
mixture was poured into aluminum foil molds, and cured in a UV chamber (CureZone 2 Con-
trol-cure) for 20 minutes at 340 nm. The surfaces were then placed in a 50 °C oven overnight to 
ensure completion of polymerization. Samples were then placed in Milli-Q water for a minimum 
of two days to rehydrate, with the water being changed daily to remove any unreacted monomers 
[36].  
4.4.3 MOLECULAR IMPRINTED MATERIALS—ACETIC ACID FUNCTIONAL 
MONOMER 
Acetic Acid imprinted materials were created using a similar process to the model silicone 
hydrogels. To each polymerization mix before the addition of the IRGACURE initiator, acetic 
acid solution with various amounts of ciprofloxacin dissolved within it were added to the 
reaction mixture, creating an approximate 0.01 M acetic acid concentration in the final 
polymerization mixture. Control materials had a solution of acetic acid added without any 
ciprofloxacin. 
4.4.4 MOLECULAR IMPRINTED MATERIALS—ACRYLIC ACID FUNCTIONAL 
MONOMER 
The imprinting of acrylic acid materials was more carefully controlled to determine the effect 
of the imprinting on the drug release characteristics of the technique. To that end, materials were 
 131 
 
created using similar procedures to the model silicone hydrogels. Before the addition of the 
IRGACURE initiator, acrylic acid was added to a final concentration of either 100 mM or 200 
mM. Ciprofloxacin powder was subsequently added to the mixture, in molar ratios to the acrylic 
acid varying from 1:4 to 1:16, and the polymerization of the materials was initiated as previous.  
4.4.5 MOLECULAR IMPRINTED MATERIALS—WASHOUT 
Materials imprinted with ciprofloxacin were rehydrated in Milli-Q water in glass jars, with the 
water being changed daily. The water used in the washout period was measured for ciprofloxacin 
concentration, and materials were only used after ciprofloxacin concentrations within the water 
were at minimal/non-existent levels. 
4.4.6 DRUG SOLUTIONS 
A 0.3% (w/v) (9.06 mM) stock solution of ciprofloxacin-HCl was created in a phosphate 
buffered saline. The pH of the solution was adjusted to 4.0 to ensure the complete solubilization 
of the ciprofloxacin at this high concentration. Using this stock solution, samples were diluted 
approximately 4,000 times to be read by a Hitachi F-4500 fluorescence spectrophotometer 
(Hitachi Ltd., Tokyo, Japan), with an excitation wavelength of 274 nm and an emission peak at 
419 nm to create a linear standard curve. This standard curve was used to correlate emission 
amounts with the concentration of ciprofloxacin within the solution.  
4.4.7 WATER CONTENT, CENTRE THICKNESS, VOLUME AND DRY WEIGHT 
DETERMINATION 
After soaking in Milli-Q water for a minimum of two days, discs of the materials were 
punched out using a #4 cork borer with a diameter of 5 mm. The water content of these discs was 
determined using the gravimetric method, using the Sartorius MV 100 (Sartorius Mechatronics 
Canada, Mississauga, ON, Canada). The dry weight of the disc was also determined. The centre 
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thickness was determined using a dial lens gauge for rigid contact lenses (Vigor Optical, 
Carlstadt, NJ, USA), and the volume was calculated from thickness and diameter data, assuming 
a cylindrical shape. 
4.4.8 DRUG LOADING INTO MATERIALS 
After determination of the water content, discs were placed in a ciprofloxacin drug loading 
solution. Three separate concentrations were used—the stock 9.06 mM, and two diluted loading 
concentrations, 0.10 mM and 0.025 mM. 2 mL of the loading solution was used, and this was 
undertaken in amber vials, as ciprofloxacin is light sensitive. Loading discs were left at room 
temperature for one week.  
4.4.9 DRUG RELEASE KINETICS 
Loaded discs were removed from the loading solution amber vials using plastic tweezers. The 
surface was partially dried on lens paper to remove any excess loading solution, and the disc 
placed into another amber vial containing 2 mL of an artificial tear solution (NaCl 90 mM, KCl 
16 mM, Na2CO3 12 mM, KHCO3 3 mM, CaCl2 0.5 mM, Na3Citrate 1.5 mM, Glucose 0.2 mM, 
Urea 1.2 mM, Na2HPO4 24 mM, HCl 26 mM, pH 7.4) [37]. The vials were then placed in a 
shaking water bath at 34 °C. At various time points, the concentration of ciprofloxacin in the 
solution was determined using spectrophotometry. For model lenses loaded with 9.06 mM 
ciprofloxacin solution, samples were removed and diluted 100X to get into the range of the 
standard curve. For the other two loading conditions, 1 mL of the release solution was removed 
from the vial, read in the spectrophotometer, and returned to the vial. Readings were taken every 
5 minutes for the first 20 minutes, then after 30, 45, 60 and 90 min. Readings were then taken 
hourly until 8 hours had passed, then daily until 14 days had passed. 
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4.4.10 STATISTICAL ANALYSIS 
Statistical analysis was performed using Statistica version 8 (StatSoft Inc, Tulsa, OK) using a 
repeated measures ANOVA, and post hoc Tukey tests as indicated. A p value of less than 0.05 
was considered statistically significant. 
4.5 CONCLUSIONS 
 In this study, model silicone hydrogels for the delivery of the antibiotic ciprofloxacin 
were developed using a molecular imprinting strategy. Synthesized materials had water contents 
in the mid to low teens, and when loaded with various solutions of ciprofloxacin they 
demonstrated different release kinetics. Loading with high concentrations of ciprofloxacin led to 
very few differences in the various imprinted materials and the control. When loaded with lower 
concentrations, the effect of the imprinting was more clearly seen, with model lenses created 
using a 4:1 ratio of acrylic acid to ciprofloxacin template consistently releasing the greatest 
amount of drug, and certain model lenses continuing to release the drug for up to 14 days. As the 
use of these contact lens combination devices will likely involve some element of overnight or 
extended wear, the results from this study using model silicone hydrogel materials has provided 
some insight into how these materials behave as drug delivery devices when formed using 
molecular imprinting.  
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In this next chapter, the results from the previous two chapters were combined to generate 
contact lenses using the molecular imprinting strategy to increase the release times of 
ciprofloxacin. These materials were evaluated for their contact lens properties, in vitro 
ciprofloxacin release rates, in vitro antimicrobial activity, and in vivo antimicrobial activity in a 
rabbit model of microbial keratitis.  
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5.1 OVERVIEW 
5.1.1 PURPOSE  
The purpose of this study was to evaluate molecular imprinted ciprofloxacin releasing silicone 
hydrogel contact lens materials in vitro and in vivo for the treatment of microbial keratitis. 
5.1.2 METHODS  
Model silicone hydrogel contact lens materials were manufactured using a molecular imprinting 
technique to modify the release kinetics of the antibiotic ciprofloxacin. The light transmission, 
wet and dry weight, centre thickness, water content and surface wettability were determined, and 
the in vitro ciprofloxacin release kinetics elucidated using fluorescence spectrophotometry. The 
materials were then evaluated for their ability to inhibit P. aeruginosa strain 6294 growth in vitro 
and in an in vivo rabbit model of microbial keratitis. 
5.1.3 RESULTS 
The novel contact lenses synthesized had similar material properties to commercial contact lens 
materials. There was a decrease in light transmission in the shorter wavelengths due to 
incorporation of the antibiotic, but over 80% light transmission between 400 and 700 nm. The 
modified materials released a statistically significantly larger amount of antibiotic and for a 
longer period of time when evaluated in vitro compared to unmodified controls (p<0.05), with 
the modified materials releasing for more than eight hours compared to only two hours for the 
control. When tested in vivo, there was no statistically significant difference between the number 
of colony forming units (CFU) recovered from corneas treated with eye drops and those treated 
with one of two modified contact lenses  (p>0.05), which is significantly less than corneas 
treated with unmodified control lenses or those which received no treatment at all (p<0.05).  
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5.1.4 CONCLUSIONS 
These novel, molecular imprinted contact lens materials developed for the extended release of 
ciprofloxacin may be beneficial to supplement or augment future treatments of sight threatening 
microbial keratitis. 
Keywords: Contact Lens, Microbial Keratitis, Drug Delivery, Molecular Imprinting, 
Ciprofloxacin 
5.2 INTRODUCTION 
 Microbial keratitis (MK), an infection of the cornea by pathogenic microorganisms, 
represents a true ocular emergency. Unless immediate treatment is initiated with appropriate 
antimicrobial agents, the probability of retaining normal vision is unlikely. 1 Epidemiological 
studies have identified certain risk factors for the development of MK, including male gender, 
younger age, overnight wear of contact lenses, smoking, poor hygiene and internet supply of 
lenses. 2-4  Unfortunately, even with all of the advances in our understanding of MK and 
implementation of solutions to lower modifiable risk, the incidence of the disease has remained 
largely unchanged. 5 Contemporary treatment of patients with MK involves the frequent use of 
topical antibiotic agents, often fortified by a compounding pharmacy. 6 In the early stages of 
treatment, drop instillation as frequently as every 15 minutes is common to quickly saturate the 
cornea to therapeutic antibiotic levels. Even with these frequent dosing schedules, practical 
considerations on the pharmacokinetics of eye drops suggests that the therapeutic windows are 
only reached for relatively short periods of time, interspersed between times of therapeutic 
overdose and underdose. 7 Indeed, measurements and modeling suggest that at most only 
between 5 and 10% of an instilled eye drop ultimately exerts therapeutic action, with the 
remainder flushed away and absorbed systemically. 8 This is disadvantageous both economically 
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and therapeutically, as useful molecules are lost without exerting a therapeutic effect, and 
systemically absorbed agents have the potential to cause side effects. Adherence to strict and 
frequent treatment regimens for the management of MK is understandably difficult for 
outpatients, thus management often requires hospitalization, costing both the heath care system 
and the individual significant amounts of time and money. 9 Economic analysis of the MK costs 
in Australia suggest that each case costs upwards of AUD $10,000. 10 Given these therapeutic, 
practical and economic challenges, development of alternative MK therapies are warranted and 
may prove to be beneficial. 
 Even though contact lenses (CLs) are risk factors for developing MK, the use of CLs as 
vehicles to deliver therapeutics to the eye has been suggested and is not a recent idea. Utilizing 
hydrogels such as CLs as a reservoir for a drug during the treatment of anterior segment disease 
was proposed as early as 1965 by Sedlacek, and has received renewed research interest of late. 11, 
12 The appeals of a CL drug delivery device are numerous. The materials have a proven track 
record of biocompatibility and patient and practitioner acceptance. 13 Modern manufacturing 
methods have driven the unit cost of each lens to affordable levels. If CLs are used in a drug 
delivery application, they can also simultaneously correct for refractive error, allowing for 
continued clarity of vision by the patient undergoing treatment. The oxygen permeability of the 
lenses have also increased significantly with the introduction of silicone hydrogel materials in 
the late 1990s, allowing for potentially extended or overnight treatments with CLs without fear 
of hypoxic complications. 14 There also exists evidence that combination CL and drug delivery 
devices would be well accepted by eye care practitioners. In surveys of practicing optometrists 
and ophthalmologists in North America, a large proportion of practitioners surveyed utilized CLs 
as bandages when indicated, and crucially, concurrently also prescribed topical medications such 
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as antibiotics and anti-inflammatories, and would be willing to accept a lens that did both 
simultaneously. 15 
 The contemporary challenge in the development of a successful drug delivery contact 
lens has been the drug release kinetics. Not surprisingly, off the shelf commercial contact lens 
materials show less than ideal drug release characteristics. The majority of lenses examined 
showed very rapid release kinetics when tested in vitro. Antibiotics (ciprofloxacin), 16 anti-
inflammatories (ketorolac, dexamethasone) 17, 18 and anti-allergy agents (ketotifen fumarate) 19 
have all been tested, and while differences in the absolute amount of the drug being released 
between commercial lens types are seen, the release time is typically limited to one or two hours. 
Given this restriction, the focus of research has centred on modifying, extending and controlling 
release times. Numerous techniques have been investigated. For example, a group has 
investigated modification of commercial materials through the incorporation of a Vitamin E 
coating, to serve as an additional diffusion barrier for drug migration. This technique allowed for 
extension of release times from several minutes to several hours in vitro, and has been used to 
investigate release of timolol, an anti-glaucoma treatment. 20 The authors were able to 
demonstrate improved intraocular pressure control using the experimental contact lens system in 
comparison with eye drops in a glaucomatous dog model. 21 A novel design involving a drug 
impregnated film sandwiched between two hydrogel pieces has also been investigated for 
delivery of antibiotics and antifungals. 22, 23 Use of such a system showed a significant increase 
in the amount of drug released and favorable release kinetics in vitro. Unfortunately, the design 
was limited by the optical properties of the lens, as the film used as the drug reservoir was 
opaque, necessitating that the lens require a small, 3mm pupil cut in the middle of the film to be 
used for vision, a design that is unlikely to resonate with eye care practitioners or patients.  
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Molecular imprinting is a strategy that has been derived from work in chromatography. 
Originally, polymers created by this technique were used to preferentially remove certain 
components from solutions. 24 In this technique, the molecule of interest to ultimately be released 
is dissolved in the pre polymerization mixture. 25 Inclusion of a separate small molecule, denoted 
as the functional monomer, to specifically interact with the molecule of interest through non 
covalent interactions such as hydrogen bonding creates shape specific and functional group 
specific complexes deemed "cavities" or "molecular memory" within the final polymerized 
product. 26 This "molecular memory" can significantly slow the movement of the drug of interest 
from the material, thus extending drug release times. 12 Previous work has demonstrated that 
selection of the appropriate functional monomer and the ratio of the functional monomer to the 
template, are the most crucial aspects in generating materials with desired extended drug release 
properties. 27 This technique has been used to successfully increase the drug release times 
observed in vitro for antibiotics, anti-inflammatories, anti-glaucoma and anti-allergy 
medications. 28-35  
 In this current study, novel silicone hydrogel contact lenses were created using a 
molecular imprinting technique to increase the release times of the fluoroquinolone antibiotic 
ciprofloxacin. The molecule acrylic acid had previously been shown to be a useful functional 
monomer to increase fluoroquinolone release times. 28, 34 The materials were tested for their 
contact lens properties, in vitro drug release characteristics, and sustained antibacterial activity in 
an in vivo rabbit model of microbial keratitis. 
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5.3 MATERIALS AND METHODS 
5.3.1 REAGENTS 
2-hydroxylethlymethacrylate (HEMA), Methacryloxy propyl tris (trimethylsiloxy) silane 
(TRIS), ethylene glycol dimethacrylate (EGDMA), acrylic acid, ciprofloxacin-HCL, Irgacure-
1173, polyvinylpyrrolidone (PVP), phosphate buffered saline (PBS) and chloroform were 
purchased from Sigma-Aldrich (Oakville, ON, Canada). Nutrient Agar was purchased from 
Sigma-Aldrich PTY Australia. BBL cation adjusted Mueller-Hinton II Broth and Dey/Engley 
Neutralizing Broth were purchased from BD Australia. Polypropylene contact lens moulds were 
kindly donated from Alcon Vision Care (formerly CIBA Vision – Fort Worth, Texas). The 
polymerizer inhibitor 4-methoxyphenol (MEHQ) was removed from the HEMA and TRIS 
monomers by passing through a column of Aldrich inhibitor removers. All other reagents were 
used as received.  
5.3.2 MOLECULAR IMPRINTED CONTACT LENS SYNTHESIS 
3.6 g of filtered HEMA was mixed with 0.4 g of filtered TRIS, 0.1 g of EGDMA and 0.3 
g of PVP. To this, a 1 mL acrylic acid and ciprofloxacin solution dissolved in chloroform was 
added so that the final concentration of acrylic acid within the mixture was 100 mM. Control 
lenses were created by omitting the ciprofloxacin in the acrylic acid solution. Various ratios of 
acrylic acid to ciprofloxacin solutions were made, ranging from 4:1 moles of acrylic 
acid:ciprofloxacin, 8:1 moles acrylic acid:ciprofloxacin and 16:1 moles acrylic acid: 
ciprofloxacin (hereby denoted as lens "4:1 Imprinted", "8:1 Imprinted" and "16:1 Imprinted" 
respectively). 1 mL of isopropanol was added as a diluent, and 0.04 g of the photoinitiator 
Irgacure 1173 added and the solution mixed for five minutes at room temperature. 100 μL of the 
solution was injected into plastic moulds, and cured for five minutes using a UV oven (Dymax 
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Silver EC Series UV Light Curing Flood Lamp System, Ellsworth Adhesives Canada, Stoney 
Creek, Ontario). The cured lenses were removed from the moulds, and lenses rinsed daily with 
acetate buffer (pH 4.0) until no ciprofloxacin could be detected by spectrophotometry. The 
lenses were then soaked in isopropanol for one day to remove any leftover monomers, before 
being rinsed and stored in PBS.  
5.3.3 DETERMINATION OF MATERIAL PROPERTIES - WATER CONTENT, WET 
AND DRY WEIGHT, LIGHT TRANSMISSION, CENTRE THICKNESS, SURFACE 
WETTABILITY 
The water content and wet and dry weight of lenses was determined using the gravimetric 
method (Sartorius MA 100, Sartorius Canada Inc, Mississauga, Ontario), where the change in 
weight as the lens was heated to 105°C over the course of 7 minutes was correlated to the water 
content of the lens. The centre thickness of a fully hydrated lens was measured using a contact 
lens thickness gauge (Vigor Contact Lens Thickness Gauge, Vigor Optical, Carlstadt, New 
Jersey). To determine the light transmission, individual lenses and 1 mL of PBS were placed into 
wells of a 24 well plate, and a wavelength scan from 300 nm to 750 nm was conducted using a 
plate reader (Spectramax M5 Microplate reader, Molecular Devices, Sunnyvale, California). The 
advancing contact angle, a measure of the surface wettability, was determined using the sessile 
drop method employing the Optical Contact Analyzer (OCA, Dataphysics Instruments GmbH, 
Filderstadt, Germany). A fully hydrated lens was removed from the PBS soaking solution, and 
the surface dried on lens paper for 20 seconds before being placed on a custom designed lens 
holder. 5 μL of High Performance Liquid Chromatography (HPLC) water was dispensed from a 
syringe, and an image of the contact of the water droplet with the lens surface after settling 
captured using a high speed camera. 36, 37 The contact angle between the settled drop and the lens 
surface was analyzed using custom software (SCA 20 software, Version 2.04, Build 4). 
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5.3.4 IN VITRO TESTING OF CIPROFLOXACIN RELEASE 
Prepared lenses were removed from PBS and placed into 4 mL of a 0.3% (3000 μg/mL) 
ciprofloxacin solution prepared in acetate buffer (pH 4.0). The lenses were autoclaved, and 
allowed to take up ciprofloxacin from the solution for one week. After one week, the amount of 
ciprofloxacin loaded into the lenses was determined using fluorescence spectrophotometry in 
comparison to previously generated standard curves (excitation wavelength 274 nm, emission 
419 nm). The lenses were then removed and the surface briefly dried on Lens Paper (VWR 
Scientific Products, Westchester, Pennsylvania) before being placed into 2 mL of PBS. 100 μL 
of PBS was removed at set intervals over the course of 24 hours, and the concentration of 
ciprofloxacin determined by spectrophotometry. After 24 hours, the lenses were removed, the 
surface briefly dried on lens paper, and placed into a second vial with 2 mL of fresh PBS, and the 
time course release was again monitored for another 24 hours. This process was repeated one 
additional time for a third day to generate release curves. 
5.3.5 BACTERIAL STRAIN AND GROWTH, MINIMUM INHIBITORY 
CONCENTRATION DETERMINATION 
 Pseudomonas aeruginosa strain 6294, a bacterial strain previously isolated in the USA 
from a human case of microbial keratitis, 38 was streaked on nutrient agar plates from -80°C 
frozen stocks and incubated at 34°C for 18 hours. A single colony was picked and grown 
overnight in Mueller-Hinton Broth before being centrifuged, rinsed in PBS and re-suspended in 
PBS to an optical density of 0.1 at 660 nm (approximately 1x108 colony forming units 
(CFU)/mL). The Minimum Inhibitory Concentration (MIC) of the test organism was determined 
using the broth microdilution method. 39 5x104 CFU of Pseudomonas aeruginosa strain 6294 
was added to each well of a 96 well plate, with each well containing a doubling dilution 
concentration of ciprofloxacin in Mueller-Hinton Broth.  The plate was incubated overnight, and 
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the turbidity of the solution in individual wells used to determine the minimum concentration of 
the antibiotic that prevents bacterial growth. 
5.3.6 IN VITRO TESTING OF ANTIMICROBIAL ACTIVITY  
 Test lenses were removed from the loading solution and briefly dipped in PBS before 
being added to 2 mL of Mueller-Hinton Broth seeded with 1x108 CFU/mL P. aeruginosa. 100 
μL was sampled hourly into Neutralizing Broth, and serial dilutions plated on nutrient agar 
plates. The plates were incubated at 34°C for 18 hours before counting for CFU. The lenses were 
removed from solution after 24 and 48 hours, briefly dipped in PBS and placed into fresh 
Mueller-Hinton bacterial solutions, and the procedure repeated. 
5.3.7 IN VIVO TESTING OF ANTIMICROBIAL ACTIVITY - RABBIT SCRATCH 
MODEL OF MICROBIAL KERATITIS 
 All animal procedures were approved by the executive of the animal care and ethics 
committee at the University of New South Wales, and performed in accordance with the ARVO 
statement for the use of animals in ophthalmic and vision research. 4 kg New Zealand White 
rabbits were sourced from S&J Hurrell in Sydney, New South Wales, Australia. After 
acclimatization for one week, the nictitating membrane was surgically removed from both eyes 
under general anaesthesia. Recovery was allowed for a minimum of one week, at which time two 
5 mm central corneal scratches on one eye were induced using a 23 gauge needle under general 
anesthesia, and 20 μL of the P. aeruginosa strain 6294 solution placed on the eye (approximately 
2x106 CFU). The eyes were held closed for 2 minutes, after which the rabbit was allowed to 
recover from the anaesthetic before being returned to the pen. Pain control was achieved through 
subcutaneous injection of 0.02 mg/kg buprenophine every 12 hours.  16 hours after the scratch 
and bacterial introduction, the rabbits were randomly assigned to one of three intervention 
 146 
 
groups: intervention by hourly instillation of 3000 μg/mL ciprofloxacin drops for 8 hours, 
intervention by one of three types of contact lenses (control, 4:1 imprinted and 8:1 imprinted) 
loaded in 30 μg/mL ciprofloxacin solution for 8 hours or no intervention for 8 hours (three 
rabbits per treatment condition). The animals were euthanized by lethal injection of 1 mL of 
sodium pentobarbital intravenously 24 hours post scratch, and the cornea excised. The cornea 
was homogenized in neutralizing broth, and serial dilutions of the homogenate plated on nutrient 
agar for 18 hours at 34°C before CFU were counted.  
5.3.8 STATISTICS 
 All statistics were performed using STATISTICA Version 7 (Tulsa, OK). Analysis of in 
vitro release curves and bacterial growth curves was done using a repeated measures ANOVA, 
with lens type as a categorical factor, time as a within effects factor and μg/g dry weight 
ciprofloxacin released or CFU as a dependent factor. Comparison of bacteria recovered from 
rabbit corneas or material properties was done using a one way ANOVA, with lens type as a 
categorical factor, and the measured property as a dependent factor. Post hoc Tukey tests were 
used as necessary. A p-value of less than 0.05 was deemed to be statistically significant. 
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5.4 RESULTS 
5.4.1 MATERIAL PROPERTIES 
 The water content, wet and dry weight, centre thickness, water content and advancing 
contact angle are summarized in Table 5-1. 
Lens Type 
Wet Weight 
(g) 
Dry Weight 
(g) 
Centre 
Thickness 
(μm) 
Water 
Content (%) 
Advancing 
Contact 
Angle (°) 
Control 0.027 (0.004) 0.016 (0.003) 63 (14) 42.3 (4.5) 94.6 (1.5) 
4:1 Imprinted 0.029 (0.004) 0.019 (0.003) 64 (15) 36.2 (3.4) 77.4 (2.0) 
8:1 Imprinted 0.028 (0.006) 0.017 (0.004) 62 (19) 43.3 (3.0) 81.5 (1.3) 
16:1 Imprinted 0.028 (0.005) 0.016 (0.002) 61 (19) 41.7 (3.0) 89.2 (2.0) 
Table 5-1 Material Properties of Experimental Lenses.  
All values are presented as averages (standard deviation) (n = 6). The imprinted 
lenses are denoted by the ratio of the moles of the functional monomer acrylic 
acid to the moles of the template ciprofloxacin. 
 There was no statistically significant difference in the wet weight and centre thicknesses 
of the lenses. The 4:1 imprinted lenses were found to have dry weights statistically different than 
the control and 8:1 imprinted lens (p<0.05). The 4:1 imprinted lens was statistically significantly 
different than all the other lenses in terms of water content (p<0.05). All the lenses were 
statistically different when compared to each other with respect to contact angle (p<0.001). 
 The light transmission of the four different lens types tested is shown in Figure 5-1. 
Increasing the amount of ciprofloxacin into the lens material lead to increased yellow coloration 
of the lens, and thus greater loss of light transmission in the shorter wavelengths. 
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Figure 5-1 Percentage Light Transmission Curves  
Control (), 4:1 imprinted (), 8:1 Imprinted () and 16:1 imprinted lenses 
(). Increased incorporation of ciprofloxacin into the material leads to increased 
yellow coloration of the lens, and a decrease in transmission in the shorter 
wavelengths. Symbols represent averages ± standard deviation (n=3). 
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5.4.2 IN VITRO TESTING OF CIPROFLOXACIN RELEASE 
 After autoclaving and allowing to uptake of ciprofloxacin from the loading solution for 
one week, the amount of ciprofloxacin taken into each lens type is presented in Table 5-2. There 
was no statistically significant difference between the amounts taken up by the different lenses. 
 
Lens Type Ciprofloxacin Loaded (μg/lens) 
Control 1383 (144) 
4:1 Imprinted 1509 (291) 
8:1 Imprinted 1133 (264) 
16:1 Imprinted 1234 (295) 
Table 5-2 Uptake of Ciprofloxacin into Each of the Four Tested Lenses.  
All values are presented as averages (standard deviations) (n=3) 
  
 The in vitro release curves over the course of three days and three releasing solutions are 
presented as Figure 5-2 a-c. On the first release day, the control material reached a plateau 
concentration after three hours, while the imprinted materials released ciprofloxacin for five 
hours or more. The plateau concentration of the control material was higher than the imprinted 
materials, although this difference was not statistically significant (p>0.05). On the second 
release day in the second release solution, the control and imprinted materials reached a plateau 
concentration after four hours and there were no statistically significant differences between 
them. In the third release medium on the third day, the control material reached a plateau 
concentration after a mere two hours, while the 4:1 and 8:1 imprinted materials continued to 
 150 
 
release for over eight hours. The plateau concentration reached by the 4:1 and 8:1 imprinted 
materials were also statistically different than the concentration reached by the control (p<0.05). 
The plateau concentration reached by the least imprinted material, the 16:1 lens, was not 
statistically different than the control.  
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Figure 5-2 In vitro Ciprofloxacin Release  
Control (), 4:1 imprinted (), 8:1 Imprinted () and 16:1 imprinted lenses () 
on Day 1 (a), Day 2 (b) and Day 3 (c) after loading in a 0.3% ciprofloxacin 
solution for one week. Symbols represent averages ± standard deviation (n=4).  
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5.4.3 IN VITRO ANTIBACTERIAL ASSAYS 
 The as tested MIC of the P. aeruginosa strain 6294 was 0.4 μg/mL. All lenses loaded 
with 0.3% ciprofloxacin were able to completely inhibit the growth of bacteria for the first two 
days, suggesting that inhibitory amounts of the antibiotic were being released from the lenses. 
The ability of the lenses to inhibit the growth of P. aeruginosa strain 6294 in Mueller Hinton 
Broth on the third day is presented as Figure 5-3. There was an initial decrease in concentration 
of bacteria as the final reserves of ciprofloxacin were released from the lenses. The rate at which 
the number of viable bacteria were decreasing is indicative of concentration of antibiotic in 
solution, suggesting that the control lens initially reaches a higher concentration than the two 
imprinted lenses, which correlates to the released data seen in Figure 5-2c. As complete 
inhibitory concentrations were not reached by any of the lenses, by the 8 hour time point the 
bacteria population began to rebound. There was a statistically significant decrease in the number 
of bacteria from the beginning to the end of the monitoring period for all three lenses tested 
(p<0.05). The differences between the lenses however was not statistically significant (p>0.05). 
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Figure 5-3 Pseudomonas aeruginosa strain 6294 Growth Curves in Presence of   
  Ciprofloxacin Releasing Contact Lenses.  
No viable bacteria were recovered from the first two growth medias on the first 
two days, as sufficient antibiotic concentrations were reached in solution. The 
presented curves are from the third bacterial solution on the third day, after a 
significant amount of antibiotic was already released from the lenses. As 
inhibitory concentrations were not reached, by the 8 hour time point the bacteria 
numbers are beginning to recover and growth is beginning to increase. Control 
(), 4:1 imprinted (), 8:1 imprinted (). Note exponential scale. (n=3) 
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5.4.4 IN VIVO MODEL OF MICROBIAL KERATITIS 
 Corneas scratched and exposed to P. aeruginosa strain 6294 began to show an infection 
response after 16 hours, characterized by development of infiltrates, discharge and redness as 
shown in Figure 5-4b. Left untreated, the severity of the infection increased dramatically over the 
next 8 hours before euthanasia of the rabbit (Figure 5-4c). Treatment intervention with a 
modified contact lens at the 16 hour point partially resolved the infiltrate or discharge by the 24 
hour point (Figure 5-4d).  
a)  
b)  
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c)  
d)  
Figure 5-4 Rabbit Model of Microbial Keratitis  
a) Cornea appearance prior to corneal scratching and bacteria introduction b) 
Cornea appearance 16 hours post scratch, showing infiltrate, redness and 
discharge c) Cornea appearance 24 hours post bacteria introduction without 
treatment showing a large increase in size and severity of the microbial keratitis 
and d) Cornea treated with experimental contact lens for 8 hours 16 hours after 
bacteria introduction. 
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 The number of CFU recovered from excised and homogenized infected corneas are 
presented in Figure 5-5. Left untreated, approximately 106 CFU per cornea were recovered, 
while treatment with hourly instillation of ciprofloxacin eye drops lead to complete sterilization 
and lack of any recoverable bacteria from the cornea after only 8 hours. Treatment with lenses 
soaked in only 30 μg/mL ciprofloxacin solutions (100 times less than the clinical drops) lead to 
differences in bacterial recovery. The number of bacteria recovered from corneas treated with the 
control (i.e. no molecular imprinting) lenses that had been soaked in ciprofloxacin was not 
significantly different than that of the non treated control lenses (p>0.05). However, there is a 
significant reduction in the number of recoverable bacteria from the corneas treated with the 
slow release, molecularly imprinted lenses (p<0.05 when compared to untreated control or 
untreated corneas). Many of the corneas treated with the imprinted lenses were rendered sterile 
through treatment, and overall no statistically significant difference was found in the number of 
bacteria recovered from those corneas and corneas treated with antibiotic eye drops (p>0.05).  
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Figure 5-5 Bacteria Recovered from Excised, Homogenized Corneas 
The bacteria were recovered 24 hours post corneal scratch and introduction of P. 
aeruginosa strain 6294, and 8 hours of different treatment conditions. Corneas 
treated with drops had 10 μl of a 3000 μg/mL ciprofloxacin solution instilled 
hourly. Lenses used in the treatment were presoaked and autoclaved in a 30 
μg/mL solution of ciprofloxacin. The number of bacteria recovered from the no 
treatment (range 105.68 - 106.08 cfu/cornea) and control lens (range 105.51 - 105.98 
cfu/cornea) treatments were significantly different than those treated with 
ciprofloxacin eye drops (range 0 - 0 cfu/cornea) or 4:1 (range 0 - 104.11 
cfu/cornea) or 8:1 (range 0 - 103.80 cfu/cornea) imprinted lenses (p<0.05). n = 3 for 
each treatment group. Note exponential scale. 
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5.5 DISCUSSION 
 The challenge in the development of contact lens drug delivery devices remains the 
relevant drug release kinetics. Previous investigations into drug release from commercially 
available materials demonstrated less than clinically useful drug release times, 40 41 prompting 
the need for custom design lenses to be developed. As seen from the drug release curves 
presented in Figure 5-2, by using a molecular imprinting technique the ciprofloxacin release 
profiles from contact lens materials were significantly altered. By incorporating acrylic acid as a 
functional monomer within the pre-polymerization mixture in various ratios to ciprofloxacin, 
materials were modified to release the antibiotic at various rates, with a ratio of 4:1 functional 
monomer to template molecule showing the greatest extension of release times. The influence of 
the ratio of functional monomer to the template on the efficiency of molecular imprinting has 
been presented in the literature. 42 Away from the optimum monomer to template ratio, cavities 
created within the polymerization structure will be inadequately or inefficiently created, and thus 
shift the equilibrium toward disassociation and release of the template, leading to faster release 
times when release studies are performed in vitro. 42 That the 4:1 ratio was shown to be the most 
effective in slowing the release of ciprofloxacin is not surprising, as the ratio had previously been 
demonstrated as most effective in experiments with molecular imprinting and norfloxacin, a first 
generation fluoroquinolone. 28 Through use of isothermal titration calorimetry, a saturation in the 
binding of norfloxacin within the hydrogels at a functional monomer to template ratio of 4:1 was 
observed, and thus would be the ratio predicted to most perfectly create the imprinted cavities 
and most prolong release times. 28 This prediction was demonstrated by the norfloxacin release 
data, as ratios above or below 4:1 did not as effectively control norfloxacin release. 28 This 
experiment was an improvement to previous in vitro experiments 34 in that the releasing medium 
was changed on a daily basis to better simulate the changing concentration gradients that are 
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likely to be seen if these materials were placed on the eye. On the initial day, the unmodified 
control lenses released a very high concentration of drug, while the modified materials released 
for longer periods but reached lower final concentrations. As the release medium solutions were 
changed, the advantage of the molecular imprinted materials began be more apparent. The 
control material continued to release extremely rapidly, and reached lower plateaus than the 
modified materials. This was best exemplified by the data from the third releasing medium on 
the third day, when the control material reached a fast plateau of ciprofloxacin concentration 
within 2 hours, while the 4:1 material continued to release for more than 8 hours, and reached a 
significantly higher concentration in solution.  
 In vitro testing of the antibacterial activity of the test materials served as a complement to 
the release of ciprofloxacin in solution. Here, the differences in the recovered bacteria were seen 
as a surrogate of the amount of ciprofloxacin released. The test organism, P. aeruginosa strain 
6294, is ciprofloxacin sensitive, with a MIC of 0.4 μg/mL. The growth of the bacteria within the 
media is a function of several factors - not only the concentration of ciprofloxacin within the 
solution, but also the initial seeding concentration of bacteria, the growth phase of the bacteria 
and the availability of resources, including nutrients and oxygen. 43-45 The plotted growth curves 
in Figure 5-3 reflect all of these factors simultaneously. There are several conclusions that can be 
reached by considering the growth of bacteria in the presence of these lenses. First, each of the 
lenses were initially inhibiting the growth of the bacteria, presumably due to release of the 
antibiotic. Second, inhibition of growth by these lenses waned over time. By the 8 hour mark, the 
bacterial population stabilized or started to grow as the limited amount of ciprofloxacin released 
from the lenses was exhausted or insufficient to prevent multiplication, leaving bacterial growth 
limited only by available resources. Third, while the differences between the different lenses 
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were not statistically significant, examination of the different growth curves can be suggestive of 
the effect of imprinting. The rate at which the population growth was reduced by the lenses is 
reflective of the concentration of the antibiotic in the solution. The control lens, as previously 
demonstrated, released the majority of the available ciprofloxacin very quickly, and reached 
higher concentrations of antibiotic in solution faster than the two slow release materials (Figure 
5-2c). Thus, the decrease in bacterial concentration from systems treated with the control 
material are expected to be faster than when treated with the two slow release lenses, which is 
what is seen (Figure 5-3). Thus, within a closed, fixed in vitro solution, the control lens released 
ciprofloxacin which reached a high concentration quickly can be considered to be a superior lens 
used to control bacterial growth.  
 In vitro testing of antibacterial activity is unfortunately an inadequate model for in vivo 
applications. In the controlled, closed system of a test tube or vial, the bacteria were exposed to 
all of the antibiotic released from the experimental materials, which would kill the bacteria cells. 
This was regardless of the rate at which the antibiotic was being released. This is in contrast to 
what occurs when antibiotic drops or lenses are placed on the ocular surface, where 
pharmacokinetic factors including tear production and drainage, epithelial/corneal penetration 
and drug metabolism play significant factors in the amount of drug exerting an effect. If the eye 
was a closed system, then the fast burst release from a control lens could be advantageous and 
quickly raise drug concentrations to effective levels. Unfortunately, because of tear drainage and 
corneal cellular barriers, it is likely that much of the antibiotic released in such a burst fashion 
will very quickly be cleared from the ocular surface, limiting its usefulness, which is why 
frequent dosing with eye drops is necessary. In contrast, with a sustained release contact lens 
supplying the antibiotic, a continual replenishment of the antibiotic is possible. A fast rise to a 
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high concentration is less likely, but over time there is greater potential for therapeutic 
concentrations to be reached, and more importantly, for them to be sustained over a longer 
period of time. This is exemplified by the in vivo results seen in Figure 5-5. Even with the 
superior performance of the control lens (i.e. normal lenses soaked in ciprofloxacin) against the 
bacteria in vitro, this superiority did not translate in the in vivo rabbit model. The control lens did 
not appreciably impact the number of recoverable bacteria compared to no treatment, 
presumably because all of the antibiotic was released at once, and any of the antibiotic not 
absorbed was quickly drained away. In contrast, the two imprinted lenses performed significantly 
better in reducing the number of recoverable bacteria, as the reserves of ciprofloxacin were 
released slowly over time and could replenish lost drug that was drained away from the surface. 
 If the field of contact lens drug delivery is to continue and be eventually accepted by both 
practitioners and patients alike, the wearer experience must be similar to regular contact lenses 
on the market. The optical transmission in the visible range needs to be acceptable for wear in 
day to day life, the water content and wettability have to remain with a certain narrow set of 
parameters to ensure acceptable comfort during wear, and the amount of oxygen being 
transmitted must be adequate to prevent complications. As shown from the results of our 
experimental lenses, while not surface treated, they had acceptable wettability measures in line 
with other non-surface treated silicone hydrogels that incorporate an internal wetting agent such 
as polyvinylpyrrolidone. 46 The light transmission in the visible range is acceptable, other than 
slight tinting of the lenses due to ciprofloxacin drug incorporation causing a mild yellow 
coloration. The centre thickness and water contents were also in line with commercial contact 
lenses. The incorporation of silicone monomers into the material will allow for superior oxygen 
transmission properties. Between the lenses, there were some significant differences in water 
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content and advancing contact angle. The water content of the lenses which incorporated the 
greatest amount of ciprofloxacin in the imprinting process, the 4:1 imprinted lenses, also had the 
lowest water content, with the 16:1 and control lenses having increasing water content 
comparatively. The one anomaly to this trend was the 8:1 imprinted lenses, which measured the 
highest water content. There were also significant differences in the advancing contact angle, 
with a trend toward lower contact angles as more ciprofloxacin was used. Considering that the 
only difference in the synthesis of all of the lenses is the amount of ciprofloxacin added, it can be 
surmised that this difference in water content and advancing contact angle is likely due to 
irreversible binding of some ciprofloxacin within the materials during synthesis. The continued 
yellow coloration of the contact lenses which had ciprofloxacin incorporation during the 
molecular imprinting process would lead credence to this theory. The permanently bound 
ciprofloxacin is not expected to have had a significant effect on the ciprofloxacin release 
characteristics from these lenses. 
 In this study, the ultimate test of the effectiveness of the modified contact lens drug 
delivery device was performance in an in vivo model of microbial keratitis in New Zealand 
White rabbits. The use of rabbits as a model for microbial keratitis is well known, as they have 
an adequate eye size to allow for contact lens wear. 47 The methods and selection of bacteria for 
infection are also critical. Classically, to achieve infections of the cornea, animal models of 
keratitis have required either passing of a silk suture soaked in a bacterial solution into the 
corneal stroma or direct injection into the corneal stroma of a bacterial solution to get a 
consistent and repeatable keratitis response. 47 The method chosen in this study involved the 
creation of a superficial scratch through the epithelium of the rabbit cornea before exposure to a 
bacterial solution. This method mimicked to some extent the contact lens rabbit model of Hume 
 164 
 
et al., but without the need to add spermidine. 48 Usage of a highly virulent strain of bacteria, P. 
aeruginosa strain 6294 allowed for consistent keratitis responses to be seen under these 
experimental conditions. The timing of the treatment was also carefully chosen for two separate 
reasons. Sixteen hours were allowed to pass so that the MK response could be seen. It was also 
chosen to mimic a more real world situation, where a patient may be reluctant to seek treatment 
after the initial insult, and rather chooses to delay medical attention until the condition and 
symptoms had significantly worsened. We were limited ethically to an experiment of no more 
than 24 hours to prevent significant pain, suffering and distress to the experimental animals. As 
is evident by the data (Figure 5-5), corneas treated with ciprofloxacin eye drops were rendered 
sterile after only the short 8 hour treatment time frame. Indeed, this was also seen in treatment 
trials with the molecularly imprinted contact lenses, as 2 out of the 3 corneas in both of the 
modified lens trials were also rendered sterile. However, the clinical picture at this time does not 
reflect the sterility of the cornea as all eyes at the 24 hour time point regardless of treatment type 
continued to show significant infiltrates, redness, edema and discharge, although the severity 
varied between the different treatment conditions. If the study could have continued for longer, 
an alternative, more clinically relevant outcome measure to recoverable bacteria could have been 
used such as time to resolution of the infiltrate and/or re-epithelialisation of the corneal surface. 
The sterility of the corneas is also in contrast to what is often seen in the experimental trials of 
novel antibiotic drops. For example, in a recent trial testing the efficacy of a new 
fluoroquinolone antibiotic drop, treatment with the new antibiotic (and other commercially 
available antibiotics) did not completely sterilize the cornea, rather it merely significantly 
impacted the number of bacteria recovered compared to non treatment controls. 49 The difference 
observed in this trial likely stems from the method of infection used. In antibiotic drop efficacy 
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studies, corneal infection are generally achieved using an intrastromal injection of the offending 
organism. In contrast, in the current study infection was preceded by a corneal scratch and break 
in the corneal epithelium. This break in the epithelium can provide an avenue for the antibiotic to 
reach the microorganisms, while in intrastromal injection models, the antibiotic must traverse 
through the significant intact epithelial barrier. The performance of the unmodified control lenses 
in comparison to the treatment with eye drops is illustrative of the dosing needed to eradicate the 
bacterial organisms. Eye drop therapy was able to sterilize the corneas, but only after repeated 
instillations over time to ensure that an adequate amount of the antibiotic reaches the ocular 
structures. Based on its in vitro release kinetics, the control lenses release ciprofloxacin as a very 
quick initial burst, and any of the drug that is not absorbed is presumably lost. In this manner, the 
dosing provided by application of a ciprofloxacin loaded, unmodified control lens behaves much 
like a single eye drop instillation. Thus, for the control lens to be effective in eradicating 
bacterial growth, the application of the contact lens would need to follow the schedule seen with 
eye drops. Repeated removal of worn lenses and replacement with loaded lenses would have 
been necessary to provide the proper dose, negating any practical advantages of the drug delivery 
system. 
 Recently, there has been a report by a research group demonstrating the feasibility of an 
extended antibiotic releasing contact lens for the prevention of ocular infections. 50 In their 
model of bacterial endopthalmitis, infection was achieved through anterior chamber injection of 
a methicillin resistant strain of S. aureus. 50 Untreated, after 24 hours approximately 105 
CFU/mL of bacteria were recovered from the experimental eyes, while treatment with topical 
fluoroquinolone eye drops only reduced the number of recovered bacteria to approximately 104 
CFU/mL. In contrast, immediate treatment after bacterial injection with their experimental 
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gatifloxacin releasing contact lenses completely prevented growth of microorganisms, proving 
the utility of their lenses in potentially preventing postoperative infections of the globe.  The 
results of the current study extend the application of antibiotic releasing contact lenses even 
further, with the aim of treatment of infection rather than mere prevention. Delay in treatment of 
the exposed animals with contact lenses or eye drops allow for the clinical signs and symptoms 
of an infection to occur, framing the results from these trials in the context of treatment of ocular 
treatments rather than prevention. 
 In conclusion, in this study, the development of a slow release ciprofloxacin contact lens 
system was achieved using a molecular imprinting strategy. Evaluations in vitro show the 
potential of these materials to release clinically relevant amounts of the antibiotic while retaining 
critically important contact lens material properties, and evidence from in vivo testing show that 
they can perform similarly to antibiotic drop therapy in models of MK. Application of these 
materials may be useful for future treatment paradigms of MK. 
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CHAPTER 6 - GENERAL DISCUSSION AND 
CONCLUSIONS 
 The aim of developing contact lens materials for drug delivery is an ambitious and 
difficult task. Within the course of this thesis, several conclusions on the potential for contact 
lenses as pharmaceutical delivery devices were made, and suggest that CLs as a drug delivery 
platform for antibiotics may be a viable strategy to treat ocular infections. 
 Experiments with commercially available contact lenses (Chapter 3) demonstrated a few 
key findings for lenses which are already on the market. Even though all of the lenses being used 
had the same dioptic power, and relatively the same size and shape, there were significant 
differences which arose between the amount of drug taken up and released, and the time needed 
for drug plateaus to be reached in vitro. This serves to highlight the fact that the material itself 
has some influence on drug release properties. There was some evidence from this study of the 
types of parameters that appeared to be contributory to the differences in properties. The water 
content of the lenses appeared to have an effect, with higher water content lenses releasing more 
of the antibiotic. This would make sense, as it is likely that some of the drug was dissolved 
within the aqueous component of the lenses themselves, and thus the lenses with greater water 
content would be expected to release more than those with lower concentrations. The surface 
charge of the lenses also had an effect. It was no coincidence that the lens which took up the 
most ciprofloxacin in this study (etafilcon A) was also negatively charged. Ciprofloxacin, by 
nature of having two ionizable groups (a carboxylic acid group and an amino group), exists as a 
positively charged molecule in the uptake solution at pH of 4.0. This would naturally lead to 
higher affinity and higher loading with the negatively charged materials. For the silicone 
hydrogels, it is interesting to examine the amount of drug taken up versus the eventual amount 
 168 
 
that was released. On the whole, the silicone hydrogel materials did not appear to have any 
difficulty in loading ciprofloxacin, as there were several examples of silicone hydrogel materials 
(such as senofilcon A and comfilcon A) taking up a comparable amount of ciprofloxacin 
compared to the hydrogels, but the amount that was eventually released into solution was 
significantly lower. It is illustrative to examine Table 3-5 for the percentage of drug released 
relative to the amount loaded. For the silicone hydrogels, there was a significant amount of the 
loaded drug which never left the lens. Whether this is due to binding of the drug to the material 
polymer is unknown. The final major conclusion from this study was that a limitation to how 
much ciprofloxacin can realistically be loaded into a contact lens exists if it is eventually to be 
worn comfortably on the ocular surface. The change in pH as lenses went from the loading 
solution to the release solution caused complete precipitation of the ciprofloxacin found within 
the highly loaded etafilcon A material, and was seen to a lesser degree in some other lenses. 
While the lens may have had an advantageous drug release profile, as evidenced by Figure 3-3 
the inability to see through the lens when worn would render it unusable. There have been 
reports within the literature of extended ciprofloxacin drop topical treatment leading to 
ciprofloxacin concretions developing within the cornea. These typically disappear after a few 
days, as the ciprofloxacin is eventually dissolved and removed. 1 
 Ultimately, the main limitation with commercial lenses was their inability to release 
ciprofloxacin for significant periods of time. In the treatment of ocular infections, it would be 
required that a drug delivery device be able to release clinically relevant amount of antibiotic for 
extended periods of time. Ideally, continued release over the course of 24 hours, or even several 
days would be beneficial to continually combat against the growth of microorganisms. None of 
the commercially available lenses tested in this study were able to sustain release for more than a 
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few hours, suggesting that while antibiotic concentrations were reached in vitro, they would be 
unable to be sustained over the long period when worn in situ. The usefulness of commercial 
contact lenses as drug delivery devices in simple soak and release techniques may be for 
pharmaceuticals whose dosing frequency is not high. It is easy to envision use of these lenses for 
such treatments such as seasonal allergy or early glaucoma, where once a day dosing is 
sufficient. We have already performed some studies on the potential of commercial lenses for the 
delivery of an anti-allergy agent ketotifen fumarate, envisaged to be used in a daily disposable 
context. 2 
 The main focus of Chapter 4 was the creation of contact lens model materials which 
would have more favorable drug release kinetics. To do this, a molecular imprinting strategy was 
employed. The results from this study demonstrated several characteristics of imprinted 
materials, and the challenges in forming materials which would have slow releasing drug release 
characteristics. During the molecular imprinting process, the proper choice of the functional 
monomer is crucial to effectively create the "memory" within the cavities. In this study, two 
functional monomers were tested, acetic and acrylic acid. While the two molecules are similar, 
acrylic acid is ultimately a more useful functional monomer because of the presence of a double 
bond within the molecule. This double bond allows for the molecule to be incorporated within 
the growing polymerization chains, making the imprinted cavities to be a permanent feature of 
the material. Acetic acid lacks this double bond, and thus would be expected to eventually be 
removed from the material over time. The ratio of the functional monomer to the template 
molecule in the polymerization mixture is also critical. Too much or too little of the functional 
monomer affects the efficiency of creating the imprinted areas within the material, and thus a 
decrease in the ability of the material to slow down the drug release. One of the studies also 
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varied the overall concentration of the functional monomer within the polymerization mixture as 
a whole. While this did have an effect, the effect was not particularly pronounced in this current 
study. 
 The greatest contribution of the molecular imprinted materials created in Chapter 4 was 
demonstration that there can be a significant difference between the amount and time that 
ciprofloxacin could be released from the molecular imprinted materials versus non imprinted 
control materials. Monitoring for up to two weeks of release time showed a continued increase in 
concentration for solutions with imprinted materials within them, and a relatively flat plateau 
reached extremely early on for the control materials. It was also demonstrated that the greatest 
effect of the molecular imprinting process versus an unmodified material can be seen when the 
materials are loaded with relatively low concentration solutions. The reason for this is that when 
there is a low amount of ciprofloxacin within the solution, materials which are imprinted have a 
higher affinity for the low amounts of drug within the solution, and will thus load more and 
release more when it is eventually placed within the release media. This has been demonstrated 
in other imprinted materials. 3 The non imprinted materials have only a concentration gradient 
pushing towards loading the ciprofloxacin, and this gradient is not very high due to the low 
loading concentration. 
 The limitations to the studies performed in Chapter 4 relate to the form of the materials 
created and the release medium. All of the materials created in Chapter 4 were made from 
components critical for silicone hydrogel contact lenses - pHEMA, EGDMA, TRIS, but they 
were not formed into contact lenses. Instead, the materials created were small, flat discs which 
were punched out of larger pieces of polymerized material. The thickness, shape and size of the 
materials thus did not completely match that of contact lenses. The medium into which the lenses 
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were releasing the drug was also static. It was sampled and returned during each of the time 
points monitored, but there was no attempt to replace the media at different times to stimulate 
tear flow and drainage, which would presumably favor a greater amount of release by inducing a 
continuous concentration gradient from the lens to the release medium. 
 The goals of Chapter 5 were to establish the feasibility of molecular imprinted contact 
lenses for the treatment of infection in vivo. The methods and successes which were developed 
within Chapters 3 and 4 were needed to pave the way for manufacturing of molded contact 
lenses, and these materials needed to be evaluated not only for their favorable drug release 
characteristics, but also their relevant contact lens properties. Some modification of the protocol 
was needed to achieve desirable contact lens properties. The ciprofloxacin needed to be pre 
dissolved with acrylic acid in chloroform to allow for acceptable light transmission properties. 
The addition of PVP was needed to improve the wettability of the lens surface. Lens molds were 
needed to achieve the shape, size and thickness of commercially available contact lenses.  
 These lenses were tested for their ability to eradicate replicating bacteria within the 
corneas of rabbits infected with a particularly virulent strain of P. aeruginosa. Here, the 
imprinting process demonstrated their worth, as they were successful in significantly reducing 
the number of viable bacteria recovered from excised corneas after only a short eight hour 
treatment period. This was in contrast to the non imprinted control lenses, whose bacterial counts 
were similar to non-treated infected corneas.  
 There are several follow up experiments which could be done to further flesh out the 
effectiveness of this drug delivery system in vivo. Multiple strains of bacteria could be used to 
generate keratitis responses, and the results of treatments with these lenses could be 
demonstrated with multiple MK causing organisms. This would be more of a function of the 
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antimicrobial properties of ciprofloxacin itself, but would be necessary before these lenses could 
possibly be used for human cases of MK. The endpoint of the in vivo experiments was limited 
ethically to only 24 hours post scratch and bacteria introduction. The outcome measure in this 
study was the number of bacteria recovered per cornea, but this does not mimic what is seen 
clinically to define whether any treatment is successful or not. Future studies using a less virulent 
strain of bacteria which would still allow for a MK response to be seen, but the possibility of a 
milder clinical course, would open up the possibility of using a more relevant clinical endpoint 
such as a comparison of the time needed to resolve the infiltrate and re-reepithelialise the corneal 
surface. 
 There results of this thesis are encouraging for the development of contact lenses as drug 
delivery devices. The knowledge gained is suggestive of other potential future projects and 
engineering challenges. For example, do the results for imprinting with ciprofloxacin translate 
into imprinting for other fluoroquinolone antibiotics such as gatifloxacin, moxifloxacin and 
besifloxacin, the newest generation and more commonly used fluoroquinolone antibiotics? Can 
the sustained release of ciprofloxacin from these materials overcome fluoroquinolone-resistant 
bacterial strains? There is also a very interesting question regarding regulatory and prescribing 
authorities. While the majority of eye care professionals are able to prescribe contact lenses and 
antibiotics, there could a case by regulatory authorities where further certification or training 
would be required before one can prescribe these sustained release devices.  
 In this thesis, a sustained ciprofloxacin releasing contact lens system was developed and 
evaluated. In vitro and in vivo data generated is very compelling regarding the potential ability of 
these lenses to be valuable in the control of ocular infections caused by P. aeruginosa. The 
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challenge, if these lenses are ever to be used in clinical practice, may lie in convincing the eye 
care practitioner of the utility of these devices in the management of ocular infections.  
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APPENDIX 1 - METHOD DEVELOPMENT AND 
TROUBLESHOOTING 
CIPROFLOXACIN SOLUTIONS 
 Ciprofloxacin, the antibiotic used in this thesis, is a second generation fluoroquinolone 
antibiotic. While it is useful clinically, its preparation within the laboratory requires some 
knowledge of the chemical properties of the drug. The family of fluoroquinolones all contain 
similar structures of a fluorinated quinolone ring, which is shown in Figure A-1a. The structure 
of ciprofloxacin is shown in Figure A-1b. There have been numerous publications describing 
laboratory techniques to detect and quantify fluoroquinolones.1-5  
a) 
N
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R
RR
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b) 
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Figure A-1 Chemical Structure of Fluoroquinolone Rings and Ciprofloxacin 
 a) Generalized structure of Fluoroquinolone rings and b) ciprofloxacin. The -R 
subgroups of the general fluoroquinolone can be substituted with various different 
chemical entities which will have effects on the chemical properties and 
antibacterial spectrum of the resultant molecule. 
  
 Spectrophotometry based analysis for the detection of ciprofloxacin has been found to be 
a sensitive and inexpensive technique to determine the concentration of ciprofloxacin within a 
solution. 6 Spectrophotometric analysis relies on the natural fluorescence of a molecule. For 
ciprofloxacin, when a liquid sample is exposed to light of wavelength of 270 to 280 nm, it will 
fluoresce and emit light with a wavelength peak of 420 nm. 6 The amount of light emitted at 420 
nm can be correlated to the concentration of ciprofloxacin within the solution. Use of this 
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technique requires a sensitive fluorescence spectrophotometer, such as the Hitachi F-4500 
(Hitachi Ltd, Tokyo, Japan) or the Spectramax M5 Microplate reader (Molecular Devices, 
Sunnyvale, California). There are two ionizable groups on ciprofloxacin, a carboxylic acid group 
and an amino group, which can be alternatively protonated/deprotonated at different pH levels. 
The listed pKa values for ciprofloxacin are 6.00 and 8.80. 7 The molecule exists as a zwitterion 
(a molecule with a positive charge on one portion of the molecule and a negative charge on the 
other portion, leading to an overall neutral charge) at physiological pH, leading to very poor 
aqueous solubility at that pH. In acidic or basic pH, there is a significant increase in 
ciprofloxacin solubility. Thus, the majority of ophthalmic preparations of ciprofloxacin are 
adjusted for pH to be slightly acidic. Ciprofloxacin ophthalmic drops are listed on their product 
monograph of having a pH of approximately 4.0. 8 Preparation within the laboratory must take 
pH into account if a stable solution is to be created. A stable solution is necessary if 
spectrophotometry is used to determine the concentration of the ciprofloxacin within the 
solution, as unreliable readings would result if a precipitated solution was examined. Heating of 
ciprofloxacin within a neutral buffer such as phosphate buffered saline (PBS) will increase 
solubility of the molecule, but after the solution cools the ciprofloxacin with simply precipitate 
out of solution. As detailed in the experimental chapters, to combat this ciprofloxacin solutions 
were created in acidic media. The most useful was a pH 4.0 acetic acid-sodium acetate buffer, as 
the pKa of acetic acid is 4.76.  
 
CONTACT LENS MANUFACTURING 
 Several difficulties needed to be overcome to manufacture the molecular-imprinted discs 
into “true” contact lenses. The majority of these challenges did not become apparent until the 
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experiments described in Chapter 5, when actual contact lenses were being formed, versus the 
thicker discs which were formed during Chapter 4.  First, as model silicone hydrogel lenses were 
being formed, some means were necessary to increase the wettability of the ocular surface. As 
the equipment and technology needed for plasma oxidation or plasma coating employed by 
Bausch and Lomb and CIBA Vision for their lenses were unavailable, it was decided to utilize 
the internal wetting agent strategy employed by VISTAKON by incorporating polyvinyl 
pyrrolidone (PVP) into the reaction mixture. Secondly, the light transmission of lenses which 
had ciprofloxacin dissolved within them was very poor. The reaction under the UV light when 
ciprofloxacin was directly loaded into the polymerization mixture led to an opaque yellow 
coloration to the thin contact lenses. To combat this, the ciprofloxacin was initially dissolved in 
chloroform with the acrylic acid functional monomer. Ciprofloxacin has significantly better 
solubility within chloroform compared to water, and the acidic pH imparted by the acrylic acid 
enhances the solubility even further. This mixture could then be added to the polymerization 
mixture before being placed within the UV oven. The third challenge to contact lens 
manufacturing was the curing time. A delicate balance is needed for the amount of time that the 
lenses are cured. If left curing for too long, the lenses became incredibly dried out, and 
developed holes where the material had pulled away from the mold. Too short of a curing time 
and the lenses produced were extremely fragile and floppy, which were signs that the 
polymerization reaction was incomplete, and there still existed liquid monomers which had not 
fully polymerized. A time of five minutes was found to be optimal for the creation of the 
molecular imprinted materials. The exact time of curing is dependent on the UV light emission 
power from the curing system. As the running age of the UV bulb increases, as well as the 
number of times the bulb has been switched on and off, the power output of the bulb decreased, 
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and the curing times had to be increased accordingly. Finally, removal of the cured contact 
lenses from the contact lens molds was occasionally problematic. The lens sometimes stuck to 
the polypropylene contact lens mold and because of their brittleness, was liable to crack or break 
if forcibly removed with tweezers or other means. This was alleviated partially by two 
modifications to the protocol. The cure time was decreased accordingly to five minutes to 
prevent overexposure and brittleness development, and lenses which were cured that still were 
difficult to remove from the molds were soaked in saline buffer. The buffer hydrated the lens and 
the lens eventually released from the mould into the solution.  
RABBIT MODELS OF MICROBIAL KERATITIS 
 There were several considerations when we considered the design of our model of 
Microbial Keratitis (MK). Methods of injection into the corneal stroma with a bacterial solution 
have the advantage of a more consistent MK response, as the bacteria have bypassed many of the 
ocular barriers and defence mechanisms. 9 This was not preferable for our experiments due to the 
artificial nature of the infection process, leading us to choose using a corneal epithelial scratch 
model of infection, as this was deemed to be more representative of the clinical reality of patients 
who develop MK.  
 The choice of experimental organism to test in our model of MK was also critical. There 
were many strains available which had been isolated from human cases of microbial keratitis. 
Unfortunately, for the majority of them tested, we were unable to generate a reliable MK 
response within the rabbit model using a epithelial scratch. Only isolate P. aeruginosa strain 
6294 allowed for consistent MK responses to be generated with this model. P. aeruginosa strain 
6294 was a particularly virulent and aggressive isolate from a human case of MK in the USA. 
The downside to using 6294 for our experiments was that the strain is ciprofloxacin sensitive; a 
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very low concentration of ciprofloxacin (0.4 μg/mL) is able to completely limit the growth of the 
bacteria in vitro. It would have proved useful to test the performance of the ciprofloxacin 
releasing contact lenses in the rabbit MK model caused by a ciprofloxacin resistant strain of 
bacteria, to see if the amount and duration of ciprofloxacin release could have overcome 
acquired bacterial resistance. Unfortunately, none of the ciprofloxacin resistant (MIC > 16 
μg/mL ) 10 isolates available were able to generate a consistent MK response with the rabbit 
scratch MK model.  
 The incubation time after bacterial introduction within the rabbit corneas was also 
elucidated with some trial and error. Initial protocols submitted for animal ethical approval had 
interventions with the contact lenses or drops occurring 8 hours post scratch/bacterial 
introduction. Unfortunately, after 8 hours there were little or no signs of active infection as the 
bacterium did not have enough time to establish and replicate on the rabbit corneas. The protocol 
was modified to allow the incubation time to be extended to 16 hours before intervention, 
allowing a repeatable MK response to be seen in the trials. 
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